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Despite the effort, time and money contributed to treat cancer, it is still the second leading 
cause of death worldwide. Boron Neutron Capture Therapy (BNCT), which is able to 
balance high therapeutic efficacy with low undesired side effects, is a promising tool to treat 
cancer. BNCT is a binary approach where two components with low-toxicity require co-
localization in tumor tissue to be activated as therapeutic agent. That is, high accumulation 
of boron-10 (10B) in tumor tissue needs to be achieved and subsequently irradiated by thermal 
neutrons. A nuclear reaction will be triggered in which boron-10 captures a neutron and 
decays into lithium while releasing an alpha particle (10B(n, α, γ)7Li). The originated particles 
generate cellular damage which subsequently leads to cell death. 
To achieve efficient and successful BNCT certain conditions need to be fulfilled. A physical 
challenge was the provisioning of neutrons in clinics, but newly developed accelerators, 
producing high intensity epithermal neutron beams, are now available. Furthermore, boron 
delivery agents able to deliver sufficient amounts of 10B selectively into tumor tissue need to 
be produced. To date, only two compounds (sodium borocaptate (BSH) and 
boronophenylalanine (BPA)) are used in clinical trials, yet, their pharmacological limitations 
arise need for new and improved BNCT drugs. 
Nanomaterials have been increasingly used in drug delivery due to their high loading abilities, 
low cytotoxicity and high bio-compatibility. Additionally, abnormal conditions in diseased 
tissue, such as inflammation or tumor growth, open the possibility of passive targeting for 
nanomaterials due to the enhanced permeability and retention (EPR) effect. 
In the current PhD thesis, we have worked on the development of small, but highly 
boronated particles as 10B carriers for the application in BNCT. Therefore, two different 
nanoparticles were developed and evaluated; one gold-nanomaterial based (AuNP) with a 
core diameter of 3 - 5 nm and one carbon based (carbon dots; CDs) with a core size of 
around 7 nm. Particles of small size come generally with the advantage of a rather fast 
clearance and elimination, hence, lower toxicity due to reduced organ and tissue uptake 
compared to bigger particles. However, high uptake in the diseased organ/tissue, such as a 
tumor, is desired. In this PhD we approached the challenge to achieve the balance between 
small and fast clearing particles but retention in tumor tissue by introducing a pre-targeting 
strategy. 
The principle of pre-targeting is based on the high specificity of monoclonal antibodies 
(mAbs) towards their target. In tumor tissue such targets can be certain over-expressed cell 
membrane receptors. In our case we worked with breast cancer tumor models, using the 
antibody Trastuzumab (Herceptin®), which targets the membrane receptor HER2. For pre-
targeting the antibody is functionalized with a moiety able to undergo a bioorthogonal click 
reaction (here trans-cyclooctene, TCO) with the drug delivery agent, itself functionalized with 
the counterpart for the click reaction (here tetrazine). The conjugated mAb is injected 
intravenously and after it is cleared from blood and healthy tissue, the drug delivery agent is 
administered. It clicks to the mAb in tumor tissue and is retained, whereas otherwhere fast 
eliminated. 
The work of this thesis started with the functionalization of monoclonal antibodies and the 





p-NCS-Bz-DFO (a desferrioxamine derivative) was used to enable the radiolabeling of the 
mAb with the positron emitter zirconium-89 (89Zr) and thus the tracking of such in vivo by 
Positron Emissions Tomography (PET) imaging. The conjugation of both ligands was 
achieved by random conjugation, that is, by coupling reactions to free available amine groups 
of lysine residues in the mAb. This method is favored due to its mild reaction conditions 
together with rather easy and fast results. However, this non-site-specific method leads to a 
mixture with a high variety of conjugates. With the ratio of moieties per mAb playing an 
important role to determine the efficacy of the functionalized conjugate, we wanted to gain 
closer insight of the obtained mAb species. Therefore, three different analytical methods 
were used: (i) a direct titration method, (ii) MALDI/TOF MS (Matrix-Assisted Laser 
Desorption-Ionization / Time Of Flight Mass Spectrometry) and (iii) UPLC/ESI-TOF MS 
(Ultra High Performance Liquid Chromatography / Electrospray ionization - Time Of Flight 
Mass Spectrometry). The aim was to not only achieve the average number of moieties per 
mAb in the heterogenic mixture, but also to obtain a distribution of the different conjugates 
present. We, furthermore, wanted to answer the question if the number of moieties available 
on the surface of the mAb correlates with the total number of attached ligands by comparing 
the direct method (giving the available ligands) to mass analytic (giving the total number of 
ligands). For these investigations we used two different FDA and EMA approved mAbs: the 
above mentioned Trastuzumab and Bevacizumab (Avastin®, targets VEGF-A, a vascular 
endothelial growth factor). The study, described in Chapter 3, showed how challenging the 
analysis of antibodies, conjugated with a respectively small ligand, is. Direct titration offered 
quantitative results about the average number of functionalizations per mAb in all cases. 
MALDI/TOF MS showed in our hands questionable results, but UPLC/ESI-TOF MS 
offered the desired insight of the distribution of conjugates, with higher accuracy for DFO- 
compared to TCO-conjugates. 
After the evaluation of the TCO-functionalized Trastuzumab for its binding affinity, 
biodistribution and internalization properties, we tackled the synthesis and characterization 
of small spherical gold nanoparticles (AuNPs), loaded with boron clusters, named COSAN 
(Cobalt bis[dicarbollide]), and functionalized with tetrazine to enable the click reaction. The 
particles, analyzed by transmission electron microscopy (TEM), showed homogeneous 
distribution, with a core size of 3-5 nm, increasing to 12-15 nm in diameter after 
functionalization. The AuNPs were radiolabeled by doping the gold core with [64Cu]CuCl2, 
allowing in vivo experiments while tracking the particles by PET imaging. Evaluating the 
distribution of the particles showed slower clearance than expected from such small particles, 
with high liver and spleen accumulation. The slow clearance from tumor tissue, with highest 
accumulation at 48 h post injection, limited improvement under pre-targeting conditions. 
Chapter 4 was concluded that the small AuNPs do not possess the desired properties for 
pre-targeting, yet, high boron loading was achieved and tumor uptake due to the EPR effect 
could be witnessed. 
To overcome the hurdle of a slow clearing boron delivery agent as experienced with the 
AuNPs, we changed the type of particles from a metal core to organic boron carbon dots 
(B-CDs). This work is described in Chapter 5. High biocompatibility, low cytotoxicity and 
rather fast and inexpensive synthesis of carbon dots suggest their potential application as 





have never before been investigated for BNCT. For the pre-targeting approach and in vivo 
studies, we functionalized with tetrazine and radiolabeled with a fluorine-18-prosthetic group 
([18F]FPyTFP), respectively. The distribution of the dots in vivo showed the desired fast 
clearance via kidney and bladder from all organs and tissue, including the tumor. When 
applying the pre-targeting strategy, the tumor accumulation was about 2.8 %ID/cm3, but the 
desired retention in tumor tissue could be achieved. Hence, B-CDs, combined with a pre-






A pesar del esfuerzo económico y humano destinado en las últimas décadas a combatir el 
cáncer, éste sigue constituyendo una de las principales enfermedades en el mundo 
desarrollado y representa la segunda causa de muerte a nivel mundial. Además, su incidencia 
se espera que aumente en los próximos años, debido a la mayor esperanza de vida, factores 
ambientales y hábitos poco saludables. Por este motivo, es imperativo desarrollar nuevas 
terapias que resulten más efectivas y produzcan menos efectos tóxicos y secundarios sobre 
los pacientes.  
La terapia de captura de neutrones por boro (BNCT, del inglés Boron Neutron Capture Therapy) 
es una estrategia terapéutica binaria, que puede combinar a priori una elevada eficacia 
terapéutica mientras se minimizan los efectos secundarios. El principio de funcionamiento 
de la BNCT es sencillo en concepto y muy intuitivo, y se basa en la capacidad que presentan 
ciertos átomos, entre ellos el 10B (el boro es un elemento con dos isótopos estables, 10B y 11B, 
con abundancias del 20 y 80%, respectivamente) de capturar neutrones térmicos. Dicha 
captura se traduce en la formación de un átomo de boro excitado, que se desintegra mediante 
fisión dando lugar a la formación de una partícula alfa y un ion de litio (reacción nuclear 
notada como 10B(n, α, γ )7Li). La partícula alfa y el ion litio tienen una energía elevada, y 
presentan una transferencia de energía lineal muy alta y un rango cercano al diámetro de una 
célula. De este modo, si se consigue acumular una cantidad suficiente de átomos de 10B de 
manera preferente o selectiva en el tejido tumoral, y posteriormente éste se irradia con 
neutrones térmicos, la reacción de captura neutrónica y subsiguiente emisión de iones resulta 
en el daño y muerte celular en la zona tumoral. Aquellas zonas en las que no hay átomos de 
boro no se ven prácticamente afectadas por la terapia (Figura 1). 
 
Figura 1: Principio de funcionamiento de la BNCT. Tras acumulación selectiva de átomos de 10B en 
las células tumorales, se lleva a cabo una irradiación neutrónica, produciendo la reacción nuclear 
10B(n, α, γ )7Li, que en última instancia produce el daño celular en el tumor, sin afectar al tejido sano.  
Para lograr que la BNCT resulte eficiente y exitosa, es necesario que se den ciertas 
condiciones. En primer lugar, su aplicación se ha visto tradicionalmente limitada por la 





cabo las intervenciones en las inmediaciones de un reactor nuclear. Sin embargo, en los 
últimos años se han desarrollado ciclotrones que permiten obtener haces de neutrones de 
intensidad y energía adecuadas para llevar a cabo los estudios terapéuticos, facilitando por lo 
tanto la traslación al entorno clínico. El segundo problema relacionado con la BNCT es la 
necesidad de desarrollar entidades químicas capaces de acumular una cantidad suficiente de 
átomos de boro en el tumor, manteniendo baja la acumulación en tejido sano y en sangre. 
Generalmente, se acepta que una concentración de 25-30 µg de 10B por gramo de tumor y 
una relación de concentración tumor/tejido sano y tumor/sangre de 4/1 son suficientes para 
garantizar eficacia terapéutica con efectos secundarios mínimos. Históricamente, se ha 
aprovechado el metabolsimo acelerado en los tumores y la sobre-expresión de determinados 
receptores para conseguir la acumulación preferencial de compuestos ricos en boro en el 
tejido tumoral. Sin embargo, y a pesar de más de 80 años de esfuerzo, en la actualidad tan 
sólo se utilizan en el entorno clínico dos compuestos: borocaptato de sodio (BSH) y 
boronofenilalanina (BPA), aunque ambos presentan poca especificidad por el tejido tumoral 
y sólo son eficaces en determinado tumores. 
Con la emergencia de la nanotecnología, se han empezado a utilizar nanosistemas como 
potenciales portadores de boro con el fin de acumular una gran cantidad de boro en el tejido 
tumoral. De hecho, es posible preparar nanomateriales con alta biocompatibilidad y larga 
circulación en sangre. Además, gracias al efecto conocido como enhanced permeability and 
retention (EPR) los nanosistemas se acumulan de manera preferente en los tumores, ya que 
los tumores presentan una vasculatura imperfecta con fenestraciones y un drenaje linfático 
deficitario. 
En esta tesis doctoral se ha combinado la experiencia previa adquirida en el grupo de 
investigación de Radioquímica e Imagen Nuclear relativa a (i) nanotecnología; (ii) química 
del boro; y (iii) imagen nuclear y experimentación animal, para abordar la implementación de 
una estrategia de pre-targeting basada en nanotecnología para su aplicación en BNCT. 
Concretamente, se ha trabajado en el desarrollo de partículas pequeñas y ricas en boro. Por 
un lado, se han desarrollado y evaluado nanopartículas de oro (AuNP) con un diámetro de 
núcleo de 3 - 5 nm, y por otro lado nanopartículas de carbono (CDs, del inglés carbón dots) 
con un tamaño de núcleo de alrededor de 7 nm. Se eligieron nanopartículas (NPs) de 
pequeño tamaño ya que éstas presentan generalmente un aclarado relativamente rápido y 
poca acumulación en los órganos del sistema reticuloendotelial (RES), actualmente conocido 
como MPS (del inglés Mononuclear phagocytic system). Esto resulta en una menor toxicidad ya 
que hay menos acumulación en tejido sano. Es importante mencionar que un aclarado rápido 
también se traduce en una menor biodisponibilidad. En consecuencia, uno de los retos de 
esta tesis doctoral consistía precisamente en conseguir un equilibrio entre el aclarado del 
organismo y la acumulación en el tejido tumoral. 
La novedad principal de la presente tesis doctoral se basa en la utilización de la estrategia de 
pre-targeting para conseguir la acumulación en tumor. Dicha estrategia es conocida y ha sido 
utilizada en el contexto de la imagen molecular, pero no de la terapia. El pre-targeting se basa 
en conseguir la acumulación de un fármaco (componente 2) utilizando para ello la 
acumulación previa de otro componente (componente 1). El componente 1 se acumula en 





determinado que se encuentra sobre-expresado en células tumorales. En el caso de la tesis 
doctoral, se ha utilizado como componente 1 un anticuerpo (mAb), concretamente 
Trastuzumab (Herceptin®), que tiene gran afinidad por los receptores de membrana HER2. 
Dicho anticuepro se funcionalizó con un ligando capaz de producir una reacción 
bioortogonal (trans-cicloocteno, TCO). El componente 2, en nuestro caso las NPs ricas en 
boro, se funcionalizaron con el grupo complementario para dar la reacción bioortogonal (en 
este caso, tetrazina). Para llevar a cabo la estrategia de pre-targeting se inyecta en primer lugar 
el mAb funcionalizado por vía intravenosa. Una vez se ha producido la acumulación en 
tumor y el aclaramiento de la sangre y tejido sano, se administra el componente 2, que se 
distribuye por todo el cuerpo pero se acumula únicamente donde es capaz de producirse la 
reacción bioortogonal con el componente 1, es decir en el tumor (Figura 2). 
 
Figura 2: esquema de la estrategia de pre-targeting. En primer lugar, se administra un anticuerpo 
funcionalizado con un grupo capaz de dar lugar a una reacción bioortogonal (1). Una vez se ha 
producido la acumulación en tumor y aclaramiento (2) se administra el segundo componente (3), que 
en este caso es una nanopartícula con una funcionalidad capaz de dar la reacción bioortogonal. La 
reacción bioortogonal entre los dos componentes se da únicamente en el tumor, produciendo la 
acumulación del segundo componente (4), momento en el que debería llevarse a cabo la irradiación 
neutrónica (5). 
El trabajo de esta tesis se inició implementado metodologías para la funcionalización de los 
anticuerpos y el análisis de los conjugados obtenidos (capítulo 3). Además del TCO, 
necesario para dar la reacción bioortogonal, se decidió incorporar un quelante bifuncional, 
concretamente p-NCS-Bz-DFO (un derivado de la desferrioxamina) con el fin de permitir el 
marcaje radiactivo utilizando el isótopo emisor de positrones zirconio-89 (89Zr), que 
permitiría de este modo su seguimiento tras administración in vivo utilizando tomografía por 
emisión de positrones (PET). La conjugación de ambos ligandos simultáneamente se logró 
mediante la conjugación aleatoria, es decir, mediante reacciones de acoplamiento a grupos 
amino disponibles, debido a la presencia de lisinas en el mAb. Este método es muy atractivo 





trata de un método no específico, y en consecuencia no se conocen a priori ni el número ni 
la distribución de las funcionalidades incorporadas, resultando generalmente en mezclas de 
conjugados. Así pues, el primer objetivo de la tesis doctoral fue establecer métodos analíticos 
para una correcta caracterización de los mAbs funcionalizados, con el fin de conocer el 
número de funcionalizaciones promedio, así como conocer mejor la distribución de mAbs 
con cada número de funcionalizaciones, y el número de dichas funcionalizaciones que están 
“disponibles” para una eventual reacción de formación del complejo (caso del DFO) o de 
reacción bioortogonal (caso del TCO). Con tal fin, se utilizó una combinación de métodos 
analíticos, incluyendo: (i) un método de valoración directa, (ii) MALDI/TOF MS (Matrix-
Assisted Laser Desorption-Ionization / Time Of Flight Mass Spectrometry) y (iii) UPLC/ESI-TOF 
MS (Cromatografía Líquida de Ultra-resolución / Ionización de Electrospray - 
Espectrometría de Masa de Tiempo de Vuelo). Para estas investigaciones, se utilizaron dos 
mAbs aprobados por la FDA y la EMA diferentes: el mencionado anteriormente 
Trastuzumab, y Bevacizumab (Avastin®, que es específico para el factor de crecimiento 
endotelial vascular VEGF-A. Los métodos de valoración directa permitieron obtener datos 
cuantitativos acerca del número de funcionalizaciones promedio por mAb. La técnica de 
MALDI ofreció resultados algo ambiguos, debido a la poca resolución de la técnica y a la 
pequeña masa molecular de las funcionalizaciones incorporadas, que impidieron una correcta 
resolución de las diferentes señales. Por contrapartida, la técnica UPLC/ESI-TOF MS 
permitió obtener datos cuantitativos fiables acerca de la presencia de diferentes grados de 
funcionalización, especialmente en el caso del DFO. 
Una vez caracterizada la funcionalización del Trastuzumab, se abordó el trabajo relativo al 
desarrollo de nanosistemas y su evaluación in vivo. En primer lugar se ensayó la síntesis y 
caracterización de nanopartículas de oro esféricas (AuNP), cargadas con clústeres de boro. 
Concretamente, como unidad rica en boro se utilizó el COSAN (Cobalto bis[dicarballuro]), 
que es un complejo mixto de cobalto que integra dos clústeres de carborano, cada uno de 
ellos con 9 átomos de boro y con carga global negativa. Asimismo, se incorporó a las NPs 
ligandos funcionalizados con tetrazina, con el fin de permitir la reacción bioortogonal con el 
TCO. Las partículas se analizaron mediante microscopía electrónica de transmisión (TEM), 
que demostró una distribución homogénea de tamaño de núcleo (3-5 nm). El marcaje de las 
NPs para su posterior evaluación mediante PET se llevó a cabo mediante dopaje del núcleo 
de oro utilizando el isótopo emisor de positrones cobre-64. La evaluación de la distribución 
de las partículas se llevó a cabo en un modelo animal de cáncer de mama, generado mediante 
inoculación subcutánea de células BT-474 en ratones inmunodeprimidos. Los estudios de 
imagen mostraron un aclarado de las NPs más lento del esperado, con alta acumulación de 
hígado y bazo. Esto resultó en una baja biodisponibilidad, y en consecuencia también en una 
baja acumulación tumoral. Posteriormente, se ensayó la estrategia de pre-targeting. Para ello, se 
ensayó en primer lugar la biodistribución del anticuerpo funcionalizado y marcado con 89Zr, 
observándose una buena acumulación en el tumor a las 24-48 horas tras la administración 
intravenosa (Figura 3). Puesto que los estudios in vivo e in vitro llevados a cabo demostraron 
que se producía la internalización del anticuerpo en las células tumorales, se decidió abordar 
los estudios de pre-targeting administrando el componente 2 (NPs de oro) a las 24 horas tras 
la administración del anticuerpo. De este modo, se adquirió un compromiso entre la 





mAb, que en última instancia reduce la probabilidad de que se produzca la reacción 
bioortogonal en el tumor. Los estudios llevados a cabo demostraron que la acumulación de 
las NPs en el tumor no es superior cuando se utiliza la estrategia de pre-targeting, cuando se 
compara con la acumulación alcanzada con las NPs inyectadas individualmente. La falta de 
resultados positivos se interpretó en términos de la retención de las NPs en el tumor. Puesto 
que dicha retención es alta, tal y como se observó en los estudios llevados a cabo sólo con 
las NPs, no se observa una mejora cuando se aplica la estrategia de pre-targeting. 
 
Figura 3: Imágenes PET obtenidas a diferentes tiempos tras administración de Trastuzumab 
funcionalizado y marcado con 89Zr, en un modelo animal de cáncer de mama generado por 
inoculación subcutánea de células BT-474 en ratones inmunodeprimidos. 
Para superar el obstáculo que supone el aclaramiento lento de las NPs, se optó 
porsteriormente por ensayar nanosistemas de menor tamaño, concretamente nanopartículas 
de base carbono, conocidas habitualemnte como carbon dots (CDs), dopadas con boro (B-
CDs). Se escogieron estos nanosistemas ya que presentan una elevada biocompatibilidad, 
baja citotoxicidad y su síntesis es relativamente rápida y económica. La estrategia planteada 
fue la misma que la expuesta anteriormente para las NPs de oro. Sin embargo, en este caso 
se utilizó como componente 2 de la estrategia de pre-targeting los mencionados B-CDs, 
preparados para presentar grupos amino libres sobre la superficie, los cuales se aprovecharon 
para incorporar las unidades de tetrazina (con el fin de permitir la reacción bioortogonal) y 
el radiomarcaje, el cual se logró utilizando el grupo prostético [18F]FPyTFP, que presenta alta 
reactividad hacia los grupos amino. 
Los ensayos efectuados con los B-CDs mediante PET en el mismo modelo animal 
anteriormente mencionado demostraron un aclaramiento y eliminación vía orina muy 
rápidos según lo esperado, y una acumulación baja en el tumor. Al ensayar la estrategia de 
pre-targeting, se obtuvo un patrón de biodistribución muy parecido, con una eliminación rápida 
y una baja acumulación en el tumor. Sin embargo, un análisis más exhaustivo de la 
acumulación de los B-CDs en tumor en función del tiempo demostró que, mientras que la 
concentración de B-CDs en el tumor disminuye con el tiempo en el grupo control 
(administración únicamente de los B-CDs), dicha concentración se mantiene constante en 
condiciones de pre-targeting. Este resultado demuestra una mayor retención de los 





corrobora que la reacción bioortogonal se produce (Figura 4). Los resultados sugieren que la 
estrategia es válida, si bien para un funcionamiento óptimo podría ser adecuado seleccionar 
un anticuerpo con menor internalización celular, y aplicar el segundo componente de la 
reacción a tiempos más largos. Así mismo, una mayor circulación (eliminación más lenta) del 
segundo componente (nanosistema) ofrecería también mejores resultados. 
 
Figura 4: Izquierda: Concentración de B-CDs en el tumor a diferentes tiempos tras administración 
intravenosa en un modelo animal de cáncer de mama. En violeta, resultados obtenidos en condiciones 
de pre-targeting. En azul, concentraciones obtenidas tras administración únicamente de los B-CDs; 
derecha: imágenes PET-CT representativas de cuerpo completo, y de acumulación selectiva en la 
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Chapter 1: General introduction 
Chapter 1: General introduction 
1.1 Cancer 
The term cancer embraces different diseases which can affect any part of the body. All in 
common have a (mostly) fast growth of cells out of their usual behavior. They penetrate into 
surrounding tissue, forming a tumor. Some cancer types even spread to other organs to form 
metastases. This stage usually leads to an immense increase of the death rate. In Figure 1 the 
incidence and mortality of the most common types of cancer worldwide are shown (2018): 
 
Figure 1: Estimated number of incident cancer cases and deaths worldwide in 2018 (both sexes, all 
ages) (1). 
As the second leading cause of death worldwide (about 1 out of 6 deaths), cancer was 
responsible for an estimated 9.6 million deaths in 2018. The highest risk factors leading to 
cancer (about 30 % of all cases) are overweight, a lack of fruit and vegetables in diet, too little 
physical activity as well as the use of tobacco and alcohol. Whilst in 2017 in high-income 
countries 90 % reported treatment services are available, in low-income countries it´s only 
26 % (2). 
The major difficulties of curing cancer are not only the variety of the different kinds of 
tumors but also the late-stage presentation and inaccessibility for diagnosis and treatment. 
Therefore, the development of new therapies and improvement of existing ones is required 
where therapeutic efficacy and harmful side effects are carefully balanced. 
1.2 Boron neutron capture therapy 
1.2.1 General discription 
Boron neutron capture therapy (BNCT) is a unique way to treat cancer. It is a binary 
approach where two non- or low-toxic components require co-localization in tumor tissue 
to become effective. In the process, a compound enriched with stable boron-10 
(approximately 20 % of the natural element boron) is injected intravenously and accumulates 
in tumor tissue. A neutron beam, directed to the affected tissue, leads to a nuclear reaction 
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(Figure 2). The high cross section of Boron-10 atoms (σ = 3840 barns) enables the capture 
of thermal neutrons and hence, the nuclear reaction 10B(n,α,γ)7Li. Gordon Locher proposed 
this principle first in 1936 (3). 
 
Figure 2: Nuclear reaction in BNCT. 10B is capable to capture thermal neutrons, resulting in the 
formation of an unstable 11B atom which ultimately disintegrates with the consequent emission of 
one alpha particle, one lithium ion and one gamma ray. 
The particles released following neutron capture are highly charged and have a high 
molecular weight. Those properties result in a high linear energy transfer (LET); that is, they 
can release a high amount of energy to the material traversed per unit distance. Therefore, 
the pathway is short with a fast loss of energy, producing a severe damage to the 
environment. Exactly these properties are used in BNCT. The emitted ions, when selectively 
or preferentially accumulated in tumor tissue, will induce severe damage on a length range 
smaller than the diameter of a single cell (4-10 µm, Figure 2) (4) and tumor cells will be 
destroyed while the surrounding healthy tissue is spared (Figure 3). Selectivity also refers to 
the fact that no other main constituent elements of the body, i.e. oxygen, nitrogen and 
carbon, have a high cross section for neutrons. Nitrogen and hydrogen are able to capture 
neutrons (nuclear reactions: 14N(n,p)14C and 1H(n,y)1H) with σ = 10-24 barns, which is 
negligible when compared to 10B cross section (3840 barns). Nevertheless, this feasibility 
limits the strength of the neutron beam due to the abundance of these elements (5). 
 
Figure 3: The principle of BNCT. If boron atoms can be selectively accumulated in tumor cells, 
neutron irradiation results in the emission of ionizing particles which result in tumor cell damage 
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For boron to be able to capture a neutron, the neutrons need to have low energy (thermal 
neutrons; E < 0.5 eV) when reaching the boron atoms. However, thermal neutrons only 
have a very limited depth of penetration into tissue (3-4 cm) and are only of use for skin 
tumors like melanoma. Nowadays neutrons with higher energy (epithermal neutrons, 
> 0.5 eV < 10 keV) are used for the beam. They lose energy during the penetration (8 cm) 
of the tissue and reach the boron enriched compound with the energy of thermal neutrons 
(5). 
 
The advantages of BNCT are the high efficiency, high selectivity towards tumor tissue and a 
high chance to target multicentric deposits of tumors at the same time. However, these 
features can only be reached by a high dose gradient between cancer cells and healthy tissue. 
Recent research is focused on (i) the availability of neutrons via neutron accelerators to 
enable BNCT away from nuclear reactors; (ii) the optimization of neutron penetration into 
tissue; and (iii) delivering a sufficient amount of boron-10 while keeping the ratio between 
tumor and normal tissue high to guarantee low background and therefore minimize side 
effects. 
1.2.2 Boron delivery agents - general requirements 
Many requirements are given for a successful boron delivery agent besides low toxicity. It 
needs to be able to deliver a sufficient amount of boron into the tumor tissue. The aim is to 
reach at least 20 µg 10B/g tumor (~109 atoms/cell). On the other hand, the uptake of boron 
in other tissue should be low, obtaining a ratio of ≥ 5 between tumor to normal tissue and 
tumor to blood. Furthermore, a rapid clearance from blood and normal tissue is desired, but 
persistence in tumor until and during neutron irradiation should happen (5). The 
development of boron-10 delivery agents capable to selectively accumulate in tumor cells at 
a therapeutic dose still remains a major challenge.  
1.2.3 From history to recent research 
In 1932 Chadwick discovered the neutron which was the fundament for Locher to describe 
in 1936 the principle of a neutron capture therapy for cancer (6). However, the first actual 
performance of a BNCT trial on a malignant glioma was not conducted until 1951, when 
finally, the graphite research reactor in Brookhaven was available as neutron source (4).  
The very first compounds to deliver 10B into tumor tissue were in the 1950s boric acid and 
its derivatives. However, they are non-selective and have a very low retention time in tumor 
tissue (see Table 1). The second generation of boron delivery agents was developed in the 
1960s. The compounds were boron-rich bio-molecules with low molecular weight, such as 
carbohydrates, amino acids, nucleic acids and small peptides. The advantages were the low 
toxicity and an increased residence time in the tumor when evaluated in animal models. The 
only two BNCT delivery agents currently used in clinical trials are from that second 
generation. Sodium mercaptoundecahydro-closo-dodecaborate (Na2B12H11SH), commonly 
known as sodium borocaptate (BSH), and the boron containing amino acid (L)-4-dihydroxy-
borylphenylalanine, known as boronophenylalanine (BPA) (Figure 4) (7; 8; 9). However, 
none of them fulfills the required criteria as described above. Most commonly used for high 
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selectivity and retention time, a high variety in tumor uptake among tumor regions as well as 
between patients (10). 
    
Figure 4: Chemical structures of sodium Borocaptate (BSH, left) and boronophenylalanine (BPA, 
right); currently the only compounds used in the clinics.  
For further improvement, compounds have to be enriched with a number of boron atoms 
as high as possible, in order to deliver a sufficient amount into tumor tissue. One alternative 
to achieve this is to attach one or more polyhedral borane anions or carboranes (boron 
clusters) to small, tumor targeting bio-molecules or to monoclonal antibodies. One such 
boron cluster analogue is the so called COSAN (cobalt bis(dicarbollide)), which is a 
metallocarborane in which a cobalt atom is sandwiched between two carboranyl clusters (11). 
The net charge of the complex, which is delocalized over the whole cluster, is -1, which 
makes COSAN an amphiphilic compound (Figure 5). 
 
Figure 5: Structure of COSAN. 
This third generation of delivery agents was hence able to transfer a higher amount of 10B 
into the tumor when coupled to targeting moieties (9; 10; 12). In Table 1 an overview of the 
three generations of boron delivery agents is shown. 
Table 1: Progress of delivery agents since the 1950th with boric acid derivatives as first generation. 
The second generation refers to boron-rich bio-molecules with low molecular weight, whereas the 














Boronated amino acid (BPA) 
 
Carbohydrate with boron cluster 
Further progress focused on the fact that the effect of BNCT is proportional to the number 
of 10B atoms accumulated in tumor cells. Hence, macromolecules such as polymers and 
dendrimers (Figure 6) containing a high number of boron atoms were developed and linked 
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become promising BNCT drug candidates. However, all of them present certain limitations 
and none of them has replaced BPA and BSH, which are still the two main compounds used 
in clinical practice. Hence, there is still room for improvements: the side effects, which occur 
mainly through insufficient tumor-to-healthy tissue ratios, still need to be reduced. 
Additionally, compounds capable to accumulate a high amount of 10B atoms in different 
types of tumors still need to be developed. 
 
Figure 6: Example of a heavy boronated dendrimer (13). 
1.2.4 Nanomaterials as boron delivery agents  
Nanoparticles (NPs) can be defined as particles with a size lower than 100 nm in at least one 
dimension. Due to their small size, their physic-chemical properties differ from bulk 
materials. Additionally, NPs present a high surface to volume ratio, can be functionalized 
with a wide range of molecules and loaded with significant amount of cargo. Because of this, 
they have emerged as key elements in the drug development pipeline. This fact is even more 
relevant in oncology, where the differences between tumor and healthy tissue allow passive 
targeting by the enhanced permeability and retention (EPR) effect. EPR is based on the 
nature of most tumors to grow fast, which results in the need to change tissue conditions. 
Angiogenesis, the growth of additional blood vessel out of existing ones, is present. 
However, these new vessels are leaky, the permeability for NPs from blood to tissue is 
enhanced, and also the lymphatic system is less developed which leads to a prolonged 
retention time of NPs in tumor tissue (Figure 7) (14; 15). 
 
Figure 7: EPR effect. The process of neoangeogenesis occurring in tumors results in leaky 
vasculature with an immature lymphatic drainage, facilitating penetration of nanoparticles from blood 
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The emergence of NPs in biomedicine has also impacted BNCT, and nanosystems have 
gained attention as boron delivery agents. The idea is to achieve a high boron loading, a 
longer circulation half-life and passive tumor targeting through the EPR effect. Liposomes, 
as example, are able to carry small boronated molecules both in their lipophilic bilayer and/or 
in their hydrophilic core (Figure 8, left) (16). Also, Micelles and other nanomaterials like 
carbon nanotubes (Figure 8, right) (17) and silicon nanowires are in research. In this project, 
however, gold nanoparticles as well as boron carbon dots are chosen as delivery agents. 
    
Figure 8: Left: Liposome, containing boronated molecules (16), right: boron cluster on a carbon 
nanotube (adapted from (17)). 
1.2.4.1 Gold nanoparticles 
Gold nanoparticles (AuNP) are one of the key materials in biomedicine. They are suitable as 
drug delivery agents for several reasons. They are biocompatible, have low toxicity, are 
tunable in shape and size (which affects their biodistribution) and easy to functionalize with 
high loadings on their surface (18). There are, among others, spherical NPs, nanorods (NR) 
and gold stars which can be easily modified on their surface by a covalent sulfide bonding. 
To influence the circulation time, surface and charge of the particles can be modified. 
Positively charged particles have a higher rate of internalization, whereas negatively charged 
particles typically show a longer blood circulation time (19). Another advantage is the 
possibility to synthesize AuNP in aqueous solutions, which makes the transfer to 
physiological media easy. Many different strategies have been reported for the preparation 
of AuNP (20), being the most commonly employed the direct reduction of chloroauric acid 
(HAuCl4) in the presence of e.g. sodium borohydride or citrate, which results in the 
formation of nearly monodisperse AuNP in sizes up to 200 nm (21). 
In this work we focused on small spherical AuNPs (core: 3-5 nm, shell: 10-15 nm) loaded 
with COSAN (see 1.2.3 From history to recent research). The low size results in a high 
surface area to volume ratio which allows heavy loading with therapeutic agents next to other 
functionalization. Furthermore, the biodistribution of smaller particles show increased 
accumulation and penetration into tumor tissue through the EPR effect (14).  
1.2.4.2 Carbon Dots 
Carbon dots (CDs) are part of the carbon allotrope family and have gained increasing 
attention since their discovery in 2004 by Scrivens et al. (22). They are quasi-spherical, smaller 
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of carbon next to hydrogen, oxygen and nitrogen. The benefits of CDs are their optical 
characteristics with an intense fluorescence together with flexible physio-chemical properties 
(e.g. hydrophilic or hydrophobic) due to variations in their synthesis and varying functional 
groups on the surface, leading to a broad field for application like metal detection, solar cells 
and biological approaches such as drug delivery agents (23). Another advantage besides their 
flexibility is a rather easy, usually one step synthesis via microwave out of relatively 
inexpensive compounds such as citric acid and ethylene diamine. 
Even though, the detailed mechanism of the formation of CDs is still unclear and surely 
different for each type of dots. However, it is commonly accepted that the major steps are 
polymerization of the single compounds followed by carbonization and formation of the 
CDs (Figure 9) (23). The most common functional groups left on the surface on hydrophilic 
CDs are carboxyl-, hydroxyl- and/or amino- groups (24). 
 
Figure 9: Schematic mechanism of CDs formation (23). 
In this work we focused on hydrophilic CDs due to the advantage that physiological buffers 
can be used as solvents and therefore, the particles can be used in biological systems. Other 
than the AuNPs, where boron was attached at the surface of the particles, carbon dots can 
be doped with boron, forming so called Boron Carbon Dots (B-CDs), using e.g. sodium 
tetraborate to form the core of the particles. 
1.3 Pre-targeting 
1.3.1 Bioorthogonal ‘click’ reaction 
Pre-targeting is based on a certain type of a chemical reaction which can occur in vivo, the 
bioorthogonal ‘click’ reaction. A coupling reaction in vivo needs to fulfill very specific 
properties. Certainly, nontoxicity of the reaction compounds but also of any possible side 
products generated by the coupling reaction. Furthermore, the reaction needs to be 
optimized for aqueous medium at the temperature of 37 °C. To gain good yields in biological 
systems a fast reaction rate which enables the coupling reaction even with very low 
concentrations is essential. If the reaction additionally does not interfere with any other 
native biochemical processes, it belongs to the field of bioorthogonal chemistry. 
Recently several such reactions were investigated and described (25; 26; 27). But one of these 
showed outstanding qualities: The inverse-electron-demand Diels Alder coupling between a 
tetrazine derivative (Tz, diene) and a trans-cyclooctene (TCO, dienophile) derivative 
(Figure 10) (28). Opposite to most click reactions described so far, this reaction does not 
need a catalyst. Moreover, the only by-product is N2, which is nontoxic, and high yields are 
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Figure 10: Scheme of an inverse-electron-demand Diels Alder reaction, example from (29). 
1.3.2 The principle of pre-targeting 
The origin of the pre-targeting strategy arose in the field of radioimmunology where a 
radiolabeled monoclonal antibody (mAb) accumulates in tumor tissue by binding to a specific 
target. This way, depending on the radionuclide, either imaging or therapy can be performed. 
However, one major drawback is a high radiation dose for the patient due to slow distribution 
and clearance (days) of mAbs from blood and healthy tissue. To prevent negative side effects 
by radiation doses to non-tumor tissue, the strategy of pre-targeting was introduced (15; 28; 
30; 31). In such a strategy, a functionalized mAb, which is enabled to undergo a 
bioorthogonal ‘click’ reaction is injected intravenously. After its accumulation in tumor tissue 
and clearance from blood and healthy tissue, a small molecule carrying the radionuclide is 
injected. This small compound distributes and clears fast from the body. However, passing 
through the tumor it will ‘click’ to the antibody and remain, resulting in high sensitivity and 
low background signal (Figure 11). 
In the context of pre-targeting, there are certain key factors that need to be taken into 
consideration: (i) a high, selective (or preferential) accumulation of the mAb in the target 
tissue (in this case, the tumor) is required; (ii) the second compound, capable to undergo the 
bioorthogonal click reaction with the mAb, needs to be injected once the mAb is cleared 
from the blood, in order to avoid the click reaction to occur in the blood, which would 
prevent the reaction taking place in the tumor; and (iii) the second compound needs to clear 
fast from the body. In the context of imaging, this results in a decrease of background signal 
and hence enhances image quality and sensitivity. In the context of therapy, the fast clearance 
prevents high radiation dose in healthy tissue. In most cases, the pre-targeting strategy does 
not result in higher accumulation than direct targeting, although higher tumor to healthy 
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Figure 11: Original pre-targeting strategy. First, a functionalized mAb is administered, which 
accumulates in the tumor tissue (1). After clearance of the unbound mAb (2), the second component 
is administered (3), and the bioorthogonal reaction occurs in the tumor (4) with consequent 
entrapment.   
Because of the above-mentioned requirements, the second component is typically a small 
molecule. However, in this work we envisaged the possibility to apply the pre-targeting 
strategy from a slightly different perspective. Our idea was based on the following rationale: 
First, a TCO-functionalized mAb is administered and accumulates in tumor tissue by binding 
to an overexpressed receptor. After the slow clearance, fast clearing boron loaded NPs 
(AuNPs or B-CDs) functionalized with tetrazine moieties (to enable the click reaction with 
TCO-functionalized mAbs) are injected. By the time that a high concentration of particles 
had reached the tumor tissue and cleared from other tissue, the irradiation with neutrons can 
take place to initiate the nuclear reaction of 10B into 7Li3+ with the release of alpha particles 
which leads to the desired cell death in tumor tissue (Figure 12). 
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1.3.3 Why pre-targeting? 
Delivery agents, such as NPs, should have a sufficient size, to ensure uptake and retention 
in the desired tissue like a tumor (32). However, this property is non-specific and therefore 
the retention is also prolonged in other tissues such as the liver which could lead to non-
desired side effects (e.g. drug induced liver injury). Moving to smaller particles the situation 
can be reversed; the clearance is too fast, the particles are not retained in tissue and are not 
able to deliver their therapeutic effect, yet toxicity is usually very low (33). Introducing pre-
targeting, using small, but highly boronated NPs, functionalized with a tetrazine moiety, the 
advantages of small and fast clearing agents can be met, that is, fast clearance from blood 
and healthy tissue and low toxicity, yet, the retention in tumor tissue is assured by the click 
reaction to the pre-injected antibody.  
1.4 The need for tracking: Nuclear imaging 
One of the key aspects in BNCT is the appropriate selection of the time window in which 
boron irradiation needs to be applied, this is, when after administration of the drug the boron 
accumulation in the tumor and both the tumor to healthy tissue and the tumor to blood 
ratios are maximal, in order to maximize therapeutic effect while minimizing off target side 
effects. Hence, there is a need to determine the pharmacokinetic properties of new chemical 
entities before their evaluation in therapeutic experiments.  This information can be obtained 
using classical pharmacokinetic studies (e.g. fluid and organ extraction followed by analysis 
using chromatographic techniques). However, an elegant and non-invasive alternative relies 
in nuclear imaging techniques.   
Nuclear imaging includes single photon emission computerized tomography (SPECT) and 
positron emission tomography (PET). Both in vivo imaging techniques are ultra-sensitive and 
minimally invasive. After administration of a trace amount of a gamma (SPECT) or positron 
(PET) emitting labeled compound, the ultimately occurring high energy photons (gamma 
ray) are detected. The origin of the decay and therefore the location of the radiolabel can be 
quantitatively calculated. These techniques are often combined with computerized 
tomography (CT) or newly also with magnetic resonance imaging (MRI) to achieve both, 
anatomical (CT, MRI) and metabolic (SPECT, PET) information. In this work we focused 
on PET-CT which has higher spatiotemporal resolution over SPECT. 
1.4.1 Positron emission tomography 
Positron emission tomography (PET) is an excellent tool to image biochemical processes in 
vivo. In PET, the distribution of a compound labeled with a positron emitter (radiotracer) can 
be followed and represented in a three-dimensional image. In most cases, the radiotracers 
accumulate in a certain area of the body and hence, make them visible by photon detectors. 
PET is most frequently used in cardiology (34), neurological (35) and oncological (36) 
diseases either for diagnosis and/or therapy progress. However, also in research PET is a 
very helpful tool (see 1.4.2 PET in drug development). 
Positron emitting isotopes decay by a β+-emission. The nucleus of these nuclides is rich in 
protons. To stabilize this unbalanced situation a proton (p) turns into a neutron (n) whereas 
a positron (β +, antiparticle of the electron, therefore also written as ‘e+’) and an electron-
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the spin preservation. The positron in contrast takes the other part of the energy and balances 
the charge. Following, the equations of the β+ decay are shown: 1) nucleus level, 2) isotopic 
level. 
𝑝1
1 + → 𝑛0
1 + 𝑒1
0 + + 𝜈𝑒0




0 + + 𝜈𝑒0
0 + 𝑄    (2) 
 
Figure 13: Schematic representation of the radioactive decay by positron emission. 
During this procedure the nuclide (X) transforms into another element (Y), the daughter 
product. Q describes the energy of the decay and the difference of the mass of the 
transformation (E = mc2). 
The emitted positron (β+), which has a specific kinetic energy related to the nuclide (although 
positrons are not emitted with a single energy but following an energy distribution, which is 
characteristic for each positron emitter), will interact with an electron of the environment 
after losing energy to a certain point and a short-lived positronium will arise (37). The 
positronium in turn decays by annihilation, a procedure in which two gamma quanta 
(photons) with the energy of 511 keV are transmitted to the opposite side of each other 
(180°). These photons are detected by PET scanners. The detection of two photons 
simultaneously by two opposite detectors (coincidence detection) defines a line of response 
(LOR). The detection of hundreds of thousands of coincidences enables the reconstruction 
of a three-dimensional image which contains quantitative information of the regional 
distribution of the radiotracer.  A drawback in PET is the fact that the emission of the 
positron is not in the exact same place as the emission of the two photons. This difference 
coincides with the distance that the positron travels before annihilating (positron range; 
typically a few millimeters), and depends on the energy of the emitted positron. Ultimately, 
this fact results in a decreased spatial resolution. However, new devices are able to statistically 
correct for this to a certain extent, and the resolution of modern PET scanners (especially 
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Figure 14: Scheme of PET principle. A positron is emitted and after travelling a certain distance 
(positron range) it annihilates with an electron, resulting in the formation of 2 photons (511 keV 
each) which are emitted in opposite directions and detected by special detectors as coincidence 
events.  
A competitive way for proton rich nuclei to stabilize is to decay via electron capture (EC). A 
proton in the nucleus absorbs an electron from the close K- or L- electron shell. The proton 
converts into a neutron with the emission of an electron-neutrino (Figure 15). The generated 
daughter nuclide is in an excited state and therefore releases excitement via x-ray or Auger 
electrons (filling of the inner-shell vacancy by an electron of a higher-energy shell of the same 
atom, the thereby released energy emits another electron and a chain reaction can arise). 
Following, the equations of the EC are shown: 3) nucleus level, 4) isotopic level. 
𝑝1
1 + + 𝑒1
0 − → 𝑛0
1 + 𝜈𝑒0
0 + 𝑄     (3) 
𝑋𝑁𝑍
𝐴 + 𝑒1
0 − → 𝑌𝑁+1𝑍−1
𝐴 + 𝜈𝑒0
0 + 𝑄    (4) 
 
Figure 15: Schematic representation of the radioactive decay by electron capture. 
Other than in the β+ decay where the freed energy is split between the β+-particle and the 
neutrino which leads to a continuous energy spectrum, here the entire energy is carried by 
the neutrino and gives a single sharp energy profile. However, as no positron is emitted this 
decay is not useful for PET and radionuclides need to be selected carefully with a high 
percentage of β+ decay, as other radiation types do not contribute to image quality but 
increase the radiation dose to the investigated subject. 
1.4.2 PET in drug development 
Besides the use of PET in clinics for diagnostic and to follow the progress of a disease and 
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pharmacokinetic properties (like biodistribution and metabolism) but also in proof of target 
(does the drug aim for the predicted target?), proof of mechanism (is a downstream 
component affected?) and proof of efficacy (to predict the outcome before clinical studies) 
of a new drug (39).  
Irrespective of the application, it has to be considered that a radionuclide (positron emitter) 
needs to be inserted into the new drug. Ideally the radioisotope ‘simply’ exchanges an existing 
stable atom, e.g. 11C for 12C, or 13N for 14N. Yet, for more complex compounds such as 
proteins, antibodies or NPs, this way of radiolabeling is not possible. Hence, the radionuclide 
is additionally attached and therefore the structure of the compound changed. In these cases, 
it becomes necessary to evaluate if behavior and properties remain unaffected. Furthermore, 
it is obligatory to keep in mind that the PET image represents the distribution of the 
radionuclide, not to the actual drug. That is, if the radiolabeling is not stable, or if the drug 
decomposes in vivo, the visible PET image is due to the fragment which contains the 
radionuclide and misinterpretation of the obtained image is possible. Because of this, 
evaluation of the stability of the label and determination of metabolism is paramount for 
proper image interpretation.  
In the particular case of pre-targeting for therapeutic applications as proposed in this PhD 
thesis, PET is very helpful as it enables: (i) the determination of the ideal time window when 
the second component has to be administered. This is, the time point at which the 
concentration of the mAb in the tumor is maximum, which can be determined by 
radiolabeling the mAb and performing PET studies at different time points after 
administration; and (ii) the time at which neutron irradiation should be performed, that is, 
the time window at which the accumulation of the second component in the tumor is 
maximum. This can be determined by radiolabeling the second component (in our case, the 
NP), and performing PET studies at different time points after administration (Figure 16). 
The radiolabeling strategy and the radionuclide to be used depend on different factors, as 
discussed below (see 1.4.3 PET nuclides).  
 
Figure 16: Timing in pre-targeting. PET imaging can provide information about the concentration 
of the labeled species over time, thus enabling appropriate selection of the time window to proceed 
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1.4.3 PET nuclides 
To acquire good-quality PET images, no matter if in clinic or in research, the choice of the 
radionuclide is critical. The most important PET nuclides are summarized in Table 2. 







in H20 [mm] 
Method of 
production 






13N 9.96 min β+ (100.0) 1.19 5.0 
12C(d,n)13N 
16O(p,α)13N 






18F 109.65 min 
β+ (96.9) 
EC (3.1) 
0.63 2.2 18O(p,n)18F 













89Zr 78.41 h 
β+ (22.3) 
EC (76.6) 
0.90 3.8 89Y(p,n)89Zr 
 
The selection of the nuclide depends on many different factors. The main required property 
for a PET nuclide is obviously the β+-decay, in best cases with a high percentage. But, also 
the energy of the positron is relevant. It should be low to have a short positron range (see 
1.4.1 Positron emission tomography) which will improve the resolution of the image. 
Another important characteristic is the half-life. It is to be taken into account that the 
radiotracer needs to be synthesized and purified, then passes a quality-control and sometimes 
needs to be delivered to another institution. Furthermore, the half-life needs to suit the 
biological half-life of the molecule under investigation so that the subject is not affected by 
a high radiation dose but the radiotracer is still detectable during its whole process.  
Besides, the chemical properties of the nuclide will dictate the way of radiolabeling, either by 
covalent binding of non-metal nuclides or through the use of a chelator which will generate 
a stable complex with a metal nuclide. 
Finally, the availability of the nuclide places a role in the selection. Some are synthesized by 
nuclide generators (e.g. 68Ga which is produced in commercially available 68Ge/68Ga 
generators) which are usually very easy to handle for daily hospital work. Many others are 
generated in a cyclotron (e.g. 18F, 11C, 89Zr, 64Cu). This equipment is much more complex and 
more expensive in maintenance. Thus, just some institutions are able to afford it. Finally, 
nuclides can be synthesized within a nuclear reactor which needs again more personal care, 
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As described above there are many factors to be considered when choosing a radionuclide. 
In this study very different components with different requirements concerning the nuclide 
had to be labeled. In the following section, a brief introduction to the PET radionuclides 
used in the context of this PhD thesis is included.   
Nuclide for antibodies - 89Zr 
 
The biodistribution of monoclonal antibodies is very slow. Therefore, a nuclide needs to be 
selected which is able to follow its nature, thus a nuclide with a long enough half-life. At 
present the most common nuclide in immuno-PET is Zirconium-89 (89Zr). Its half-life is 
3.27 days (78.41 h) and is therefore ideal to monitor the pharmacokinetic of mAbs in tumors.  
The most common way to produce 89Zr is the bombardment of an natural yttrium foil with 
protons in a cyclotron via the nuclear reaction of 89Y(p,n)89Zr (40). After irradiation the metal 
foil is dissolved in acid (6 M HCl), then purified by a hydroxamate column (e.g. functionalized 
Waters Sep-Pak® Plus Accell CM cation exchanged resin), which can selectively trap 89Zr 
and be finally eluted with oxalic acid (41).  
The decay of 89Zr to stable Yttrium-89 (89Y) occurs to 76.6 % by electron capture (EC) and 
22.3 % by positron emission (β+-decay), which makes it suitable for PET. However, before 
stable 89Y forms, a metastate of 89mY is generated which de-excites in only 16 seconds to its 
stable nuclide, with emission of a gamma ray with an energy of 909 keV. A scheme of the 
decay is shown in Figure 17. 
       
Figure 17: Decay scheme for 89Zr (max energy shown). 
Finally, the chemical route for radiolabeling the mAb needs to be considered. As 89Zr is a 
metal, a covalently bound chelator is used to build a stable complex in physiological 
89Zr properties at a glance 
t1/2 = 3.3 d = 78.4 h = 4704.6 min 
EC: 76.6 % 
β+: 22.3 % 
 Eave(β+) = 397 keV 
Emax(β+) = 897 keV 
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conditions with the nuclide. To date desferrioxamine (DFO) - chelators are the state of the 
art. The labeling conditions are very mild which allows to label mAbs without denaturizing 
them. The p-isothiocyanatobenzyl-DFO (p-SCN-Bz-DFO) can be covalently bound to 
amine groups of lysine residues present in the amino acid sequence forming a thiourea bond 
(Figure 18). Recently, Vugts et al. are investigating more stable chelator-radionuclide 
complexes like the tetrahydroxamate chelator called DFO* (DFO star) (42). 
 
Figure 18: Schematic representation of mAb conjugation with p-SCN-Bz-DFO and labeling with 
89Zr  
Nuclide for AuNP- 64Cu 
 
There are several different methods to radiolabel NPs with a metal-nuclide, e.g. (i) using pre-
radiolabeled synthons, which are incorporated into the NPs during production; (ii) direct NP 
activation where the radioisotope is generated in situ using nuclear reactions; and (iii) after-
loading, where the isotope is incorporated, attached or entrapped after the synthesis of the 
NPs (43). Labeling on the surface allows adding the radiolabel as last step after the synthesis 
and functionalization of the particles, simplifying the handling during those procedures and 
minimizing radiation dose to the operator. However, the labeling is an additional moiety, 
which might change the surface properties. Therefore, in this work we focused on the 
incorporation of the radio metal into the gold core during synthesis, by doping the core with 
64Cu (44). Even though the radiolabeling yield is usually lower, the high stability of the label 
and preventing changes to the properties are significant advantages (43). 
Using 64Cu with its half-life of almost 13 hours gives the necessary flexibility for the 
evaluation of NPs. It is used for both, smaller molecules as well as bigger and slower clearing 
components. Therefore, it is ideal to monitor smaller AuNPs, which distribute faster than 
big compounds like antibodies, but slower than small molecules. 
The production of 64Cu can be done either with a cyclotron or a nuclear reactor. However, 
the most common methodology is by the 64Ni(p,n)64Cu (45) nuclear reaction. In this process, 
64Cu properties at a glance 
t1/2 = 12.7 h = 762.0 min 
EC: 43.8 % 
β- = 38.4 % 
β+ = 17.8 % 
 Eave(β+) = 278 keV 
Emax(β+) = 653 keV 
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a gold disk, electroplated with enriched nickel-64 is irradiated in the cyclotron with protons. 
After the bombardment 64Cu is separated from 64Ni by an ion exchange column. The 
enriched nickel can be recovered and reused which makes the pricey procedure more cost-
efficient (46). 
The isotope Copper-64 is highly unusual as it decays by three different processes; into 64Ni 
with 43.8 % electron capture and 17.8 % positron emission, which makes it suitable for PET, 
and with 38.4 % to 64Zn by beta minus (electron, β-) emission, which makes it also eligible 
for therapy (Figure 19). 
 
Figure 19: Decay scheme for 64Cu (max energy shown). 
Nuclide for B-CDs - 18F 
 
Whereas antibodies and AuNPs are rather slow distributed and cleared from the in vivo 
subject by elimination mainly through liver and spleen, B-CDs are eliminated in only minutes 
through the kidneys. Therefore, a radionuclide with shorter half-life can be chosen. 18F is 
probably the most used PET-nuclide and with a half-life of close to 2 hours ideal to evaluate 
the distribution of B-CDs. However, other than 89Zr and 64Cu, 18F is no metal and needs to 
be coupled to the molecule by covalent bonding. Yet, the possible coupling reactions are 
limited to the product of the 18F production by cyclotron. Its either produced as [18F]F- or as 
[18F]F2 enabling fluorinations by nucleophilic or electrophilic substitution, respectively (47). 
Furthermore, a late introducing of the radiolabel in the synthesis is favored. Therefore, and 
to increase possibilities of radiolabeling, so called prosthetic groups are introduced. Those 
are small organic molecules, radiolabeled in very few steps, containing a functional group 
which enables easy binding to another component, like e.g. NPs (48; 49). 
18F properties at a glance 
t1/2 = 1.8 h = 109.8 min 
EC: 3.1 % 
β+: 96.9 % 
 Eave(β+) = 250 keV 
Emax(β+) = 633 keV 
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In this work [18F]F- was produced by irradiating 18O-enriched water ([18O]H2O) with protons 
leading to the nuclear reaction of 18O(p,n)18F. A precursor (TfO-Me3NPyTFP
+) was 
fluorinated to obtain the prosthetic group [18F]F-Py-TFP (Figure 20) which could be coupled 
to amine residues of the B-CDs (50). 
 
Figure 20: [18F]F-Py-TFP prosthetic group. 
Besides its convenient half-life, a decay into 18O of 97 % by positron emission and only 3 % 
electron capture makes 18F an almost perfect PET nuclide. Furthermore, the low energy of 
its positrons leads to high resolution PET images. A scheme of its decay is shown in 
Figure 21. 
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Chapter 2: Motivation and objectives 
2.1 Justification of the study: the PET3D project 
Drug development usually takes a lot of time, money and resources, such as chemicals, 
biologicals and in vivo subjects. Positron emission tomography (PET) can be used to minimize 
the use of experimental animals, and accelerate the whole process by identifying poor 
candidates at early stages in the process, thus saving time and money while increasing the 
effectiveness to design and develop drugs.  
The PET3D project (PET imaging in Drug Design and Development) originated out of this 
statement. It is a MSCA-ITN (Marie Skłodowska-Curie Actions Innovative Training 
Network), funded by the European Commission under the H2020 – MSCA-ITN-2015 
program (grant agreement No. 675417) for a duration of 4 years (June 2016 – May 2020) (1). 
The aim of the project was to train 15 early stage researchers (ESR), located at 8 different 
institutions in Europe, to become experts in PET imaging and drug development. The 
institutions involved were the University of Aberdeen (with Professor Matteo Zanda as 
project coordinator, later in Loughborough University), the VUmc Amsterdam (now UMC), 
the Vrije Universiteit Brussel, the University of Bergen, CIC biomaGUNE in Donostia-San 
Sebastián (host of this PhD), the European Institute for Molecular Imaging in Münster and 
two industrial partners, Imanova (now Invicro; UK) in London and AstraZeneca in Mölndal 
(Sweden). Covering the main diagnostic/therapeutic areas in which PET is used (oncology, 
cardiovascular and central nervous system) PET3D was coordinated in five research work 
packages (WP) (Figure 1). 
 
Figure 1: Research work packages of the European project PET3D: WP1: ‘Nanoparticles and Small 
Molecule Tracers in Oncology PET Imaging’; WP 2: ‘Biologicals as Tracers in Oncology PET 
Imaging’; WP 3: ‘Pre-targeted Labeling of Biomolecules in Oncology PET Imaging’; WP 4: 
‘Cardiovascular PET Imaging’; WP 5: ‘CNS PET Imaging’. 
The advantages of using PET in drug development have already been discussed in chapter 
one (1.4.2 PET in drug development). Besides the evaluation of pharmacokinetic properties, 
questions like ‘What and where is the disease?’, ‘Is the disease accurately targeted by the therapy?’ and ‘Is 
the treatment effective?’ can be answered before going into the third clinical phase, not only 
preventing a late failure of the drug in the process of evaluation, but also achieving an 
immense improvement in time and cost (2). 
The PhD in hand, titled “A pre-targeting approach to boron neutron capture therapy: 
towards multipurpose Boron-Enriched Therapeutic Agents” was carried out in the frame of 
WP3, ‘Pre-targeted Labeling of Biomolecules in Oncology PET Imaging’. It builds on the 
existing knowledge (including chemistry, radiochemistry, nanotechnology and in vitro and in 
vivo analysis) in the radiochemistry and molecular imaging group at CIC biomaGUNE under 
the supervision of Dr. Jordi Llop. His expertise in boron chemistry, radiochemistry, 
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current research projects, and invited national and international lectures. The core of the 
experimental work was executed at the host institution CIC biomaGUNE in Donostia-San 
Sebastián, Spain. Additionally, secondments were carried out taking advantage of the 
expertise existing in other institutions of PET3D. The expertise in antibodies (conjugation 
and radiolabeling) available in the radiology and nuclear medicine group with Dr. Daniëlle 
Vugts at the VUmc (now UMC) in Amsterdam, Netherlands, and the expertise in medicinal 
chemistry (bioorthogonal click chemistry) at the Institute of Medical Sciences at the 
University of Aberdeen, Scotland, in the group of Prof. Matteo Zanda. 
Cancer, still being the second leading cause of death worldwide (8), brings great need in the 
design and development of new drugs. This PhD focuses on the promising cancer therapy 
of BNCT (see Chapter 1). Even though there are already successful clinical trials being 
conducted, the lack of a boron delivery agent able to deliver a sufficient amount of 10B into 
tumor tissue combined with high selectivity has limited the use of BNCT and impeded the 
move to become a more standardized therapy. To reach the aim of this PhD, the 
development of novel BNCT agents on multi-functionalized NPs, able to selectively 
accumulate boron atoms in tumor tissue using a pre-targeting strategy, the following 
objectives were appointed. 
2.2 Objectives 
The specific objectives of this PhD thesis were: 
1. To select and radiolabel a cancer cell targeting monoclonal antibody (mAb) suitable for 
pre-targeting; to optimize the trans-cyclooctene (TCO) functionalization of the selected 
candidate to enable the in vivo click reaction. 
2. To analyze the randomly conjugated antibody, comparing mass analysis with direct 
methods, to predict the efficiency for pre-targeting. 
3. To investigate the pharmacokinetic properties of the functionalized antibody in a 
subcutaneous tumor mouse model using PET-CT. 
4. To investigate the internalization of the antibody in vitro and in vivo. 
5. To design, synthesize, characterize and radiolabel multifunctionalized nanoparticles (gold 
NPs and boron-carbon dots), heavily loaded with boron to ensure a sufficient delivery 
to tumor tissue, and functionalized with tetrazine to enable the in vivo click reaction with 
the TCO functionalized antibody. 
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3.1 Introduction 
Over the last decades monoclonal antibodies (mAbs) have experienced a huge increase in 
interest as scientific tool as well as human therapeutics. Their unrivaled property is a very 
high specificity towards their target (antigen) with high affinity and avidity. This property is 
due to the antigen binding site of the mAbs (Figure 1). 
 
Figure 1: Schematic structure of an immunoglobulin type mAb (IgG), consisting out of two heavy 
chains (light grey) and two light chains (dark grey), as well as the antigen binding fragment (Fab) and 
the constant fragment (Fc). The black connections visualize disulfide bonds. 
Monoclonal antibodies can be functionalized with a wide variety of molecules to introduce 
different properties. For example, by generating antibody-drug conjugates to act as drug 
carriers in which the targeting properties of the mAb are combined with the therapeutic 
abilities of the drug (1; 2); additionally, they can be functionalized with imaging capabilities 
by attaching radionuclides or fluorescent dies, enabling subsequent in vivo tracking using 
nuclear imaging techniques such as Positron Emission Tomography (PET) or Single Photon 
Emission Computed Tomography (SPECT) (3), or enabling their tracking both at 
microscopic and macroscopic levels using different optical microscope modalities or 
tomographic techniques, respectively (4; 5). Finally, they also can be functionalized with 
molecules capable to undergo bioorthogonal reactions in vivo, to be applicable in pre-targeting 
strategies (6; 7; 8). 
When tackling the modification of mAbs, several aspects are to be considered. Most 
important, the conditions need to be mild to prevent denaturation and degradation of the 
protein and therefore loss of its biological function. Then, the newly formed bond must be 
stable under physiological conditions and finally it must not significantly compromise the 
specificity of the antibody-antigen binding site. To overcome issues related to the latter, over 
the last years many groups have investigated site-specific conjugation (3; 9; 10; 11), which 
consists of conjugating the functionality to a selective functional group of the mAb, usually 
present on both heavy chains. Common methods are functionalizing the glycans or reducing 
the sulfide bonds and using the resulting reactive groups to couple the ligand (Figure 2). 
Advantages of the site-selective conjugation are a defined number of ligands per antibody, 
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Figure 2: Schematic presentation of site-specific conjugation by reducing disulfide bonds (black) or 
functionalizing glycans (blue). 
However, more frequently used is the random conjugation (6; 12; 13; 14), where the ligand 
is attached to the accessible primary amines group of lysine residues via N-
hydroxysuccinimide ester (NHS-ester) or isothiocyanates, or to the thiol group of cysteine 
residues via maleimides through thio-Michael addition reactions (Figure 3). Disadvantages 
of those methods are the lack of site-specificity and stoichiometric control, the production 
of a high heterogeneity of conjugates and the risk of modifications to the antibody-antigen 
binding site (15). Despite these aspects, the mild reaction conditions together with the 
straightforward and rather easy procedure to functionalize mAbs are advantage enough to 
be the preferred method. 
 
Figure 3: Schematic presentation of random conjugation by using primary amine groups of lysine 
side chains or thiol groups of cysteine side chains. 
For this PhD project two different antibody modifications were performed, using random 
conjugation to lysine residues: (i) the conjugation with a metal chelator, a desferrioxamine 
derivative (p-NCS-Bz-DFO), to enable radiolabeling with the PET radionuclide Zirconium-
89 (89Zr); and (ii) the functionalization with trans-cyclooctene (TCO-NHS) to allow the 
bioorthogonal click reaction with a tetrazine functionalized component required for the pre-
targeting strategy. Each mixture of conjugates (Figure 4) was analyzed using a variety of 
analytical methods, including a direct titration method (photometric for TCO, radiometric 
for DFO) and mass analysis, including MALDI/TOF MS (Matrix-Assisted Laser 
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(Ultra High Performance Liquid Chromatography / Electrospray ionization - Time Of Flight 
Mass Spectrometry). The approach, using different analytical methods, was initiated to enable 
comparison between the direct method, which gives an average number only of available 
moieties, and the mass analysis, which gives an average number of all bound moieties per 
mAb and, with the help of mathematical fittings, the distribution of the different conjugates 
present in the heterogenic mixture. 
 
Figure 4: Schematic presentation of the obtained heterogenic conjugates after random conjugation 
to lysine residues. Although the average ratio of ligand per mAb is usually determined, closer insight 
in the reality of the obtained heterogenic mixture is more challenging. 
Conjugation and analysis have been performed on two different antibodies, both FDA and 
EMA approved. Bevacizumab (sold under the trade name Avastin®) is a humanized mAb 
that targets VEGF-A (vascular endothelial growth factor) and hence inhibits the growth of 
blood vessels (16). Due to the presence of angiogenesis in most cancer types, VEGF-A is 
generally overexpressed in tumors. Trastuzumab (sold under the trade name Herceptin®), 
also humanized, targets HER2, an extracellular domain of the epidermal growth factor 
receptor (EGFR) (16). The pathway of HER2 leads to cell division and growth. By 
Trastuzumab binding to HER2, an immune-mediated response is induced, which causes 
internalization and down-regulation of HER2, hence suppressing cell growth. Herceptin is 
used to treat gastric tumors as well as breast cancer in which HER2 is overexpressed. 
3.2 Objectives 
The specific objectives of this work were: 
1. To conjugate the two antibodies, Bevacizumab and Trastuzumab, in different molar 
ratios with the ligands TCO-NHS or p-NCS-Bz-DFO. 
2. To analyze the obtained conjugates with direct titration methods; photometric for 
TCO, radiometric for DFO. 
3. To analyze the obtained conjugates with mass analysis: MALDI/TOF MS and 
UPLC/ESI-TOF MS, and compare the results to those obtained in Objective 2. 
3.3 Results and discussion 
3.3.1 TCO conjugation – direct method 
TCO is usually attached to mAbs to enable pre-targeting strategies. For an efficient in vivo 
click reaction to occur, the TCO not only needs to be attached to the mAb, but also available 




Chapter 3: Conjugation and analysis of monoclonal antibodies 
characterization it is important to determine not only the average ratio of TCO-moieties per 
antibody after random conjugation, but also those that are available for reaction, as a small 
moiety like TCO (152 Da; compared to the antibody: 150 kDa) could be masked by 
hydrophobic interactions with the mAb (17). 
First, we tackled the determination of available TCO-groups, information that can be 
obtained using titration methods. Therefore, we used a tetrazine-fluorophore compound (6-
methyl-tetrazine-sulfo-Cy3 = mTzCy3), which undergoes a fast click reaction with the TCO 
moiety, to establish a direct photometric method. In brief, the antibody was conjugated with 
different molar-equivalents of TCO-NHS (60 min at room temperature), purified via spin 
filtration, and mTzCy3 added to induce the click reaction (Figure 5). After incubation (5 min 
at room temperature) the functionalized mAb was purified again, the UV-VIS-spectra 
measured and the concentration of both, mAb and fluorophore, determined. 
 
Figure 5: TCO conjugation followed by mTzCy3 coupling to determine the average ratio of 
TCO/mAb via titration, a direct photometric method. 
UV-VIS-spectrophotometric measurements were carried out with a NanoDrop® 
Spectrophotometer. It uses the Lambeert-Beer’s Law (𝐴 = ɛ ∗ 𝑙 ∗ 𝑐; A = absorbance, ɛ = 
extinction coefficient, l = path length, c = concentration) to calculate the concentration from 








 (taken from datasheet of Jena Bioscience). The advantages of NanoDrop® 
are the fast analysis and the small amount of sample necessary per measurement.  
However, to ensure plausibility of the method and investigate possible interferences during 
the assays (which could alter the determination of concentration needed to calculate the ratio 
of available TCO per mAb), a preliminary evaluation was performed by measuring the 
absorbance of different compounds (containing functional groups which are involved in the 
protocol) at different concentrations in an individual fashion (Figure 6) and after the click 
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Figure 6: UV-VIS spectra of A) mTzNH2, B) mTzCy3, C) TCO-OH, D) TCO-NHS, E) NHS-OH, 
F) mAb. 
The spectra show that TCO itself has no light absorbance. However, both tetrazine (A) and 
NHS (E) spectra show their maximum absorbance at around 260 nm which can also be 
found in the TCO-NHS (D) spectrum (Figure 6). Taking into account that the maximum 
absorbance of the mAb is at 280 nm (F) interference could apply. However, during the 
procedure tetrazine moieties would be clicked to TCO moieties resulting in a different 
chemical structure, which may lead to a different absorbance profile. The NHS moiety on 
the other hand is cleaved off during the conjugation of the mAb with TCO-NHS and isn’t 
present anymore after purification. Hence, measurements of clicked compounds in different 
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Figure 7: UV-VIS spectra after click reaction in different ratios to each other of A) mTzNH2 + 
TCO-OH, B) mTzNH2 + TCO-NHS, C) mTzCy3 + TCO-OH, D) mTzCy3 + TCO-NHS. 
Looking at the spectrum after the click reaction between mTzNH2 and TCO-OH (A) the 
signal at 260 nm disappears, whereas after the addition of TCO-NHS the signal can still be 
observed due to the NHS moiety (B). The same behavior can be witnessed using mTzCy3 
instead of mTzNH2 (C, D). Hence, the chemical change of tetrazine during the click reaction 
resolves the possible interference with the mAb signal. 
To further evaluate the method a titration with mTzCy3 was carried out to assure a 
quantitative binding of mTzCy3 to all available TCO moieties. Therefore, Bevacizumab was 
reacted with 30 eq. TCO-NHS for 90 min at RT, purified, split into 6 fractions and 3 each 
incubated with either 1/6th or 1/3rd moles mTzCy3 of the initial amount of TCO-NHS 
(divided by 6 for the 6 fractions). In this case, using initially 30 eq. of TCO-NHS per mAb it 
would be 5 and 10 eq. mTzCy3 per mAb. The determined ratios of conjugated TCO per 
mAb were with 1.12 ± 0.03 for 1/6th and 1.13 ± 0.09 for 1/3rd not significant different and 
it was concluded that the reaction was already quantitative with 1/6th moles mTzCy3 of the 
initiated amount of TCO-NHS (Table 1). 
Table 1: Results of study to ensure quantitative reaction between Bevacizumab-TCO (30 eq. TCO-
NHS) and mTzCy3 with 1/6th and 1/3rd moles mTzCy3 per initiated TCO-NHS after 60 min 





1/6th 1.12 ± 0.03 
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Also, a kinetic study, quenching the mTzCy3 incubation at different time points (1 - 45 min), 
was carried out. Therefore, Bevacizumab was reacted with 50 eq. TCO-NHS for 60 min at 
RT, purified, split into 7 fractions and incubated at room temperature with 1/6th moles 
mTzCy3 (in relation to initiated TCO-NHS). After each time point the reaction was stopped 
by spin filtration. The determined ratios of conjugated TCO per mAb didn’t alter 
significantly between 1 min and 45 min (Table 2), which led to the conclusion that already 
after 1 min a quantitative reaction was achieved. This outcome was expected as the reaction 
between TCO and tetrazine, the inverse-electron-demand Diels Alder reaction, is known and 
used for its very fast and clean reaction (see Chapter 1, paragraph 1.3.1 Bioorthogonal ‘click’ 
reaction). 
Table 2: Results of kinetic study for the click reaction between Bevacizumab-TCO and mTzCy3 













In conclusion, it could be shown that there is no interference in the UV-VIS spectra with the 
mAb signal due to tetrazine or NHS after the click reaction and a quantitative binding of 
mTzCy3 could be assured to all available TCO moieties after one minute incubation using 
1/6th moles of the initial amount of TCO-NHS. Therefore, the plausibility of the method 
was approved and the evaluation of the mAb conjugation could be performed. 
Once demonstrated that the titration method shows no interferences and that the reaction 
between TCO and tetrazine is quantitative, we tackled the determination of the number of 
TCO moieties attached and available at the mAb for different mAb/TCO reaction ratios. 
With that aim, and as described above, the antibody was reacted in different molar ratios 
with TCO-NHS, purified and incubated with mTzCy3 (Figure 5). After purification by spin 
filter samples were measured using UV-VIS spectrophotometry (Figure 8) and the 
concentrations of the antibody as well as the concentrations of the fluorophore (which equals 
the concentration of bound and available TCOs) were determined. 
Noteworthy, precipitation of mAb was observed when high molar ratios of TCO per mAb 
(≥100:1) were used. The precipitation is, most likely, due to reduced solubility of highly 
loaded mAbs, either due to loss of their net surface charge by conjugation to lysine residues 
and/or due to increased hydrophobicity as a consequence of incorporation of ligands (18). 
The precipitation phenomenon was clearly reflected in the UV-VIS spectra, were lower 
antibody concentrations were found at high TCO/mAb ratios due to worse recovery from 
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Figure 8: UV-VIS spectra of the direct analysis of mAb-TCO conjugates (here Bevacizumab) with 
the tetrazine-fluorophore (mTzCy3); TCO was coupled in molar ratios of 1:20, 1:30, 1:40, 1:50, 1:100, 
1:200 and 1:0 as control. 
Table 3: Results of conjugation efficacy (average TCO/mAb) by direct analysis for Bevacizumab 
and Trastuzumab (values are expressed as mean ± standard deviation, n(Bevacizumab) ≥ 3, 
n(Trastuzumab) ≥ 2). 
 Bevacizumab Trastuzumab 
Coupling ratio 
mAb:TCO-NHS 
Resulting average conjugate 
TCO/mAb 
1:0 0.0 ± 0.0 0.0 ± 0.0 
1:20 0.6 ± 0.0 1.0 ± 0.3 
1:30 1.0 ± 0.1 1.6 ± 0.1 
1:40 1.3 ± 0.1 2.0 ± 0.5 
1:50 1.9 ± 0.4 2.1 ± 0.1 
1:55  2.5 ± 0.8 
1:100 2.9 ± 0.4  
1:200 5,2  
The results show that, even after optimizing the reaction conditions, independent of the 
ratio, the coupling of TCO-NHS to Bevacizumab had a yield of roughly 3 %, to Trastuzumab 
about 5 %. In other words: out of 30 deployed TCO-NHS only about 1 and 1.6 TCO were 
bound to Bevacizumab or Trastuzumab, respectively. The most likely reason for the low 
yield is the instability of NHS-ester in aqueous conditions. The hydrolysis of TCO-NHS into 
TCO-OH and NHS-OH is faster than the aminolysis, the desired coupling reaction to the 
amine group (19). The results shown in Table 3 for high ratios of TCO-NHS (1:100 and 
1:200) per mAb need to be handled with doubts. As mentioned before, precipitation of the 
mAb was observed and full recovery of the conjugated mAb from the spin filter wasn’t 
possible. That could have resulted in a false determination of bound TCO/mAb as it is likely 
that a fraction of mAb with higher conjugations was precipitated, not recovered and 
therefore not embraced in the asserted result. To yet enable a comparison between the 




























Chapter 3: Conjugation and analysis of monoclonal antibodies 
of the maximum absorbance between the fluorescence (corresponding to available TCO, at 
550 nm) and the mAb (at 280 nm) was determined, using the average of all measurements, 
and is presented in Table 4 as well as in a normalized UV-VIS spectra (Figure 9). 
Table 4: Ratio of the absorbance for Bevacizumab conjugations with TCO between the maximum 
absorbance of the fluorescence (corresponding to TCO) at around 550 nm and the maximum 




Ratio of absorbance 









Figure 9: Normalized UV-VIS spectra of the direct analysis of mAb-TCO conjugates (here 
Bevacizumab) with the tetrazine-fluorophore (mTzCy3); TCO was coupled in molar ratios of 1:20, 
1:30, 1:40, 1:50, 1:100, 1:200 and 1:0 as control. 
The absorbance-ratio between the fluorophore and the mAb show clearly that the 
conjugation, even though it is a random conjugation, increases proportional to the ratio of 
the initial reaction-ratio. Looking closer to the higher ratios; the 1:100 reaction is with 1.1 
close to the expected ratio, which would be 1.2, twice the ratio of 1:50, whereas the 1:200 is 
with only 1.6 further away, verifying the theory, that we weren’t able to determine the real 
ratio due to the precipitation of highly conjugated antibody. 
3.3.2 DFO conjugation – direct method 
The conjugation with the chelator p-NCS-Bz-DFO enables the radiolabeling of antibodies 




























Chapter 3: Conjugation and analysis of monoclonal antibodies 
Bevacizumab or Trastuzumab; however, this time the coupling was not through an NHS 
ester as for TCO but via isothiocyanate coupling. For the direct evaluation of the obtained 
average conjugate, titrations with 89Zr spiked Zirconium were performed (Figure 10) (20). 
Therefore, the production of a “cold” (non-radioactive) Zirconium oxalate solution 
(90Zr(C2O4)2) with precise defined concentration was necessary. Zirconium chloride was 
dissolved in 4 M HCl and a trace of 89Zr (0.1 - 0.2 µCi; 3700 - 7400 Bq) was added. The 
solution was passed over a hydroxamate column to trap Zr4+. After washings with 
hydrochloric acid and water the column was eluted with 1 M oxalic acid and Zr-oxalate 
collected in different fractions. The radioactivity of each was measured in a gamma counter 
(Wallach Wizard, PerkinElmer) and used to determine the concentrations. After the 
zirconium oxalate solutions were decayed the titration could be performed. Therefore, 
Trastuzumab was conjugated with different molar-equivalents (3, 5, 10 eq.) of p-NCS-Bz-
DFO and purified. For each conjugation four equal fractions were taken and respectively 
incubated with a different ratio (0, 1, 2 and 3 molar eq. Zr4+ per mAb) of “cold” Zirconium 
(90Zr-oxalate), which however, contained the same trace of “hot” Zirconium (89Zr-oxalate, 
radioactive). After purification with size exclusion column (PD10 GE Healthcare) the 
radioactivity of each of the four mAb fractions was determined and the fraction with zero 
eq. of “cold” zirconium was normalized to 100 % labeling yield. The percentage calculated 
for the other fractions presented the amount of captured Zirconium out of the excess. 
Naturally, the more “cold” zirconium was added, the less “hot” zirconium was bound and 
the labeling yield decreased (Figure 11). Out of those relations the average amount of p-NCS-
Bz-DFO per mAb could be calculated. 
 
Figure 10: p-NCS-Bz-DFO conjugation and Zirconium titration to determine average ratio of 
DFO/mAb via direct radiometric method. 
 
Figure 11: Graphical representation of PD10 purification after 89Zr spiked labeling to visualize 
different labeling yields respectively to the excess of “cold” Zirconium. 
The results of the p-NCS-Bz-DFO conjugation to Bevacizumab and Trastuzumab are shown 
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(3 eq.) 25 % (5 eq.) and 14 % (10 eq.), whereas Trastuzumab achieves yields of only 4 % 
(3 eq.) 14 % (5 eq.) and 13 % (10 eq.). Unexpected is the very low yield for Trastuzumab 
with 3 eq. p-NCS-Bz-DFO. A possible explanation could be a wrong determination of the 
deployed “cold” Zirconium oxalate solution, which was produced on site out of Zirconium 
chloride (𝑍𝑟𝐶𝑙4 + 𝐶2𝐻2𝑂4 ∗ 2 𝐻2𝑂
𝐻𝑦𝑑𝑟𝑜𝑥𝑎𝑚𝑡𝑒 𝑐𝑜𝑙𝑢𝑚𝑛  
→                 𝑍𝑟(𝐶2𝑂4)2 ) as described above. A 
repetition of the experiments, including the production of Zirconium oxalate followed by 
the titration of the DFO conjugated mAb, should be carried out. 
Table 5: Results of conjugation efficacy (average DFO/mAb) by direct analysis for Bevacizumab 
and Trastuzumab (values are expressed as mean ± standard deviation, n = 2). 
 Bevacizumab Trastuzumab 
Coupling ratio 
mAb:p-NCS-Bz-DFO 
Resulting average conjugate 
DFO/mAb 
1:3 0.87 ± 0.32 0.13 ± 0.01 
1:5 1.26 ± 0.33 0.70 ± 0.35 
1:10 1.47 ± 0.30 1.31 ± 0.20 
The objective of this chapter was the determination of obtained ratios after random 
conjugation between ligand and antibody, using different analytical methods to reveal 
possible differences of the number of available and actually attached ligands. After the direct 
analysis by titration of the two ligands, TCO and DFO, mass analyses were performed. 
3.3.3 Analysis with MALDI/TOF MS 
MALDI is a mild, fast and rather easy method to determine the mass of biomolecules; 
consequently, it is a commonly used method to analyze antibody-drug-conjugates (18). A 
typical antibody spectrum shows two signals, corresponding to the single and double charged 
species of the mAb (Figure 12). By attaching a ligand to the mAb, such as a drug or chelator, 
the mass increases by a multiple number of the mass of the moiety, leading to a shift of the 
peak center. Hence the antibody loading can be calculated from the change of the peak 
position. 
To analyze the antibody-samples by MALDI a buffer exchange from PBS (storage buffer) 
into 0.1 % TFA in water was performed via spin filtration. The samples were measured using 
the dried droplet method on a polished stainless-steel probe (Bruker Daltonics) using 1 µL 
sample mixed with 1 µL sDHB matrix (for details see 3.5 Experimental part.) 
 
Figure 12: MALDI spectrum of native Bevacizumab, showing the single (150 000 m/z) and double 




Chapter 3: Conjugation and analysis of monoclonal antibodies 
As mentioned before, using random conjugation to lysine residues of the mAb yields in a 
variety of conjugates (Figure 4). Together with the fact that the ligands used in this work are 
small (TCO: 152 Da and DFO: 753 Da) compared to the size of the mAb (150 kDa) the 
shift of the peak center between the native mAb and its conjugates was small and difficult to 
identify as such. Additionally, MALDI-TOF has a relatively poor mass accuracy for large 
molecules like mAbs (18) and does therefore not give high enough resolution to separate the 
different species obtained after random conjugation. Hence, mathematical fittings were 
executed to determine the distribution of present conjugates. The peak of the native mAb 
was used as reference and fitted with a Lorentz distribution. To analyze the conjugates the 
multiple mass of the ligand was added to the Lorentzian fit of the native mAb (Figure 13).  
  
Figure 13: Left: Lorentzian fit to the single charged MALDI signal of native Bevacizumab; right: 
Lorentzian fit of mAb conjugates with 0 (red), 1 (green) and 2 (blue) DFO added, overlaying the 
single charged MALDI signal of Bevacizumab conjugated with 5 eq. DFO (black). 
Finally the spectra of the conjugates were fitted to identify the percentage of different 
conjugates obtained after random conjugation of either 3, 5 or 10 eq. p-NCS-Bz-DFO or 30, 
40 or 50 eq. TCO-NHS to the two different antibodies Bevacizumab and Trastuzumab 
(Figure 14 and Figure 15, Table 6 and Table 7). 
 
Figure 14: Mathematical fittings of exemplary MALDI spectra of Bevacizumab conjugated with 0, 
3, 5 or 10 eq. DFO (raw data in black) and fitted with Lorentzian distribution for the conjugates with 
0 (red), 1 (blue), 2 (green) and 3 (gold) DFO.  
3 eq. DFO 0 eq. DFO 
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Figure 15: Mathematical fittings of exemplary MALDI spectra of Bevacizumab conjugated with 0, 
30, 40 or 50 eq. TCO (raw data in black) and fitted with Lorentzian distribution for the conjugates 
with 0 (red), 1 (green), 2 (blue) and 3 (gold) TCO. 
 
Table 6: Results of conjugation efficacy (average DFO/mAb) by MALDI analysis for Bevacizumab 
and Trastuzumab. In bold the average conjugate, below the percentage of mAb with 0, 1, 2 or 3 DFO 
(values are expressed as mean ± standard deviation, n = 2). 











0.50 ± 0.27 
62.09 ± 13.04 % 
25.52 ± 0.48 % 
12.40 ± 13.88 % 
0.25 ± 0.36 
78.71 ± 30.11 % 
17.44 ± 24.66 % 






0.78 ± 0.09 
47.52 ± 7.16 % 
26.95 ± 4.93 % 
25.53 ± 2.23 % 
0.28 ± 0.31 
77.53 ± 27.25 % 
16.85 ± 23.34 % 







0.95 ± 0.59 
41.37 ± 16.33 % 
34.11 ± 9.80 % 
13.13 ± 10.02 % 
11.39 ± 16.11 % 
0.49 ± 0.13 
57.97 ± 3.52 % 
35.03 ± 6.38 % 




30 eq. TCO 
40 eq. TCO 50 eq. TCO 
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Table 7: Results of conjugation efficacy (average TCO/mAb) by MALDI analysis for Bevacizumab 
and Trastuzumab. In bold the average conjugate, below the percentage of mAb with 0, 1, 2 or 3 TCO 
(values are expressed as mean ± standard deviation, n = 2). 











0.65 ± 0.36 
67.64 ± 17.79 % 
- 
32.36 ±17.79 % 
1.20 ± 1.13 
40.11 ± 56.72 % 
- 







1.76 ± 0.13 
- 
45.57 ± 8.39 % 
32.41 ± 4.10 % 
22.02 ± 4.29 % 
2.15 ± 0.41 
- 
19.82 ± 28.03 % 
45.39 ± 14.87 % 







2.45 ± 0.76 
- 
19.80 ± 28.00 % 
15.85 ± 20.31 % 
64.35 ± 48.30 % 
2.04 ± 0.20 
- 
31.14 ± 11.96 % 
33.30 ± 4.37 % 
35.56 ± 7.59 % 
Even though MALDI/TOF MS is a common method to evaluate antibody-drug-conjugates, 
in our hands the results were not optimal. Looking at the values the expected trends can 
mostly be adumbrated (moiety/mAb increases with higher molar ratios in the coupling 
reaction whereas non/low-conjugated mAb decreases). Yet, the high standard deviation 
reveals that the results might be questionable, probably due to the low mass of the attached 
moiety, which makes the fitting process difficult. Comparing the two different mAbs with 
each other, Bevacizumab presents more reasonable values and overall higher conjugation 
yields than Trastuzumab. 
Finally, the second mass analytical method UPLC/ESI-TOF MS was performed. It has 
supposedly higher mass accuracy and resolution than MALDI (18). 
3.3.4 Analysis with UPLC/ESI-TOF MS 
LCMS is a tandem of liquid chromatography (LC) and mass spectrometry (MS) with very 
high sensitivity and selectivity, using LC to separate species in a heterogenic mixture 
combined with MS for mass analysis. Analyzing antibodies leads to a wide range of different 
charged molecules (other than in MALDI where only the single and double charged mAb-
species emerge), which again results in a spectrum showing numerous signals of highly 
charged species (Figure 16, left). Even though the resolution for LCMS is higher than for 
MALDI, a complete separation between the obtained mAb-derivatives after random 
conjugation is challenging or even impossible. Looking at a LCMS spectrum of, for example, 
DFO conjugated mAb, each peak of a charged species does show a signal split into numerous 
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Figure 16: Left: section of an LCMS spectrum of native Bevacizumab with charged species between 
+49 and +38; right: section of a denoised LCMS spectrum of Bevacizumab conjugated with 5 eq. p-
NCS-Bz-DFO between species charged with +40 and +38. Framed in red, the exemplary chosen 
respectively mAb species for mathematical fittings with charge +39. 
To analyze the spectra of the different conjugates one signal of charge was chosen to apply 
mathematical fittings. First, to improve the spectra, a denoising algorithm was performed. 
Doing so, the spectrum of the native mAb presents not the, at first expected, Gaussian shape 
signal but a signal with many sub-signals, like a flame. This appearance is most likely due to 
glycan variations (21). Interestingly, this phenomenon is also visible in the LCMS of the 
conjugated mAbs, however, only in the respectively first shoulder of each signal/charge 
which corresponds to the percentage of the heterogenic mixture that doesn’t show 
conjugation, hence, is still native mAb (Figure 17). 
 
 
Figure 17: Raw LCMS data (black) of Bevacizumab conjugated with 0, 3, 5 or 10 eq. p-NCS-Bz-
DFO, improved with a denoising algorithm (red). 
Next, to fit the data, bigaussian lineshapes were used (as for this work we weren’t interested 
in the glycans we handled the signal of the native mAb as Gaussian distribution) to identify 
the distribution of the different conjugates obtained after random conjugation of either 3, 5 
or 10 eq. p-NCS-Bz-DFO or 30, 40 or 50 eq. TCO-NHS to the two different antibodies 
Bevacizumab and Trastuzumab. Native mAb was used as reference to force the position of 
5 eq. DFO 
0 eq. DFO 3 eq. DFO 
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the center. The fitted positions of the conjugates were calculated by the formula: 
𝑐𝑒𝑛𝑡𝑒𝑟𝑛𝑒𝑤 = 𝑐𝑒𝑛𝑡𝑒𝑟𝑛𝑎𝑡𝑖𝑣𝑒 𝑚𝐴𝑏 ∗
150 000+𝑛∗753
150 000
 (Figure 18). 
     
Figure 18: Mathematical fittings of exemplary LCMS spectra for DFO conjugations of Bevacizumab, 
using bigaussian lineshapes (top of the images: denoised data in black, fitted lineshape in red), 
obtaining mAb derivatives (bottom of the images) with 0 (black), 1 (red), 2 (blue) or 3 (green) DFO. 
As mentioned above, the analysis of the obtained mAb derivatives is quite challenging due 
to the small size of the ligands compared to the mAb. This is even more obvious looking at 
TCO, which only contains 1/5th of the mass compared to DFO. Hence, LCMS spectra show 
no separation or shoulders, only a broadening of the signal can be observed (Figure 19). The 
fittings were also performed with bigaussian lineshapes. 
 
Figure 19: Mathematical fittings of exemplary LCMS spectra for TCO conjugations of Bevacizumab, 
using bigaussian lineshapes (top of the images: denoised data in black, fitted lineshape in red), 
obtaining mAb derivatives (bottom of the images) with 0 (black), 1 (red), 2 (blue) or 3 (green) TCO. 
5 eq. DFO 10 eq. DFO 
0 eq. DFO 
0 eq. TCO 30 eq. TCO 
40 eq. TCO 50 eq. TCO 
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The following two tables (Table 8 and Table 9) show the results of the fittings; represented 
are the values of the average obtained conjugate (moiety/mAb) as well as the determined 
percentage of each species in the obtained mixture of conjugates. 
Table 8: Results of conjugation efficacy (average DFO/mAb) by LCMS analysis for Bevacizumab 
and Trastuzumab. In bold the average conjugate, below the percentage of mAb with 0, 1, 2 or 3 DFO 
(values are expressed as mean ± standard deviation, n = 2). 












0.63 ± 0.11 
51.13 ± 4.54 % 
35.87 ± 0.48 % 
11.75 ± 3.25 % 
1.26 ± 1.78 % 
1.02 ± 0.01 
34.81 ± 1.55 % 
35.74 ± 2.07 % 
21.62 ± 0.11 % 







1.02 ± 0.01 
33.00 ± 1.61 % 
38.42 ± 0.92 % 
22.14 ± 1.77 % 
6.43 ± 1.08 % 
1.21 ± 0.05 
27.14 ± 1.62 % 
35.60 ± 1.21 % 
26.47 ± 2.68 % 







1.48 ± 0.08 
17.06 ± 1.78 % 
34.10 ± 2.85 % 
32.15 ± 2.55 % 
16.69 ± 2.07 % 
1.65 ± 0.15 
15.83 ± 5.47 % 
26.30 ± 1.74 % 
35.10 ± 5.05 % 
22.77 ± 2.17 % 
The results of the LCMS analysis for DFO conjugations (Table 8) show very nicely the 
expected trends that could merely be seen with MALDI. The amount of chelator coupled to 
mAb increases with higher equivalents of DFO during the reaction, from 0.6 and 1.0 DFO 
per mAb with 3 equivalents to 1.5 and 1.7 DFO/mAb after the reaction with 10 eq. p-NCS-
Bz-DFO (Bevacizumab and Trastuzumab, respectively). Also, looking at the distribution of 
species in each conjugate mixture, the amount of non-modified mAb decreases, whereas the 
amount of higher conjugated mAbs increases with higher equivalents of DFO (e.g. from 
1.3 % to 16.7 % for Bevacizumab with 3 DFO). Comparing the two different mAbs with 
each other Bevacizumab presents overall slightly lower conjugation yields than Trastuzumab. 
Looking at the TCO conjugations (Table 9) much higher standard deviations can be 
witnessed, which can be explained by the, as above mentioned, smaller size of the ligand. 
Having such big errors does make it difficult to talk about trends or discuss the results; the 





Chapter 3: Conjugation and analysis of monoclonal antibodies 
Table 9: Results of conjugation efficacy (average TCO/mAb) by LCMS analysis for Bevacizumab 
and Trastuzumab. In bold the average conjugate, below the percentage of mAb with 0, 1, 2 or 3 TCO 
(values are expressed as mean ± standard deviation, n = 2, *n = 1). 











0.57 ± 0.04 
53.74 ± 9.22 % 
35.55 ± 14.61 % 
10.70 ± 5.39 % 
0.58 ± 0.55 
60.56 ± 28.51 % 
20.52 ± 1.76 % 







0.66 ± 0.01 
57.61 ± 8.64 % 
25.80 ± 5.82 % 
9.30 ± 13.15 % 
7.30 ± 10.32 % 
1.22 ± 0.81 
44.25 ± 39.47 % 
13.49 ± 19.08 % 
18.76 ± 0.53 % 












0.95 ± 0.75 
51.21 ± 35.72 % 
17.68 ± 17.77 % 
16.26 ± 3.04 % 
14.85 ± 21.00 % 
3.3.5 Comparison between the different methods 
If we look at the results obtained after conjugations with the chelator DFO (Table 10), 
correlations can be seen between all three methods for both antibodies. However, MALDI 
deviates the furthest, especially for Trastuzumab, in the average value of DFO/mAb 
compared to the other two methods. The most trustworthy method to analyze DFO 
conjugates, confirmed with the lowest standard deviation, is the LCMS method. One 
question that we wanted to answer by using different analysis methods was if the number of 
ligands per mAb is smaller when using direct methods compared to mass analytic, which 
would reveal that some of the ligands, bound to the mAb, are not actually available due to 
interactions with the mAb. Leaving the ratios obtained by MALDI aside due to its 
questionable results (explained above), we can see slightly higher ratio for DFO conjugations 
for Trastuzumab with the LCMS method compared to the direct method. However, for 
Bevacizumab an opposite trend is visible. Taking into account that the standard deviation 
for the direct method is relatively high, no clear answer can be given. Yet, an increase in n 
could lead to more significant results. 
Table 10: comparison of DFO conjugation efficacy between different analytical methods for 
Bevacizumab (top) and Trastuzumab (bottom) (values are expressed as mean ± standard deviation, 
n = 2). 
Bevacizumab direct LCMS MALDI 
Coupling ratio 
mAb:p-NCS-Bz-DFO 
Resulting average conjugate 
DFO/mAb 
1:3 0.87 ± 0.32 0.63 ± 0.11 0.50 ± 0.27 
1:5 1.26 ± 0.33 1.02 ± 0.01 0.78 ± 0.09 
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Trastuzumab direct LCMS MALDI 
Coupling ratio 
mAb:p-NCS-Bz-DFO 
Resulting average conjugate 
DFO/mAb 
1:3 0.13 ± 0.01 1.02 ± 0.01 0.25 ± 0.36 
1:5 0.70 ± 0.35 1.21 ± 0.05 0.28 ± 0.31 
1:10 1.31 ± 0.20 1.65 ± 0.15 0.49 ± 0.13 
Looking at the ligand/mAb ratios after conjugation with the pre-targeting ligand TCO 
(Table 11) correlations are more difficult to observe. The trend, to obtain higher conjugated 
antibodies with increased equivalents of ligand during the conjugation reaction, is visible in 
all methods for Bevacizumab, yet, for Trastuzumab only for the direct method. But high 
standard deviations make the results by MALDI and LCMS questionable. The most 
trustworthy method to analyze TCO conjugates, confirmed with the lowest standard 
deviation, is the direct method. As explained earlier, the small molecular mass of TCO 
compared to the mAb makes mass analysis challenging. Yet again, an increase in n could lead 
to more significant results. 
Table 11: comparison of TCO conjugation efficacy between different analytical methods for 
Bevacizumab (top) and Trastuzumab (bottom) (values are expressed as mean ± standard deviation, 
n(direct) ≥ 2, n(mass) = 2). 
Bevacizumab direct LCMS MALDI 
Coupling ratio 
mAb:TCO-NHS 
Resulting average conjugate 
TCO/mAb 
1:30 1.0 ± 0.1 0.57 ± 0.04 0.65 ± 0.36 
1:40 1.3 ± 0.1 0.66 ± 0.01 1.76 ± 0.13 
1:50 1.9 ± 0.4 1.74 2.45 ± 0.76 
Trastuzumab direct LCMS MALDI 
Coupling ratio 
mAb:TCO-NHS 
Resulting average conjugate 
TCO/mAb 
1:30 1.6 ± 0.1 0.58 ± 0.55 1.20 ± 1.13 
1:40 2.0 ± 0.5 1.22 ± 0.81 2.15 ± 0.41 
1:50 2.1 ± 0.1 0.95 ± 0.75 2.04 ± 0.20 
3.4 Summary and conclusion 
This chapter describes the analysis of two different monoclonal antibodies (Bevacizumab 
and Trastuzumab), randomly conjugated with two different ligands (trans-cyclooctene and a 
desferrioxamine derivative) by three different methods (one direct titration and two mass 
analyses: MALDI and LCMS). The direct method enables the determination of the average 
number of available ligands per mAb via titration, whereas the mass analyses reveal the 
average of the total number of attached moieties and furthermore allow the determination 
of the distribution of conjugates in the obtain heterogenic mixture. 
The direct method of the TCO conjugation, a titration with a tetrazine-fluorophore, shows 
reliable and reproducible results. The low yield of the conjugation (several tenfold molar 
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ester. For the DFO conjugation much lower reaction ratios are sufficient as the coupling is 
performed via isothiocyanate. The direct method for DFO, the titration with radioactive 
spiked zirconium oxalate, is somewhat more complex and susceptible, compared to the TCO 
titration, which is documented by higher standard deviations. However, the results show the 
expected trend and correlate with the LCMS analysis.  
Even though, MALDI is a commonly used method to analyze antibody drug conjugates, in 
our hands the results were questionable; high standard deviations and major differences in 
results compared to both other methods were witnessed. 
The analysis of mAb conjugates with such small ligands is clearly challenging. However, 
looking at the LCMS spectra, high mass accuracy and resolution can be observed after DFO 
conjugation. Yet, the analysis of TCO conjugations, with TCO being still 5 times smaller 
compared to DFO, shows much higher standard deviations, hence less accuracy. 
Overall, the two different antibodies showed quite similar trends and values. However, 
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3.5 Experimental part 
3.5.1 Reagents 
All reagents were obtained from Sigma-Aldrich unless otherwise stated. Deionized water 
(18 MΩ) was used in all reactions. p-NCS-Bz-DFO was obtained from CheMatech (cat. No. 
C121). Both antibodies (Bevacizumab and Trastuzumab) were purchased from Roche 
Farma, S.A. España. [89Zr]ZrC2O4 (in 1 M oxalic acid) was produced in house by a (p, n) 
reaction of natural yttrium-89 and isolated with a hydroxamate column following standard 
protocol. 
3.5.2 Instrumentation 
UV-Vis spectra were measured with a Jasco V630BIO Spectrophotometer or with 
NanoDrop® ND-1000 V3.5.2 
Gamma counts were measured using a Wallach Wizard, PerkinElmer (Waltham, MA, USA) 
gamma counter. 
MALDI/TOF MS analyses were performed using a UltrafleXtreme III, Bruker Daltonics 
(frequency-tripled (355 nm) Nd:YAG laser) with positive ion mode / Linear mode m/z 30-
180 kDa laser fluence 90% / Laser frequency 1000 Hz and Laser shots accumulated >5000. 
The samples were measured using the dried droplet method on a polished stainless-steel 
probe (Bruker Daltonics) using 1 µL sample mixed with 1 µL sDHB matrix (10 mg/mL 
super-DHB in 25 % acetonitrile and 75 % TFA (0.1 %) in water). 
UPLC/ESI-TOF MS analyses were performed using an AQUITY UPLC separation module 
coupled to an LCT TOF Premier XE mass spectrometer (Waters, Manchester, UK). An 
Acquity BEH C4 column (150x2.1 mm, 1.7 µm) was used as stationary phase. The elution 
buffers were A (water and 0.1% TFA) and B (Acetonitrile and 0.1% TFA). The column was 
eluted with a gradient: t=0 min, 95% A, 5% B; t=2 min, 95% A, 5% B; t=35 min, 25% A, 
75% B; t=40 min, 25% A, 75% B; t=41 min, 95%A, 5% B; t=45 min, 95%A, 5% B. Total 
run was 45 min, injection volume was 10 µL and the flow rate 200 µL/min with a column 
temperature of 70 °C. The detection was carried out in positive ion mode, monitoring the 
most abundant isotope peaks from the mass spectra (M+H+). 
3.5.3 Chemistry; TCO conjugation 
Conjugation of TCO-NHS to mAb 
The mAb was diluted in PBS (phosphate-buffered saline, pH 7.4) to a concentration of 1.5 
– 3.0 mg/mL. The pH was adjusted to 8.6 – 8.9 with 0.1 M Na2CO3. TCO-NHS (trans-
cyclooctene-NHS-ester, 20 mM in DMSO) was added in different ratios (0, 20, 30, 40, 50, 
55, 100 and 200 molar eq. TCO-NHS per mAb). After incubation (60 min, RT) non-reacted 
TCO-NHS was removed by spin filtration (100 kDa, 12000 rpm) and the conjugated mAb 
washed three times with PBS. After recovering the mAb from the filter with PBS its 
concentration was determined by NanoDrop®. 
TCO conjugation – direct analysis - photometric 
An aliquot of the TCO-conjugated mAb (0.05 mg) was taken and 5 – 10 molar eq. 6-Methyl-
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the fluorophore-labeled mAb was purified by spin filtration (100 kDa, 12000 rpm) and 
washed four times with PBS. After recovering the mAb from the filter with PBS the 
concentrations of mAb and mTzCy3 were determined by NanoDrop®. The ratio between 
mTzCy3 (which correlates to the available TCO moieties) and mAb was calculated. 
Determination of quantitative reaction between mAb-TCO and mTzCy3 
The mAb was diluted in PBS (phosphate-buffered saline, pH 7.4) to a concentration of 
1.0 mg/mL. The pH was adjusted to 8.7 – 9.0 with 0.1 M Na2CO3. 30 molar eq. TCO-NHS 
(trans-cyclooctene-NHS-ester, 20 mM in DMSO) were added and incubated for 90 min at 
room temperature. Non-reacted TCO-NHS was removed by spin filtration (100 kDa, 
12000 rpm) and the conjugated mAb washed three times with PBS. After recovery from the 
filter the mAb-TCO was split into 6 fractions and 3 each were incubated with 1/6th or 1/3rd 
molar 6-Methyl-Tetrazine-Sulfo-Cy3 (mTzCy3, 1 mg/mL in DMSO) of the initial amount 
of TCO-NHS. After 60 min incubation at RT the fluorophore-labeled mAb was purified by 
spin filtration (100 kDa, 12000 rpm) and washed four times with PBS. After recovering the 
mAb from the filter with PBS the concentrations of mAb and mTzCy3 were determined by 
UV-VIS spectrophotometry. The ratios between mTzCy3 and mAb were calculated and 
compared to each other. 
Kinetic study between mAb-TCO and mTzCy3 
The mAb was diluted in PBS (phosphate-buffered saline, pH 7.4) to a concentration of 
1.0 mg/mL. The pH was adjusted to 8.7 – 9.0 with 0.1 M Na2CO3. 50 molar eq. TCO-NHS 
(trans-cyclooctene-NHS-ester, 20 mM in DMSO) were added and incubated for 60 min at 
room temperature. Non-reacted TCO-NHS was removed by spin filtration (100 kDa, 
12000 rpm) and the conjugated mAb washed three times with PBS. After recovery from the 
filter mAb-TCO was diluted to 2 mL with PBS and 5 eq. (in relative to the mAb) 6-Methyl-
Tetrazine-Sulfo-Cy3 (mTzCy3, 1 mg/mL in DMSO) were added. The mAb-TCO sample 
was split into 7 fractions of 250 µL and each reaction quenched by spin filtration (100 kDa, 
12000 rpm) after 1, 5, 10, 15, 20, 30 and 45 min incubation at room temperature. After 
further washings with PBS the mAb-TCO-mTzCy3 was recovered with PBS from the filter 
and the concentrations of mAb and mTzCy3 determined by UV-VIS spectrophotometry. 
The ratios between mTzCy3 and mAb were calculated and compared to each other. 
3.5.4 Chemistry; DFO conjugation 
Conjugation of Df-Bz-NCS to mAb 
The mAb was diluted in PBS to a concentration of 1.5 – 3.0 mg/mL. The pH was adjusted 
to 8.6 – 9.1 with 0.1 M Na2CO3. p-NCS-Bz-DFO (5 mM in DMSO) was added in different 
ratios (0, 3, 5 and 10 molar eq. per mAb). After incubation (45 min, 37 ºC) non-reacted p-
NCS-Bz-DFO was removed by spin filtration (100 kDa, 12000 rpm) and the conjugated 
mAb washed three times with PBS. After recovering the mAb from the filter with PBS its 
concentration was determined by NanoDrop®. 
Radiolabeling of mAb with 89Zr 
Radiolabeling of mAb-DFO with 89Zr was performed by incubation with [89Zr]ZrC2O4 in a 
1 M oxalic acid solution. Therefore 50 µl of 1 M oxalic acid containing 89Zr (0.6 mCi = 
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volume adjusted to 0.5 mL with 0.5 M HEPES buffer. After 1 h incubation at room 
temperature the mAb was purified by sephadex G-25 size exclusion column (NAP5® GE 
Healthcare) and PBS. Incubation and purification were monitored by iTLC (mobile phase: 
20 mM citric acid + 60 mM EDTA 9:1 acetonitrile; Rf(mAb) = 0, Rf(89Zr-EDTA) = 0.6). 
The radiochemical yield was 68 %. 
Production of 90Zr-oxalate solution 
To produce Zirconium oxalate out of ZrCl4 a hydroxamate functionalized resin was prepared 
and activated to work as a column. Therefore 100 mg of the resin was suspended in 4 mL 
saline and transferred into an Alltec® tube (volume 1 mL) with frit. The resin was washed 
with 20 mL acetonitrile, 30 mL saline and 12 mL 2 M HCl and pushed dry with air. 4 mg 
Zirconium chloride was dissolved in 4 M HCl and a trace of 89Zr (0.1 - 0.2 µCi = 3700 – 
7400 Bq) was added. The volume was adjusted to 15 mL with 4 M HCl and transferred to 
the hydroxamate column. For washings 4 times 2.5 mL 2 M HCl were used followed by 2 
times 3 mL MQ-water. Finally, the column was eluted with 6 times 0.5 mL 1 M oxalic acid. 
All fractions were measured in a gamma counter (Wallach Wizard, PerkinElmer, Waltham, 
MA, USA) and the concentration of each calculated. The samples were stored to decay before 
used. 
DFO conjugation – direct analysis - radiometric 
The procedure to analyze DFO conjugated mAb was based on Meares et al. (20). Solutions 
of spiked zirconium oxalate in four different concentrations (0, 1, 2, 3 eq. Zr4+ per mAb with 
0.1 - 0.2 µCi = 3700 - 7400 Bq each) were prepared. The pH was neutralized with 2 M 
Na2CO3, stabilized by HEPES buffer (0.5 M) and the antibody (0.45 mg each) added (final 
volume 500 µL). After one hour incubation at RT the four solutions were purified by 
sephadex G-25 size exclusion column (PD 10® GE Healthcare). The collected zirconium-
labeled mAbs were measured in a gamma counter, the yield of the mAb with zero eq. 
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4.1 Introduction 
This chapter describes the process towards the in vivo evaluation of pre-targeting in the 
application of boron neutron capture therapy (BNCT). As boron delivery agent, small 
spherical gold nanoparticles (AuNPs) were loaded with boron clusters and functionalized 
with tetrazine to enable the click reaction with a trans-cyclooctene (TCO) functionalized 
monoclonal antibody (mAb) for the pre-targeting approach. The process starts with the 
functionalization of a tumor targeting antibody and the subsequent evaluation of its bio-
activity. Afterwards the boron delivery agent had to be synthesized, multifunctionalized and 
characterized for its physical properties as well as its bio-compatibility. After verifying that 
the two components, the mAb-TCO and the tetrazine-AuNPs are able to undergo the click 
reaction with each other, the pre-targeting strategy could be evaluated in vitro and in vivo. 
4.1.1 The antibody 
For this project a tumor targeting antibody was necessary. Trastuzumab is a well-known 
humanized antibody, approved by both the Food and Drug Administration (FDA) and the 
European Medicinal Agency (EMA), and has a high target specificity and binding affinity to 
human epidermal growth factor (HER2) receptors. Those receptors are overexpressed on 
the cell membrane of some breast and gastric tumors, and even though some HER2(+) 
tumor cell lines can build resistance against Trastuzumab as drug, the HER2 expression does 
not decrease (1). Furthermore, several articles are already published using Trastuzumab 
successfully as pre-targeting component (2; 3; 4). However, it is important to keep in mind 
that many mAbs, once bound to their target, tend to internalize (transfer into the cytoplasm). 
That property is known for Trastuzumab and may give issues in the pre-targeting strategy as 
the antibody needs to stay available on the cell membrane long enough for the second pre-
targeting component (in this case the AuNPs) to reach the tumor and click to the antibody. 
Thus, the TCO functionalized Trastuzumab not only needs to be evaluated for its preserved 
binding affinity to HER2 but also for its behavior towards internalization (Figure 1). 
 
Figure 1: Illustration of the antibody’s pathway in pre-targeting on cell level. The functionalized 
antibody (Trastuzumab-TCO) needs to be evaluated for its binding affinity to its target (HER2) as 
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4.1.2 Small AuNPs as boron delivery agents 
AuNPs are very versatile; they can vary in chemical and physical properties as well as in shape 
and size. The increase of popularity over the last decade is also due to their ability of a high 
surface loading, low toxicity, their optical properties and rather easy modifications of their 
chemical properties by surface functionalization. After the evaluation and biodistribution 
studies of different sized and shaped AuNPs, previously conducted in our group (11) (and 
ongoing PhD of Krishna Reddy Pulagam), we chose small (core size 3-5 nm), spherical 
particles. The biodistribution of smaller particles shows an increased accumulation and 
penetration into tumor tissue through the EPR effect and a shift of the elimination can be 
observed towards smaller particles from liver and spleen to kidneys and bladder which means 
faster clearance (5). Their high surface area-to-volume ratio allows a high amount of cargo, 
such as PEG to stabilize the particles and increase their bio-compatibility next to a high 
loading of the boron cluster COSAN (Cobalt bis[dicarbollide], Figure 2, right) to enable the 
delivery of a sufficient amount of Boron-10 into tumor tissue for the application in BNCT. 
Finally, functionalization with a tetrazine moiety was necessary to enable pre-targeting 
(Figure 2, left). 
   
Figure 2: Left: Schematic figure of a small, spherical AuNP, stabilized with PEG and functionalized 
with tetrazine and COSAN, right: the structural details of the boron cluster COSAN. 
4.1.3 Internalization of nanomaterials 
Internalization plays a key role in this work. The TCO-conjugated antibody may not 
internalize too fast to stay available on the cell membrane for the AuNP (the second 
component of the pre-targeting strategy) to attach. On the other hand, a subsequent 
internalization of the mAb-AuNP complex would be appreciated as the efficacy and 
selectivity increases for BNCT agents in case of localization in the cytoplasm, closer to the 
cell nucleus. 
The internalization of nanomaterial depends on many cofactors, such as particle size and 
shape, charge and surface properties as well as the type of cell line. For example, positively 
charged particles have increased nonspecific internalization, whereas negatively charged have 
longer blood circulation time. The main mechanism for cell uptake is the endocytic pathway, 
forming endosomes which convert from early (characterized by lower pH of around 6-6.5) 
to late endosomes and finally into lysosome (Figure 3) (5). The aggressive endosomal or 
lysosomal environment (low pH and hydrolytic enzymes) leads to degradation and 
subsequently to the release of nutrients and particle fractions whereas receptors and other 
cellular structures are recycled to the cell membrane. In tumor cells higher such activity can 
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Figure 3: Schematic representation of the endocytic pathway. 
Endocytosis can be further classified in different subsections. The most important ones are 
clathrin-mediated, caveolae-mediated and clathrin/caveolae-independent endocytosis 
(Figure 4). The majority of receptor-mediated internalization of nanoparticles occurs through 
the clathrin-mediated endocytosis. The caveolae-mediated endocytosis on the other hand is 
found in a variety of cellular processes such as cholesterol homeostasis, signal transduction 
and the endocytosis of proteins forming flask-shaped infoldings (60-80 nm), so called 
caveolae, which then convert into caveosomes. The major difference to endosomes is their 
neutral pH, resulting in lower aggressiveness. Also, negative surface charges have been found 
to induce cell uptake predominantly via caveolae (6).  Furthermore, it is shown that the 
caveolin-1 protein is involved in the receptor endocytosis of HER2, which is localized in 
caveolae and target for Trastuzumab. Hence, HER2 degradation occurs through the 
caveolae-mediated endocytosis (7).  
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4.2 Objectives 
The specific objectives of this work were: 
1. To establish a BT-474 breast cancer xenograft mouse model. 
2. To functionalize the mAb Trastuzumab with TCO. 
3. To evaluate cell binding capacity, in vivo biodistribution and its internalization (both 
in vitro and in vivo) of Trastuzumab-TCO.  
4. To synthesize, characterize and radiolabel AuNPs functionalized with boron-rich 
molecules and tetrazine moieties.  
5. To evaluate the pre-targeting strategy for AuNPs (in vitro and in vivo). 
4.3 Results and discussion 
4.3.1 Establishment of a BT-474 cancer xenograft mouse model 
In order to evaluate the behaviour of the conjugated mAb, the functionalized AuNP and the 
approach of pre-targeting in vivo, a mouse model with human cancer xenografts had to be 
generated. Using the antibody Trastuzumab focused the choice to HER2 overexpressed 
tumors. We established a breast cancer mouse model with the BT-474 cell line on female 
NOD.CB17-Prkdcscid/J mice. With that aim, 5-6 weeks old mice were operated to implant 
a 17β-estradiol pellet subcutaneously at their neck, needed to enable the tumor to grow. 
24 hours after pellet implantation, 10x106 BT-474 tumor cells per animal (in sterile 
PBS:Matrigel 1:1) were subcutaneously inoculated at the flank of the mouse. Prior to each 
inoculation a Lonza Mycoplasma test was carried out to ensure that the cells weren’t 
contaminated. The sizes of the tumors were measured every 2-3 days with a digital caliper 
and volumes calculated (𝑉 =
short diameter2∗ long diameter
2
). At the time the tumour reached 
200-300 mm3 (around 2 weeks after inoculation, Figure 5) in vivo studies could be performed. 
The defined human endpoints were: (i) weight loss greater than 20 % in one week, (ii) one 
or more of the following clinical signs: abdominal distension, dyspnoea, cachexia or stooping, 
(iii) the absence of response to stimuli and lethargy, (iv) a tumor larger than 1500 mm3 in 
volume and (v) ulcerated or necrotic tumors or wounds / aggressions severe infected. 
 
Figure 5: Graphical representation of tumor growth of BT-474 breast cancer xenografts on 
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4.3.2 Functionalization of Trastuzumab with TCO 
For the pre-targeting stratgey the antibody Trastuzumab needed to be functionalized with a 
TCO ligand to enable the in vivo click reaction to a tetrazine component. Therefore the 
commercial available TCO-NHS was used and randomly conjugated to freely available 
amines of lysine residues in the antibody (Figure 6). 
 
Figure 6: Illustration of the TCO-NHS conjugation to Trastuzumab. 
TCO-NHS was used in 50-55 eq. excess to the antibody and incubated for 60 min at room 
temperature with a pH between 8.6 and 9.1 and a mAb concentration of 3 mg/mL (see 4.5 
Experimental part for details). Those conditions led to an average conjugate of about two 
TCO per mAb (the determination of achieved TCO moieties per antibody is explained in 
details in Chapter 3 of this thesis). 
4.3.3 Evaluation of Trastuzumab-TCO by cell binding assays 
To ensure that the modification of the antibody by TCO conjugation did not compromise 
its binding ability to the target, binding assays were perfomed. Breast cancer cells (BT-474 
cell line) were used as target which overexpress the cell membrane receptor HER2. One way 
to determine the binding is a radiometric method using an assay developed by Lindmo in 
1984 (9). The modified and radiolabelled mAb is incubated with cell suspensions in different 
concentrations. 
To radioabel the mAb-TCO, conjugation with a DFO-chelator (p-NCS-Bz-DFO) was 
required (Figure 7). The dual conjugation was done in a one pot synthesis at 37 °C for 45 min. 
After purification the antibody was radiolabeled by incubating with 89Zr-oxalate at room 
temperature for one hour, followed by purification with a sephadex size exclusion column 
into PBS. The labeling was monitored by radio-TLC (radio thin-layer chromatography) using 
iTLC-SG chromatography paper (Agilent Technologies) and 20 mM citric acid + 60 mM 
EDTA/acetonitrile solution (9/1 v/v) as the stationary and mobile phases, respectively 
(Figure 8, for details see 4.5 Experimental part). After incubation unbound antibody was 
removed and the immunoreactive fraction plotted (Figure 9). The assay demonstrates that 
the modified mAb was not significantly compromised with preserved binding yields up to 
90 %.
 
Figure 7: Schematic representation of TCO- and DFO-conjugation followed by 89Zr-radiolabeling 
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Figure 8: Chromatograms of radio-TLCs monitoring the radiolabeling of Trastuzumab with 89Zr. 
Left: reaction mixture (72 % labeled), right: after purification with size exclusion column. 
 
Figure 9: Lindmo cell binding plot of [89Zr]-Trastuzumab on BT-474 cells. 
To confirm the obtained results by the Lindmo assay, flow cytometry based on fluorescence-
activated cell sorting (FACS) was performed. Therefore the TCO conjugated Trastuzumab 
was fluorophore-labelled with mTzCy3 (6-Methyl-Tetrazine-Sulfo-Cy3) via the inverse-
electron-demand Diels Alder click reaction between TCO and tetrazine. The studies were 
first performed with different concentrations of mAb (0.01 - 0.1 mg/mL) during 30 min 
incubation (Figure 10 C) followed by a study with different incubation time points (5 – 
30 min), using the concentration that showed the best labeling results (Figure 10 D). The 
experiments showed that with a concentration of 0.1 mg/mL and an incubation time of only 
5 min over 80 % of the cells were labeled with Trastuzumab-TCO-mTzCy3. These results 
confirm that there is no significant decrease in the binding affinity of the modified mAb 
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Figure 10: FACS studies, to monitor cell binding capability of TCO conjugated Trastuzumab; A) 
and B) density dot plots: A) gating for live, non-labeled BT-474 cells, B) gating for singlets allowing 
discrimination of doublets; C) and D) histogram of fluorescent BT-474 population with control (non-
labeled): C) different concentrations of Trastuzumab (30 min incubation), D) different incubation 
times of Trastuzumab (0.1 mg/mL). 
4.3.4 Evaluation of Trastuzumab-TCO by biodistribution studies 
After illustrating that the binding capacity of the TCO conjugated Trastuzumab is preserved, 
biodistribution studies in BT-474 breast cancer xenograft mice were perfomed. On one hand 
to proof tumor uptake in vivo, but also to determine the time point for the injection of the 
second component of the pre-targeting approach. To do so, the time when the mAb 
concentration in tumor is high, but low in blood and other tissue, needed to be found 
(Figure 11). 
 
Figure 11: Fictitious time activity curves representing the concentration of drug in the tumor (blue 
line), blood (red line) and healthy tissue (green line) after intravenous administration. The time 
window in which the concentration in the tumor is high and the concentrations in blood and healthy 
tissue are low is shown. 
In order to perform trackable in vivo studies Trastuzumab was, as above, not only conjugated 
with TCO but also radiolabeled with 89Zr. Doses of about 100 µg TCO-Trastuzumab-DFO-
89Zr were injected intravenously into breast cancer xenograft bearing mice (n = 3). PET-CT 
scans were performed approximately 1 h, 8 h, 24 h, 48 h and 72 h post-injection using an 
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Figure 12: Representative coronal PET images (maximum intensity projections) obtained at different 
time points after intravenous administration of [89Zr]-DFO-Trastuzumab-TCO. PET images have 
been co-registered with CT images (maximum intensity projections) for localization of the radioactive 
signal. Positions of the heart, liver, bladder and tumor are indicated. 
 
Figure 13: PET quantification of organ/tissue uptake at 1 h, 8 h, 24 h, 48 h and 72 h post-injection 
(values are expressed as mean ± standard error mean, n = 3) to represent the biodistribution of [89Zr]-
DFO-Trastuzumab-TCO. 
The PET images, confirmed by PET quantification (Figure 13), show increasing tumor 
uptake with its maximum at 48 h (24.5 % ID/cm3). If after 8 h there is still high uptake in 
organs like heart and liver, at 24 h post-injection the background signal is drastically reduced 
and the tumor is clearly visible. At later time points, typical for 89Zr images, using DFO as 
chelator, the bones, like knees, shoulder and backbone, show uptake of 89Zr due to impaired 
stability of the radio-complex in vivo (10). The results were confirmed by ex vivo experiments 
after the last PET scan at 72 h post injection, extracting the organs and analysing via gamma 
counter (Wallach Wizard, PerkinElmer) (Figure 14). 
 
Figure 14: Concentration of radioactivity in different organs/tissues, as determined by gamma 
counting, at t = 72 hours after administration of [89Zr]-DFO-Trastuzumab-TCO (values are 
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4.3.5 Trastuzumab-TCO internalization studies in vitro and ex vivo 
For the pre-targeting strategy the first injected TCO-functionalized mAb needs to stay 
available long enough, that is, on the cell membrane, for the second injection, the tetrazine 
functionalized component, to reach the tumor and “click” to the antibody. However, many 
mAbs, once bound to their target, tend to internalize from the cell membrane into the cell 
cytoplasm. Hence, to obtain insight of the behaviour of Trastuzumab, internalization studies 
were performed. First, in vitro monitoring of TCO-Trastuzumab fluorophore-labeled with 
mTzCy3 (6-Methyl-Tetrazine-Sulfo-Cy3) via the click reaction to TCO was carried out using 
BT-474 cells and fluorescence microscopy (Figure 15). Images were acquired using a 
confocal microscope (Zeiss LSM 880) and analyzed by the ZEN-ZEISS software. 
 
Figure 15: Representative images by confocal fluorescence microscopy of BT-474 cells incubated 
with Trastuzumab-TCO-Cy3 (green) over time. Nucleus stained with Hoechst33342 (blue), 
lysosomes with Lysotracker-deep-red (red). Merged signal of mAb and lysosome in yellow. Top and 
middle: Image taken after 1 h and 24 h incubation time. Bottom: 3D images (Z-stack) after 1 h and 
24 h incuabtion time. 
Looking at early time points, the cell membrane is clearly visible, revealing that Trastuzumab 
bound to the HER2 cell membrane receptors. However, after one hour incubation at 37 °C 
some Cy3 fluorescence is already found in the cytoplasm. It correlates with the red stained 
lysosomes (yellow signal in the merged image) leading to the conclusion that a fraction of 
Trastuzumab-HER2 complexes already internalized. Still, compared to the 24 h incubation 
time point a huge difference can be seen. Over time most mAb internalized resulting in an 
image with spread Cy3 signal over the cytoplasm, correlating with the Lysotracker-deep-red 
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Yet, the goal is the evaluation of the pre-targeting strategy in vivo. The antibody, other than 
in vitro, first needs to reach the tumor and attach to the membrane before internalization can 
occur. Hence, to find the right time point for the injection of the second pre-targeting 
component internalization studies with radiolabeled Trastuzumab were performed in vivo. To 
do so, we took advantage of the possibility of using two different labeling strategies, either 
using 89Zr- or 131I. After internalizing into the cell plasma, Iodine is cleaved off and released 
from the cell, whereas Zirconium remains there. Hence, for the experiment, one batch of 
Trastuzumab was conjugated with p-NCS-Bz-DFO and, after purification, radiolabeled by 
incubation with 89Zr(C2O4)2 as described above. Another batch of Trastuzumab was 
radiolabeled with 131I (t1/2 = 8.02 days, beta minus decay) using the Iodogen-coated method. 
In brief, a vial was coated with Iodogen, a solution of Trastuzumab in sodium phosphate 
buffer added and incubated for 4 min with [131I]NaI (for radiolabeling details see 4.5 
Experimental part). After purification by sephadex G-25 size exclusion column (PD10® GE 
Healthcare) the different labeled Trastuzumab (131I and 89Zr) were mixed in a 1:1 ratio of 
their activity (Figure 16, left). Four mice were injected intravenously and ex vivo studies were 
executed 24 h (n = 2) and 48 h (n = 2) post injection. The activity of the extracted tumors 
was measured in a gamma counter (Wallach Wizard, PerkinElmer). As the gamma spectra of 
the two nuclides are varying enough (represented with a high resolution gamma spectrum in 
Figure 16, right) signal separation can be achieved. Hence the respective tumor uptake of 
radiolabeled antibody from each species can be obtained (Figure 17). 
 
Figure 16: Left: Illustration of ex vivo internalizing studies. A 1:1 mix of mAb, labeled with either 
Iodine-131 or Zirconium-89, is injected intravenously to a mouse. After defined time points ex vivo 
studies were performed and tumor uptake measured via gamma counter. Right: gamma spectra of 
the mixed radionuclides 131I and 89Zr. 
  
Figure 17: Tumor uptake determined by gamma counting after ex vivo studies at 24 h and 48 h after 
administration of 89Zr-labeled (blue) and 131I-labeled (grey) mAb to evaluate the internalization of 
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The determined uptake of Trastuzumab in tumor is significantly different if determined with 
Iodine-131 or Zirconium-89. [89Zr]Trastuzumab reaches 11.2 and 13.7 %ID/g respectively 
at 24 h and 48 h post injection. [131I]Trastuzumab instead shows only uptake of 5.0 and 
4.8 %ID/g, decreasing in-between the time points (Figure 17). This outcome does not only 
confirm the internalization of Trastuzumab but also the increase of internalized fraction over 
time. By setting the uptake of [89Zr]Trastuzumab as 100 % and the uptake of 
[131I]Trastuzumab as the fraction which is not yet internalized (that is 131I not cleaved off and 
released from the cell) the percentage of internalized fraction increases from 55 % at 24 h to 
65 % at 48 h post-injection. This calculation naturally is only estimation, as, among others, 
we don’t take into account the time needed after internalization for cleavage and release of 
131I from the cell; however, it gives insight of the internalization rate of Trastuzumab. 
Importantly, it also confirms that a fraction of the antibody remains on the cell membrane 
and hence pre-targeting is viable.  
Looking at the two experiments, the biodistribution (Figure 13) and internalization of 
Trastuzumab (Figure 15 and Figure 17), the time point for the injection of the second 
component in the pre-targeting strategy was set to 24 h after the mAb injection, balancing 
between tumor uptake, sufficient clearance from blood and healthy tissue and internalization 
of the antibody. 
With the completed evaluation of TCO conjugated Trastuzumab we moved to the second 
component of the pre-targeting approach, the boron delivery agent. Therefore, we 
synthesized and characterized heavily boronated gold nanoparticles (AuNPs), functionalized 
with a tetrazine derivative as counterpart for the in vivo click reaction with TCO of the mAb. 
4.3.6 Synthesis and characterization of gold nanoparticles 
 
Figure 18: Schematic representation of synthesis and functionalization of AuNPs. 
After the evaluation and biodistribution studies of different sized and shaped AuNPs, 
previously conducted in our group (11) (and ongoing PhD of Krishna Reddy Pulagam), the 
particles chosen for the pre-targeting approach were small (core size 3-5 nm), spherical 
particles, synthesized in aqueous medium (12). For the final experiment, the in vivo studies of 
pre-targeted AuNPs, radiolabeled particles were required. The approach was to synthesize 
copper-64 (t1/2 = 12.7 h) alloyed particles to obtain core labeled AuNPs, hence, for the 
characterization of the AuNPs copper alloyed particles were synthesized (Figure 18). 
Therefore, a solution of Chloroauric acid (HAuCl4) and CuCl2 in water was reduced with 
sodium borohydride (NaBH4) and stabilized with thiolated amino-polyethylene glycol (HS-
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light yellow of HAuCl4 to a dark red, typical for AuNPs. After the particle settled for 2 h at 
room temperature, purification was performed by spin filtration (30 kDa) with PBS 
washings. To functionalize the particles with tetrazine for the pre-targeting approach, a NHS 
ester of such was used able to bind to free amine groups of the PEG-amine. Therefore, the 
pH of the AuNP suspension was adjusted to 8-9 with 0.1 M NaOH and Tetetrazine-PEG5-
NHS added. After 1 h incubation at room temperature the particles were purified by spin 
filtration and the last step launched. To functionalize in the matter of BNCT with high 
Boron-10 loadings, COSAN, a boron cluster, was attached. Therefore, COSAN was 
previously thiolated at the position of a BH group, which has a high electron density and can 
easily be functionalized. COSAN was reacted with tetrahydropyran to form intermediate [1], 
followed by ring opening with potassium thioacetate into intermediate [2]. To obtain the final 
compound, COSAN-SH, basic hydrolysis with sodium methoxide (NaOMe) was performed 
(Figure 19) (11). The coupling of such to the gold core of the AuNPs via thiol linkage 
occurred during one hour incubation at room temperature. Spin filtration was executed for 
purification, the AuNPs recovered in PBS and analyzed for their UV-VIS absorbance, shape, 
size, charge and composition. 
 
Figure 19: Synthesis of functionalized COSAN-SH; (i) Tetrahydropyran, dimethylsulphate, H2SO4; 
(ii) Potassium thioacetate; (iii) NaOMe, MeOH. 
UV-Vis absorbance is an easy and fast method and can be used to monitor each step of the 
synthesis and functionalization of the particles. If the core of the AuNPs is formed correctly 
the typical plasmon, dependent on shape and size of AuNPs, will be visible. For the particles 
in hand the light absorbance by the plasmon is not very intense, this is due to their small size, 
but still clearly visible between 430 and 630 nm. The functionalization steps can be 
monitored due to the maximum absorbance of tetrazine at around 270 nm, and of COSAN 
at around 315 nm (Figure 20). 
 
Figure 20: UV-VIS spectra of the PEG-amine stabilized AuNP core (light grey), functionalized with 
tetrazine (dark grey, max absorbance at 270 nm) and functionalized with tetrazine and COSAN 
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Another analysis method to see if the synthesis and functionalization of the AuNPs was 
successful is by transmission electron microscopy (TEM). An image of the non-
functionalized particles shows the shape and size, as well as if the distribution is 
homogeneous. Furthermore, using a negative staining on the functionalized particles 
confirms the presence of the organic layer (due to COSAN and PEG5-Tetrazine) around the 
cold core in bright grey (Figure 21). 
 
Figure 21: Representative TEM images to visualize shape and size of AuNPs; Left: PEG-amine 
stabilized AuNP, right: tetrazine- and COSAN-functionalized AuNP (with negative staining), 
showing in bright grey an organic layer around the metal core. 
The TEM analysis showed a rather homogeneous distribution of spherical particles with a 
core diameter of 3-5 nm and an increase of the particle size due to the functionalization to 
12-15 nm. 
To determine the hydrodynamic diameter of the particles dynamic light scattering (DLS) was 
performed (Figure 22). It describes the size distribution by volume and showed a clear 
difference between the non-functionalized particles and the COSAN- and tetrazine- 
functionalized ones. The size increased from 27.27 ± 3.99 d.nm to 39.61 ± 0.74 d.nm. 
 
Figure 22: Size distribution ranges as determined by DLS (volume distribution) for small, spherical 
AuNP; Black: non-functionalized, PEG-amine stabilized AuNPs, grey: tetrazine- and COSAN-
functionalized AuNPs. 
The particles are stabilized with PEG-amine, leaving free amine groups on the surface of the 
AuNPs. Measuring the zeta potential (ζ-potential) leads therefore to a positive value (7.87 ± 
9.36 mV). However, after coupling tetrazine, which reduces the amount of free amine 
groups, and after attaching COSAN, a single negatively charged molecule, brings the zeta 
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Figure 23: Zeta-potential values measured for non-functionalized, PEG-amine stabilized and 
tetrazine- and COSAN-functionalized AuNPs. 
Finally, the composition of the AuNPs was investigated by ICP-MS analysis (Inductively 
Coupled Plasma Mass Spectrometry), determining the concentrations of gold, boron and 
cobalt. In order to assure that stable COSAN is present on the surface of the particles, a 
molar ratio of boron to cobalt of 18:1 should be determined (see schematic structure of 
COSAN in Figure 24). With an obtained ratio of 18.2 the stability of COSAN attached to 
the AuNPs was confirmed. Furthermore, the boron loading of the particles was identified 
by determining the amount of boron to be 195 µg per mg gold, showing high boron loadings 
of the particles. 
          
Figure 24: Schematic structures of COSAN, showing the ratio of boron to cobalt with 18:1. 
To evaluate bio-compatibility of the multifunctionalized AuNPs, cytotoxicity studies on BT-
474 breast cancer cells were performed. The cells were treated with 5, 10, 20, 60, 80 and 
120 µM (gold concentration) of AuNPs for up to 72 h. Analysis by standard MTT assay 
showed, with overall cell survivals over 90 %, no induced cell death due to the particles in 
BT-474 cells, indicating negligible cytotoxicity (Figure 25). 
 
Figure 25: Cell viability in the presence of multifunctionalized AuNPs for 24 h, 48 h and 72 h on 
BT-474 breast cancer cell line; cells were incubated with increasing concentrations of AuNPs and cell 
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For further studies on the BT-474 cell population fluorescence microscope experiments were 
performed. For most drug delivery agents in cancer therapy the ideal situation is 
internalization of such into the cancer cell cytoplasm before releasing the drug. It leads to 
higher efficacy and selectivity. This also includes the case of BNCT and its boron delivery 
agents. The neutron capture and the subsequent release of alpha particles and lithium ions 
has highest efficacy with boron close to the cell nucleus, due to the short path length of the 
emitted particles. In the case of pre-targeting the ideal situation would be for the AuNPs (the 
boron delivery agent) to “click” to the mAb, followed by internalization of the mAb-AuNP 
complex. To evaluate the internalization of the multifunctionalized AuNPs as such, a 
fluorophore-label was attached with TCO-Cy3, undergoing the click reaction with tetrazine 
and incubated overnight with BT-474 cells. To visualize co-localization between the AuNPs 
and the lysosomes, the location where internalized particles will be found, the lysosomes 
were stained with Lysotracker-deep-red. Images were taken using a live cell Axio Observer 
fluorescence microscope (Zeiss) and analyzed by the ZEN-ZEISS software, showing a clear 
co-localization between the AuNPs and the Lysosomes and therefore internalization of such 
after overnight incubation (Figure 26). As mentioned, cell uptake is a desired property for 
boron delivery agents, as for the pre-targeting strategy a co-internalization of the antibody-
AuNP complex is favored. Yet, it can be expected, that the click reaction between the mAb 
and the AuNP is faster than the cell uptake of the particles alone, hence no restrictions were 
expected for pre-targeting due to the ability of the particles to internalize. Additionally, the 
internalization of the AuNPs without interacting with the antibody should neither result in 
decreased efficacy, and can be considered as a parallel uptake mechanism that contributes to 
accumulation of the boron atoms in the interior of the cells. 
 
Figure 26: Representative images by live cell fluorescence microscopy of multifunctionalized AuNPs 
after overnight incubation. In green: AuNPs, fluorophore-labeled with TCO-Cy3, in red: Lysosomes, 
stained with Lysotracker-deep-red, in blue: nucleus, stained with Hoechst33342. Merged signals of 
AuNPs colocalizing with lysosomes appear in yellow. 
After the successful synthesis and functionalization of the AuNPs, including a complete 
characterization and with confirmed bio-compatibility, we could move to the evaluation of 
pre-targeting. To do so, at first, proof was needed for the click reaction to occur between the 
TCO functionalized Trastuzumab and the tetrazine functionalized AuNPs. Therefore, an 
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respective controls was executed. The AuNPs derivatives were visible on the gel due to their 
red color. To visualize the mAb species after the electrophoresis a staining of the gel with 
coomassie blue was performed. As control each component was applied sole to the gel 
(Figure 27, line 1+2: Trastuzumab without and with TCO, line 6+7: AuNPs with and without 
tetrazine). Furthermore, a mix between either non-functionalized Trastuzumab and 
multifunctionalized AuNPs (Figure 27, line 3) or functionalized Trastuzumab and AuNPs 
without tetrazine functionalization (Figure 27, line 5) was applied; separations could be 
obtained. When applying the mixture of Trastuzumab-TCO and fully functionalized AuNPs 
(Figure 27, line 4) a merged signal appears showing combined signal of red AuNPs and blue 
antibody, confirming that the click reaction took place. 
 
Figure 27: Agarose gel electrophoresis, stained with coomassie blue, to demonstrate occurance of 
click reaction between Trastuzumab-TCO (mAb-TCO) and multifunctionalized AuNPs (AuNP-Tz) 
(line 4). Including controls with non-functionalized Trastuzumab (mAb) and AuNPs without 
tetrazine functionalization (AuNP). 
4.3.7 Radiolabelling of gold nanoparticles  
To be able to track the AuNPs in vivo, a positron emitting radionuclide was inserted. The 
possibility to synthesize copper alloyed AuNPs allows the incorporation of the radionuclide 
copper-64 in the core (12). The synthesis of the radiolabeled particles was carried out 
following the procedure described above; however, CuCl2 was spiked with radioactive 
[64Cu]CuCl2. This radionuclide is produced as a solution in 0.1 M HCl. Therefore, before 
tackling the preparation of the NPs, this solution was neutralized by adding an equivalent 
volume of a 0.1 M NaOH solution. To purify the AuNPs after the labeling by spin filtration, 
a 1 mM EDTA (Ethylenediaminetetraacetic acid) solution was used to remove all loosely 
bound 64Cu. The labeling was monitored by radio-TLC using iTLC-SG chromatography 
paper (Agilent Technologies) and 20 mM citric acid + 60 mM EDTA solution as the 
stationary and mobile phases, respectively. The functionalization of the particles was 
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The radiochemical yield was low with only 5-10 %. However, competitive stability tests 
showed after 46 h at 37 °C in a 1 mM EDTA solution 98 % of 64Cu were still bound to the 
AuNPs determined by iTLC (Figure 28). 
 
Figure 28: Chromatograms of radio-TLCs monitoring the radiolabeling of AuNPs with 64Cu. Left: 
reaction mixture (7.4 % labeled), right: after purification with spin filtration, followed by verification 
of stability by incubation for 46 h in 1 mM EDTA solution at 37 °C (98 % labeled). 
4.3.8 Pre-targeting gold nanoparticles in vitro 
In vitro experiments were conducted to evaluate the pre-targeting strategy between TCO-
Trastuzumab and multifunctionalized AuNPs. Therefore, the AuNPs were fluorophore-
labeled with Cy3-NHS ester which binds to the PEG-amines of the particles. BT-474 cells 
were seeded in an ibidi µ-slide 8-well-plate (30 000 cells/well) and incubated overnight to 
adhere. Three different experimental groups were chosen and studied in parallel to enable 
comparison. 
(i) Pre-targeting: Trastuzumab-TCO + fully functionalized, Cy3-fluorophore 
labeled AuNPs 
(ii) Control 1: Trastuzumab non-functionalized + fully functionalized, Cy3-
fluorophore labeled AuNPs 
(iii) Control 2: fully functionalized, Cy3-fluorophore labeled AuNPs 
BT-474 cells were primarily stained with Hoechst33342 and Lysotracker-deep-red to 
visualize the nucleus and the lysosomes. The mAb for group (i) and (ii) was incubated for 30 
min at 37 °C. The media with unbound mAb was removed, the Cy3-fluorophore labeled 
AuNPs added to all groups and incubated for 10 or 30 min (Figure 29 for experimental set-
up). Images were taken using a live cell Axio Observer (Zeiss) fluorescence microscope. 
However, when analyzing the images with the ZEN-ZEISS software no difference could be 
witnessed between the three different experimental groups (Figure 30). 
 
Figure 29: Ibidi 8-well-plate with experimental set-up for the evaluation of pre-targeting AuNPs on 
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Figure 30: Representative images by fluorescence microscopy evaluating pre-targeting AuNPs on 
BT-474 cells. As control incubation of AuNP alone (iii) and with non-functionalized Trastzumab (ii) 
were performed. After 30 min incubation of mAb incubation of AuNPs followed for either 10 min 
(top) or 30 min (bottom). Nucleus stained with Hoechst33342 (blue), AuNPs with Cy3-NHS (green), 
lysosomes with Lysotracker-deep-red (red). Merged signal of AuNPs and lysosome in yellow. 
The images of the different experimental groups showed very similar cell uptake of the 
fluorophore labeled AuNPs but with an increased signal after 30 min incubation compared 
to the 10 min incubation. We expected significant differences in the pre-targeting experiment 
after 10 min incubation of the AuNPs. If the TCO functionalized Trastuzumab was available 
on the cell membrane and if the click reaction occurred, an intense signal on the cell 
membrane should have been visible, which should decrease with longer incubation time due 
to internalization of the receptor-mAb-AuNP complex (2). However, after 10 min 
incubation of the AuNPs the fluorophore signal was low in all three cases and spread over 
the cell, co-localizing with the lysosomes, suggesting that internalization of the AuNP took 
already place. About the outcome of the experiments can be speculated; most likely 
Trastuzumab internalized too fast and wasn’t available anymore for the click reaction with 
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at room temperature or at 4 °C to reduce internalization. Yet, the fast cell uptake in all three 
groups was not expected after the internalization studies done before. Yet, recalling the ex 
vivo internalization studies of Trastuzumab (see paragraph 4.3.5 Trastuzumab-TCO 
internalization studies in vitro and ex vivo) which confirms the presence of a fraction of 
Trastuzumab on the cell membrane even after 48 h, we expected a different outcome for the 
pre-targeting evaluation in vivo. 
4.3.9 Pre-targeting gold nanoparticles in vivo 
As the last step in the evaluation of our pre-targeting approach for multifunctionalized 
AuNPs as boron delivery agent in the application of BNCT, in vivo studies were performed. 
With that aim, three groups were formed out of female, BT-474 breast cancer xenograft 
bearing NOD/SCID mice. For all experiments fully functionalized and 64Cu-radiolabeled 
AuNP were used (approximately 190 µg gold with 30-50 µCi (1-2 MBq) per mouse). In case 
of the pre-targeting group (G1, n = 4) 100 µg Trastuzumab-TCO per mouse was injected 
intravenously 24 h before the AuNPs. As control group (G2, n = 3) Trastuzumab without 
TCO conjugation was injected intravenously 24 h before the AuNPs. The last group, also 
used as control, received only AuNPs (G3, n = 4) (Figure 31). 
G1 – pre-targeting G2 - control G3 - AuNP 
   
Figure 31: Experimental set up with three experimental groups for in vivo evaluation of pre-targeting 
multifunctionalized AuNPs. G1, the pre-targeting group, was injected with Trastuzumab-TCO 
followed by multifunctionalized AuNPs after 24 h. The control group G2 was injected with non-
functionalized Trastuzumab followed by multifunctionalized AuNPs after 24 h. The third group (G3) 
received only multifunctionalized AuNPs. 
PET-CT scans were performed approximately 1 h, 6 h, 24 h and 48 h post injection using 
the β- and X-cube micro system of Molecubes. All experiments were confirmed by ex vivo 
studies after the last PET scan. We first analyzed the third group, using PMOD software, to 
evaluate the biodistribution and tumor uptake of the AuNPs alone. The particles show a 
rather typical distribution for spherical gold nanoparticles (Figure 32 and Figure 34 top), 
however with higher liver and spleen uptake to what was expected for particles of such small 
size (core size 3-5 nm) (maximum at 6 h post injection with 31.4 ± 17.3 %ID/cm3, 
respectively at 24 h with 13.5 ± 10.6 %ID/cm3). Yet, in organs such as heart, lung and 
kidneys a steady decrease can be observed over time reaching around 5 %ID/cm3 24 h post 
injection. The uptake in muscle, commonly used as reference for “healthy tissue”, stays below 
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Figure 32: Accumulation of multifunctionalized [64Cu]AuNP in different organs at different time 
points after intravenous administration, analyzed by PET imaging (values are expressed as mean ± 
standard error mean, n = 4). 
A closer look to the tumor uptake revealed its maximum at 24 h post-injection with 
4.8 ± 1.9 %ID/cm3 followed by a slow clearance (Figure 33 and Figure 34, bottom). This 
result gives reason to believe that these nanoparticles follow the passive targeting by the EPR 
effect. 
 
Figure 33: Tumor uptake of multifunctionalized [64Cu]AuNP at different time points after 
intravenous administration, analyzed by PET imaging (values are expressed as mean ± standard error 
mean, n = 4). 
 
Figure 34: Representative PET images obtained at different time points after intravenous 
administration of [64Cu]AuNPs. Top: coronal PET images (maximum intensity projections), bottom: 
representative axial PET images (average of 10 slices), positions of the tumor indicated. All images 
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The control group G3, with solely AuNPs, showed slow elimination of the particles from 
the tumor at t > 24 hours, hence, we anticipated that the pre-targeting strategy may increase 
tumor accumulation by improving retention. Yet, a faster clearance from major organs and 
blood would be desirable for optimal pre-targeting results. 
The analysis of the control (G2) and the pre-targeting (G1) group showed very similar 
biodistribution to the AuNP-group (G3). Analyzing the tumor uptake, a different pattern 
was expected for the pre-targeting group with a prolonged stay of the particles in tumor 
tissue, however, no significant difference could be observed between each group at any time 
point (Figure 35, left). After the 48 h PET-CT scan ex vivo studies were performed, 
confirming the obtained results from PET quantification by extracting the organs and 
analysing via gamma counter (Wallach Wizard, PerkinElmer) (Figure 35, right). 
  
Figure 35: Tumor uptake of [64Cu]AuNP in different experimental groups (purple: pre-targeting, 
green: control with non-TCO-functionalized mAb, blue: solely AuNP). Left: analyzed by PET 
imaging at different time points after intravenous administration. Right: analyzed by gamma counting 
48 h after administration. (Values are expressed as mean ± standard error mean, G1 and G3: n = 4, 
G2: n = 3). 
Furthermore ICP-MS analyses were performed after the radioactivity of the extracted organs 
was decayed. Liver, spleen and tumor were digested to determine their content of gold and 
boron. To not falsify the results of the boron determination no glass was used in any step 
during the process. Organs were digested in aqua regia overnight at 70 °C. The samples were 
filtered through cotton and diluted with 2 % HNO3 to enable ICP-MS analysis. Good 
correlation between the ICP-MS and ex vivo data was achieved which leads to the conclusion 
that the functionalized AuNPs are stabile in vivo (Figure 36). 
 
Figure 36: Amount of gold and boron in tumor at 48 hours after intravenous administration of pre-
targeted [64Cu]AuNP, as determined by gamma counting (dark purple) and ICP-MS (light purple). 
Values for gamma counting are obtained by multiplying the %ID/cm3 (values from Figure 35) by the 
relative load of boron and gold in the nanosystems. (Values are expressed as mean ± standard error 
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4.4 Summary and conclusion 
This chapter described the process towards the in vivo evaluation of pre-targeting in the 
application of BNCT. We sucessfully functionalized the tumor targeting antibody 
Trastuzumab for the pre-targeting approach obtaining a conjugate with an avergae of two 
TCO per mAb. Bio-acitivity of such didn’t show significant impairment due to the 
modification acertained by cell binding assays. To enable in vivo studies, a BT-474 breast 
cancer xenograft mouse model on NOD/SCID mice was established and biodistribution 
studies of the functionalized Trastuzumab executed. Highest tumor uptake was reached at 
48 h after intravenously injection with close to 25 %ID/cm3. Cell internalizing studies by 
fluorescence microscopy of the TCO conjugated and Cy3-flourophore labeled mAb revealed 
cell uptake already within the first hour at 37 °C, reaching substantially complete uptake 
within 24 h. Also in vivo studies were performed to determine Trastuzumab internalization 
using a mixture of 89Zr- and 131I-radiolabelled Trastuzumab, showing significant difference 
between tumor uptake of each species. Hence, partial internalization of Trastuzumab in vivo 
was confirmed. Looking at the two experiments, the biodistribution and internalization of 
Trastuzumab, the time point for the injection of the second component in the pre-targeting 
strategy was set to 24 h after mAb injection, balancing between tumor uptake, sufficient 
clearance from blood and healthy tissue and internalization of the antibody. 
As boron delivery agent small spherical gold nanoparticles (AuNPs) were loaded with the 
boron cluster COSAN and functionalized with tetrazine to enable the click reaction with 
TCO-Trastuzumab for the pre-targeting approach. The AuNPs were successfully 
synthesized, multifunctionalized and characterized for its physical properties (UV-VIS, 
TEM, DLS, Z-potential, ICP-MS) as well as its bio-compatibility (cytotoxicity, cell 
internalization). Incorporation of the positron emitter 64Cu was executed by synthesizing a 
copper alloyed gold core, enabling in vivo tracking of the AuNPs. 
Finally, it was verified by agarose gel electrophoresis that the two components, the 
Trastuzumab-TCO and the tetrazine-AuNPs, are able to undergo the click reaction with each 
other and the pre-targeting approach could be evaluated. Therefore in vitro and in vivo studies 
were performed, using fluorescence microscopy on BT-474 cells and PET-CT analysis on a 
BT-474 breast cancer xenograft mouse model, respectively. For both experimental set-ups 
control groups were generated by using non-functionalized Trastuzumab as well as AuNPs 
alone. However, no significant differences could be observed in vitro or in vivo between the 
three groups. Cell and tumor uptake respectively were similar for all cases. 
For the work of this PhD thesis the aim was to use nanoparticles with fast clearance to 
prevent toxicity to non-tumor tissue but present the possibility to carry a high amount of 
boron next to the functionalization with tetrazine to enable pre-targeting. Looking at the 
biodistribution of the AuNPs in hand the high liver uptake and rather slow clearance from 
other organs such as kidneys and lung as well as the tumor showed that these particles do 
not possess the desired properties for pre-targeting. Yet, high boron loading was achieved 
and tumor uptake due to the EPR effect could be witnessed. Hence, investigation in the 
particles as boron delivery agents should be continued; however, pre-targeting could not 
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4.5 Experimental part 
4.5.1 Reagents 
All reagents were obtained from Sigma-Aldrich unless otherwise stated. Milli-Q water 
(resistivity 18.2 MΩ·cm at 25 °C) was used in all experiments. p-NCS-Bz-DFO was obtained 
from CheMatech, Cy3-NHS was purchased from BroadPharm, mTzCy3 from Jena 
Biosciense and Cy3-TCO from AAT Bioquest. The antibody Trastuzumab was purchased 
from Roche Farma, S.A. España. [89Zr]ZrC2O4 (in 1 M oxalic acid) was produced in house 
with an IBA Cyclone 18/9 cyclotron using a (p, n) reaction on natural yttrium-89 and isolated 
with a hydroxamate column following standard protocol. [64Cu]CuCl2 (in 0.1 M HCl) was 
produced in house with an IBA Cyclone 18/9 cyclotron using a (p, n) reaction on a gold 
disk, electroplated with enriched nickel-64 and isolated with an ion exchange column 
following standard protocol. [131I]INa (in 0.1 M NaOH) was purchased from PerkinElmer. 
A stock of BT-474 cells was kindly donated from biodonostia (San Sebastián, Spain). Animals 
were purchased from Charles River Laboratories France. 
4.5.2 Instrumentation 
UV-Vis spectra were measured in a Jasco V630BIO Spectrophotometer or in NanoDrop® 
ND-1000 V3.5.2 
Flow cytometry based on fluorescence-activated cell sorting (FACS) studies were performed 
using a BD FACS Canto II Flow Cytometer and analyzed by FlowJo V7.6.5. 
Cell observer microscopy experiments were carried out using a Zeiss Axio Observer 
Fluorescence microscope using Ibidi clear bottomed µ-slide 8-well microscopy plates and 
analyzed by ZEN2012-ZEISS. 
Confocal cell microscopy experiments were carried out using a Zeiss 880 Confocal 
Fluorescence microscope using Ibidi clear bottomed µ-slide 8-well microscopy plates and 
analyzed by ZEN2012-ZEISS. 
Transmission electron microscopy (TEM) was performed using a JEOL JEM-1400 plus 
microscope (Jeol, Tokyo, Japan) working at 120 kV. The carbon film of copper grids (CF400-
Cu) was treated under air plasma in a glow discharge system (K100X, Emitech, Kent, UK, 
40 mA during 2 min) just before sample preparation. For TEM examinations, a single drop 
(1μL) of the NPs solution was placed onto a copper grid coated with a carbon film (Electron 
Microscopy Sciences, Hatfieled, PA, USA). After 1 min, the drop was removed with filter 
paper and the sample was incubated with 3 µL of uranyl acetate 0.5% (3 min). 
ICP-MS measurements were performed on a Thermo iCAP Q ICP-MS (Thermo Fisher 
ScientificGmbH, Bremen, Germany). An ASX-560 autosampler was coupled to the ICP-MS 
(CETAC Tech, Omaha, NE, USA). 
DLS and ζ-potential measurements were performed using a Malvern Zetasizer Nano ZS 
system (Malvern Instruments, Malvern, UK). The particle size measurement settings were: 
3 measurements/14 runs/10s in scattered mode at 173° angle. Measurements were 
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Gamma counts were measured using a Wallach Wizard, PerkinElmer (Waltham, MA, USA) 
gamma counter. 
Radio-thin layer chromatography (radio-TLC) was performed using iTLC-SG 
chromatography paper (Agilent Technologies, CA, USA) and 20 mM citric acid + 60 mM 
EDTA/acetonitrile solution (9/1 v/v) as the stationary and mobile phases, respectively. TLC 
plates were analyzed using a TLC-reader (MiniGITA, Raytest). 
PET experiments were performed using an eXploreVista-CT small animal PET-CT system 
(GE Healthcare) or the β- and X-cube micro system of Molecubes. Anesthesia was induced 
with 3-5 % isoflurane and maintained by 1.5-2 % of isoflurane in 100% O2. 
4.5.3 Tumor growth 
Cells 
BT-474 cells were cultured in DMEM medium (100X, 10378-016 Gibco; 10 % fetal bovine 
serum, 1 % penicillin-streptomycin) at 37 °C with 5% CO2 in a humid atmosphere. Cells 
were confirmed to be free of mycoplasma contamination. 
Animals 
All animal experiments were performed in accordance with the Spanish policy for animal 
protection (RD53/2013), which meets the requirements of the European Union directive 
2010/63/UE regarding the protection of animals used in experimental procedures. All 
experimental procedures were approved by the Ethical Committee of CIC biomaGUNE and 
authorized by the local authorities. All animals were housed in ventilated cages and fed on a 
standard diet ad libitum. The studies were performed on female NOD.CB17-Prkdcscid/J 
mice. 
Tumor growth 
To grow BT-474 cell line breast cancer xenografts on female NOD.CB17-Prkdcscid/J mice 
5-6 weeks old mice were operated to implant a 17β-estradiol pellet (belma technologies) 
subcutaneously at their neck. The next day 10*106 BT-474 tumor cells were inoculated per 
animal subcutaneously at the flank of the mouse. Prior to each inoculation a Lonza 
Mycoplasma test was carried out to ensure that the cells weren’t contaminated, finally cells 
were diluted in sterile PBS:Matrigel (1:1). The sizes of the tumors were measured every 2-3 
days with a digital calliper and volumes calculated (𝑉 =
short diameter2∗ long diameter
2
). At the 
time the tumour reached 200-300 mm3 (around 2 weeks after inoculation in vivo studies could 
be performed. The defined human endpoints were: (i) weight loss greater than 20 % in one 
week, (ii) one or more of the following clinical signs: abdominal distension, dyspnoea, 
cachexia or stooping, (iii) the absence of response to stimuli and lethargy, (iv) a tumor larger 
than 1.5 cm in average diameter and (v) ulcerated or necrotic tumors or wounds / aggressions 
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4.5.4 Chemistry and Radiochemistry - Trastuzumab 
Conjugation of TCO-NHS to Trastuzumab 
The mAb was diluted in PBS (phosphate-buffered saline, pH 7.4) to a concentration of 
3.0 mg/mL. The pH was adjusted to 8.6 – 9.1 with 0.1 M Na2CO3. 50-55 moles eq. TCO-
NHS (20 mM in DMSO) was added. After incubation (60 min, RT) non-reacted TCO-NHS 
was removed by spin filtration (100 kDa, 12000 rpm) and the conjugated mAb washed three 
times with PBS. After recovering the mAb from the filter with PBS its concentration was 
determined by NanoDrop®. 
Conjugation of TCO-NHS and Df-Bz-NCS to Trastuzumab 
The mAb was diluted in PBS to a concentration of 1.5 – 3.0 mg/mL. The pH was adjusted 
to 8.6 – 9.1 with 0.1 M Na2CO3. TCO-NHS (20 mM in DMSO, 55 eq.) and p-NCS-Bz-DFO 
(5 mM in DMSO, 5 eq.) was added. After incubation (45 min at 37 ºC) purification was 
performed by spin filtration (100 kDa, 12000 rpm) and the conjugated mAb washed three 
times with PBS. After recovering the mAb from the filter with PBS its concentration was 
determined by NanoDrop®. 
Conjugation of Df-Bz-NCS to Trastuzumab 
The mAb was diluted in PBS to a concentration of 1.5 – 3.0 mg/mL. The pH was adjusted 
to 8.6 – 9.1 with 0.1 M Na2CO3. p-NCS-Bz-DFO (5 mM in DMSO, 5 eq.) was added and 
incubated for 45 min at 37 ºC. Purification was performed by spin filtration (100 kDa, 12000 
rpm) and the conjugated mAb washed three times with PBS. After recovering the mAb from 
the filter with PBS its concentration was determined by NanoDrop®. 
Radiolabeling of Trastuzumab with 89Zr 
Radiolabeling of the DFO conjugated mAb with 89Zr was performed by incubation with 
[89Zr]ZrC2O4 in a 1 M oxalic acid solution. Therefore 50 µl of 1 M oxalic acid containing 
89Zr 
(0.6 mCi = 22.2 MBq) were neutralized with 2 M sodium carbonate, 450 ug mAb was added 
and the volume adjusted to 0.5 mL with 0.5 M HEPES buffer. After 1 h incubation at room 
temperature the mAb was purified by sephadex G-25 size exclusion column (NAP5® GE 
Healthcare) and PBS. The incubation and purification was monitored by iTLC (mobile phase: 
20 mM citric acid + 60 mM EDTA 9:1 acetonitrile). Radiochemical yield of the purified 89Zr-
Trastuzumab was 64.2 ± 21.6 % (n = 5). 
Radiolabeling of Trastuzumab with 131I 
An Eppendorf tube was coated with 75 µg Iodogen (1,3,4,6-tetrachloro-3α,6α-diphenyl 
glycoluril). 50 µL 0,5 M sodium phosphate buffer, 427 µL 0,1 M sodium phosphate buffer 
and 19 µL (0,4 mg) Trastuzumab (21 mg/mL) were added. Finally 4 µL of [131I]INa (200 µCi 
= 7.4 MBq in 0.1 M NaOH). After 4 min incubation at room temperature the reaction was 
quenched with 100 µL VitaminC solution (25 mg/mL milliQ water, pH = 5). Labeling was 
monitored by iTLC (mobile phase: 20 mM citric acid + 60 mM EDTA). The radiolabeled 
mAb was purified using sephadex G-25 size exclusion column (PD10® GE Healthcare) and 
VitaminC solution (5 mg/mL saline, pH ≈ 5). Radiochemical yield of the purified 131I-
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Fluorophore-labeling of Trastuzumab-TCO with mTzCy3 
To a solution of Trastuzumab-TCO in PBS (1.5 - 3.0 mg/mL) 5 eq. mTzCy3 (6-Methyl-
Tetrazine-Sulfo-Cy3, 1 mg/mL in DMSO) was added and incubated for 5 min at room 
temperature. The fluorophore-labeled mAb was purified by spin filtration (100 kDa, 12000 
rpm) and washed four times with PBS. After recovering the mAb with PBS from the filter 
the concentrations of mAb and mTzCy3 were determined by NanoDrop®. 
4.5.5 Chemistry and Radiochemistry - AuNP  
Synthesis of AuNPs 
For the synthesis of AuNPs the protocol of Yongfeng Zhao et al. was used as base (12). In 
a 10 mL glass vial 0.9 mL MQ water were mixed with 10 µL HAuCl4 (100 mM in MQ, 0.4 mg, 
1 eq), 10 µL CuCl2 (10 mM in MQ, 0.1 mg, 1 eq) and 25 µL NH2-PEG5k-SH (10 mM in MQ, 
2.5 mg, 0.25 eq). Under vigorous stirring 100 µL NaBH4 (40 mM in MQ, 0.2 mg, 4 eq; freshly 
prepared) were added drop wise. After 2 min the stirring was stopped and the particles were 
allowed to settle for 2 h at room temperature. Purification was performed by spin filtration 
(30 kDa, 12 000 rpm) including 3 washings with PBS (phosphate buffered saline, pH 7.4) 
and the particles were recovered from the filter in 400 µL PBS. 13 µL COSAN-SH (20 mM 
in EtOH, 0.1 mg, 0.25 eq) were added and incubated for 1 h at room temperature. After 
purification via spin filter as described above the pH of the AuNP suspension was adjusted 
to 8 - 9 with 0.1 M NaOH and 25 µL Tz-PEG5-NHS (20 mM in DMSO, 0.3 mg, 0.5 eq) 
were added. After 1 h incubation at room temperature the particles were purified by spin 
filtration and recovered in 400 µL PBS. The AuNPs were analyzed by UV-Vis, DLS, Z-
potential, ICP-MS and TEM. 
Fluorophore-labeling of AuNP with TCO-Cy3 
The multifunctionalized AuNPs (450 µL in PBS, 0.2 mg/mL) were incubated with 3 µL 
TCO-Cy3 (10 mM in DMSO) for 5 min at room temperature. The particles were purified by 
spin filtration (30 kDa) and recovered in PBS. The labeling was confirmed by UV-VIS 
spectra. 
Fluorophore-labeling of AuNP with Cy3-NHS 
The multifunctionalized AuNPs (450 µL in PBS, 0,2 mg/mL) were adjusted in pH to 8.6-8.9 
and 5 µL Cy3-NHS (1 mg/mL in DMSO) were added. After 1 h incubation at room 
temperature particles were purified by spin filtration (30 kDa) and recovered in PBS. The 
labeling was confirmed by UV-VIS spectra. 
Agarose (1.5 %) gel electrophoresis  
A 1.5 % agarose gel was prepared following standard protocol. In brief 1.5 g agarose were 
suspended in 100 mL Tris-Borate-EDTA (TBE) buffer and heated until it almost reached its 
boiling point. The solution was poured in a gel chamber, the comb placed and let settle to 
polymerize. Samples were prepared in 20 µL aqueous batches, including 5 µL loading buffer. 
10 µL were loaded on the gel and run for approximately 1 h at 100 V. To visualize the 
antibody on the gel it was incubated 1 hour in coomassie blue, followed by 2 days in 
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Radiosynthesis of AuNPs 
For the synthesis of 64Cu labeled AuNPs the protocol of Yongfeng Zhao et al. was used as 
base (12). In a 10 mL glass vial 0.9 mL MQ water were mixed with 10 µL HAuCl4 (100 mM 
in MQ, 0.4 mg, 1 eq), 64CuCl2 (in 0.1 M HCl, 2.5 mCi = 92.5 MBq), neutralized with NaOH 
(0.1 M) and 25 µL NH2-PEG5k-SH (10 mM in MQ, 2.5 mg, 0.25 eq). Under vigorous stirring 
100 µL NaBH4 (40 mM in MQ, 0.2 mg, 4 eq; freshly prepared) were added drop wise. After 
2 min the stirring was stopped and the particles were allowed to settle for 2 h at room 
temperature. Purification was performed by spin filtration (30 kDa, 12 000 rpm) including 3 
washings with 1 mM EDTA and the particles were recovered from the filter in 400 µL PBS. 
The radiolabeling and purification was monitored by iTLC (mobile phase: 20 mM citric acid 
+ 60 mM EDTA, Rf(AuNP) = 0, Rf(64Cu-EDTA) = 0.5). 13 µL COSAN-SH (20 mM in 
EtOH, 0.1 mg, 0.25 eq) were added and incubated for 1 h at room temperature. After 
purification via spin filter as described above the pH of the AuNP suspension was adjusted 
to 7.8 – 8.8 with 0.1 M NaOH and 25 µL Tz-PEG5-NHS (20 mM in DMSO, 0.3 mg, 0.5 eq) 
were added. After 1 h incubation at room temperature the particles were purified by spin 
filtration and recovered in 400 µL PBS. The radiochemical yield was 6.5 %. 
4.5.6 in vitro studies 
Lindmo assay  
The assay was perfomed using the protocol of Lindmo as base (9). The binding assay for 
Trastuzumab was set up using one concentration of mAb (10-15 ng/mL) and different 
dilutions of 0.5 mL BT-474 cells in PBS/1%BSA (2.8 - 0.2*106 cells/mL) in triplicates. The 
lowest concentration was prepared twice, the second set serving as non-specific binding 
(NSB) control (containing 2 µL of 5 mg/mL non-labelled mAb). To each cell dilution 0.5 mL 
of modified and radiolabelled Trastuzumab was added and incubated in a head over head 
rotator at 4 °C over night. The cell suspensions were centrifuged, 500 uL of the supernatant 
seperated and all samples (pellets and supernatans) meassured in a gamma-counter. The 
activity meassured from the supernatants was substratced from the pellet activity and the 
immunoreactive fraction calculated. 
FACS study with Trastuzumab-TCO-mTzCy3 
BT-474 cells were seeded in a 24-well-plate (500 000 cells/well) and incubate overnight to 
adhere (37 °C, 5% CO2). The media was removed and 0.5 mL fresh media added to the 
control wells of non-labeled and viability. To the other wells 0.5 mL of Cy3-fluorophore-
labled Trastuzumab (0.1, 0.05 or 0.01 mg/mL) were added. The incubation (5, 10, 15, 20 and 
30 min) at room temperature was stopped by removing the media and detach cells with 
trypsin. The suspensions were transferred into FACS tubes, centrifuged, the supernatant 
removed and resuspend in 0.5 mL PBS. 0.1 mL viability (Zombie) control was added to all 
samples (except non-labeled control) and incubated for 13-30 min at room temperature. The 
samples were washed with FACS-buffer (10 mM PBS/1%BSA) via centrifuge and resuspend 
in 0.2 mL for FACS measurements. 
In vitro internalizing studies of Trastuzumab-TCO-mTzCy3 
BT-474 cells were seeded in a poly-L-Lysine treated ‘Ibidi’ µ-slide 8-well-plate 
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atmosphere). The media was removed and 0.1 mL Hoechst 33342 (1 µg/mL) added to stain 
the nucleus. After 10 min incubation (37 °C, 5% CO2, humid atmosphere) 0.1 mL 
Lysotracker-deep-red (1 µg/mL) was added to stain the lysosomes. After 20 min incubation 
(37 °C, 5% CO2, humid atmosphere) media was removed and 0.3 mL of Cy3-labeled 
Trastuzumab (10 µg/mL in media) added. After 1 h incubation (37 °C, 5% CO2, humid 
atmosphere) the media was removed and replaced with fresh media. The images were taken 
at different time points with a fluorescence confocal microscope (Zeiss LSM 880). Controls 
of single staining for each fluorophore were included. Images were analyzed by ZEN-ZEISS 
software. 
Cytotoxicity studies of AuNPs 
To determine cell viability, BT-474 human breast cancer cells were incubated with 
multifunctionalized AuNPs over 24 h, 48 h and 72 h. Cells were seeded (3×104 cells/well, 
100 µL/well, 96-well plate), allowed to adhere overnight in complete media and maintained 
in a humid atmosphere at 37 °C and 5 % CO2. Then, media was removed and cells were left 
untreated (control) or incubated with the AuNP-containing formulations, diluted accordingly 
in media. The experiments were performed in triplicates. After the desired time, cell 
supernatant was removed and 100 µL/well of MTT reagent (Roche), diluted in the 
corresponding media to the final concentration of 0.25 mg/mL, was added. After 1 hour 
incubation at 37 °C and 5 % CO2, the excess reagent was removed and formazan crystals 
were solubilized by adding 200 µL of DMSO per well. The optical density of each well was 
measured in a TECAN Genios Pro 96/384 microplate reader at 550 nm. Data was 
represented as the percentage of cell survival compared to control wells. 
In vitro internalizing studies of AuNP-Tz-TCOCy3 
BT-474 cells (ps. 17) were seeded in a poly-L-Lysine treated ‘Ibidi’ µ-slide 8-well-plate 
(30 000 cells/well in 0.3 mL) and incubate overnight to adhere (37 °C, 5% CO2, humid 
atmosphere). The media was removed and 0.1 mL Hoechst 33342 (1 µg/mL in media) added 
to stain the nucleus. After 10 min incubation (37 °C, 5% CO2, humid atmosphere) 0.1 mL 
Lysotracker-deep-red (1 µg/mL in media) was added to stain the lysosomes. After 20 min 
incubation (37 °C, 5% CO2, humid atmosphere) media was removed and 0.3 mL of Cy3-
labeled AuNP (20 µg/mL in medium) added. After 2 h incubation (37 °C, 5% CO2, humid 
atmosphere) the media was removed and replaced with fresh media. The images were taken 
with a Cell Axio Observer Fluorescence Microscope. Controls of single staining for each 
fluorophore were included. Images were analyzed by ZEN-ZEISS software. 
In vitro pre-targeting studies of Trastuzumab-TCO and Cy3-AuNP-Tz 
BT-474 cells (ps. 17) were seeded in a poly-L-Lysine treated ‘Ibidi’ µ-slide 8-well-plate 
(30 000 cells/well in 0.3 mL) and incubate overnight to adhere (37 °C, 5% CO2, humid 
atmosphere). The media was removed and 0.1 mL Hoechst 33342 (1 µg/mL in media) added 
to stain the nucleus. After 10 min incubation (37 °C, 5% CO2, humid atmosphere) 0.1 mL 
Lysotracker-deep-red (1 µg/mL in media) was added to stain the lysosomes. After 20 min 
incubation (37 °C, 5% CO2, humid atmosphere) media was removed and 0.1 mL 
Trastuzumab-TCO (1.0 µM) added. After 30 min incubation (37 °C, 5% CO2, humid 
atmosphere) the media was removed and 0.3 mL of Cy3-labeled AuNP (20 µg/mL in 
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atmosphere), the media removed and replaced with fresh media. The images were taken with 
a Cell Axio Observer Fluorescence Microscope. Controls of single staining for each 
fluorophore were included. Images were analyzed by ZEN-ZEISS software. 
4.5.7 in vivo studies 
Ex vivo studies to explore Trastuzumab internalization in vivo 
Trastuzumab was labeled in two batches, one with 89Zr, the other one with 131I. A mixture 
out of the two was created to obtain a 1:1 ratio of their activity (e.g. per mouse 5 µCi = 
0.185 MBq each). Four mice were selected out of female, BT-474 breast cancer xenograft 
bearing NOD/SCID mice and injected intravenously, each with about 100 µg Trastuzumab. 
Ex vivo studies were performed 24 h (n = 2) and 48 h (n = 2) post injection. Extracted 
organs were measured in a gamma counter (Wallach Wizard, PerkinElmer, Waltham, MA, 
USA) using a dual method enabling separate determination of 89Zr and 131I counts. The 
percentage of injected dose per gram (%ID/g) was calculated for the tumor uptake at both 
time points and for each radionuclide. 
In vivo PET imaging studies 
Biodistribution of Trastuzumab: Three animals were selected out of female, BT-474 breast 
cancer xenograft bearing NOD/SCID mice. In those experiments aimed at determining the 
biodistribution of the mAb, [89Zr]Trastuzumab (100 µg, 100 µL, 2.4-2.6 MBq) was injected 
via tail vein. Imaging studies were conducted using positron emission tomography (PET) in 
combination with computerized tomography (CT), using an eXplore Vista-CT small animal 
PET-CT system (GE Healthcare). Static whole-body images (2 beds) were acquired at 1, 8, 
24, 48 and 72 h after administration. PET images were analysed using PMOD image analysis 
software (PMOD Technologies Ltd, Zürich, Switzerland). 
Pre-targeting evaluation: Three groups of animals (G1 and G3: n = 4, G2: n = 3) were 
selected out of female, BT-474 breast cancer xenograft bearing NOD/SCID mice. 
Approximately 100 µg per mouse of TCO functionalized Trastuzumab (~2 TCO/mAb) 
were injected intravenously via tail vein for the pre-targeting group. The same amount 
respectively of non-functionalized Trastuzumab for the control group. 24 h post injection 
the multifunctionalized and 64Cu-radiolabeled AuNPs (200 µg gold in 100 µL PBS with 30-
50 µCi (1.1-1.9 MBq) per mouse) were injected intravenously. The same amount was injected 
to the third group which did not receive Trastuzumab beforehand. Imaging studies were 
conducted using positron emission tomography (PET) in combination with computerized 
tomography (CT), using the β- and X-cube micro system of Molecubes. Static whole-body 
images (1 bed) were acquired in a 511 keV ± 30 % energetic window at 1 h, 6 h, 24 h and 48 
h post injection (acquisition time 20 min for 1 h and 6 h, 45 min for 24 h and 60 min for 48 
h). PET images were analyzed using PMOD image analysis software (PMOD Technologies 
Ltd, Zürich, Switzerland). 
Digestion of organs for ICP-MS analysis 
ICP-MS analysis was performed for gold, boron and cobalt. The organs/tissue liver, spleen 
and tumor were digested from one animal per group. No glass could be used in any way 
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were dissolved in aqua regia overnight at 70 °C. To each sample 0.5 mL H2O2 was added, 
the samples filtered through cotton and the volume adjusted to 15 mL with 2 % HNO3. 
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Chapter 5: Pre-targeting boron carbon dots 
5.1 Introduction 
Carbon dots (CDs) are used in a broad field of applications such as sensing for metals, 
chemicals and biologicals, improvement of solar cells and biological approaches like bio 
imaging and drug delivery (1; 2). Having a closer look to boron doped carbon dots (B-CDs) 
and their use in biological approaches, metal- and chemo-sensing combined with bioimaging 
are the most common applications. Existing B-CDs are developed to detect among others 
blood sugar (3), H2O2 (4), dopamine (5) and a variety of metals, like Cr(VI) (5), Hg(II) (6), 
Al(III) (7), Cu(II) and Fe(III) (8). 
The presence of boron atoms in B-CDs, together with the high biocompatibility, low 
cytotoxicity and rather fast and inexpensive synthesis, suggests their potential application as 
boron-10 delivery agents in the context of Boron Nature Capture Therapy (BNCT). Yet, to 
the best of our knowledge, B-CDs have never before been investigated for BNCT. 
In this work we prepared and characterized boron doped carbon dots, functionalized with a 
tetrazine moiety to enable pre-targeting. To evaluate the approach in vivo, the same tumor-
mouse-model was used as in Chapter 4 for the pre-targeting of AuNPs. Hence, as targeting 
counterpart TCO-functionalized Trastuzumab was used. To enable Positron Emission 
Tomography (PET) imaging of B-CDs, these were radiolabeled with the positron emitter 
fluorine-18, and PET studies were carried out to determine tumor accumulation of the B-
CDs (see Figure 1 for schematic representation of the work included in this chapter). 
 
Figure 1: Schematic representation of the pre-targeting strategy using tetrazine functionalized and 
18F-radiolabeled B-CDs. 
5.2 Objectives 
The specific objectives of this work were: 
1. To synthesize and characterize tetrazine-functionalized boron carbon dots (B-CDs) 
2. To develop a radiolabeling strategy for the incorporation of the positron emitter 
fluorine-18 to tetrazine-functionalized B-CDs (B-CDs-Tz). 
3. To evaluate the capacity of B-CDs-Tz to accumulate in the tumor, using a mouse 
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5.3 Results and discussion 
5.3.1 Synthesis, functionalization and characterization of B-CDs 
The strategy of pre-targeting relies in the fact that the second component, administered after 
the administration of the functionalized antibody, presents a fast clearance. In imaging 
experiments, this minimizes background signal and radiation dose on healthy organs. In 
therapy, a fast clearance guarantees fast elimination of the drug, thus minimizing off-target 
side effects. Noteworthy, circulation time should be sufficient to enable the click reaction to 
occur in the site of action, in our case the tumor.  
We decided to synthesize small-sized, hydrophilic, boron doped carbon dots. With that aim, 
a microwave vessel was loaded with citric acid (1 eq.), ethylenediamine (10 eq.), sodium 
tetraborate (borax, 3 eq.) and water. The synthesis was carried out in 5 min under microwave 
heating at 220 °C, 200 W and 370 PSI (Figure 2). Purification was performed by sephadex 
size exclusion column (NAP5® GE Healthcare), and the collected fractions were lyophilized 
to obtain a beige solid (Figure 3, left) which was analyzed in terms of chemical composition, 
size, shape and fluorescence properties. 
 
Figure 2: Schematic representation of the synthesis of hydrophilic B-CDs under microwave heating. 
A typical characteristic, which can be used as first indication of a successful synthesis of B-
CDs, is their intense fluorescence (Figure 3, right). 
  
Figure 3: B-CDs after synthesis and lyophilization (left), under UV light (365 nm, right). 
To determine if the obtained particles were homogeneous and to analyze their shape and 
size, Atomic Force Microscopy (AFM) analysis was performed. Images show spherical 
particles with a size distribution in diameter between 3 and 10 nm with an average of 6.7 ± 
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Figure 4: Representative AFM images to visualize shape and size of B-CDs with height profiles 
corresponding to lines shown in the images.  
One critical aspect in BNCT is the amount of boron of the compound, which should be as 
high as possible to guarantee therapeutic efficacy. To analyze the content of the B-CDs, X-
ray Photoelectron Spectroscopy (XPS) analysis was performed and the relative atomic 
percentage of the B-CDs was determined (Table 1). Carbon had with 44 at% the highest 
representation, followed by oxygen with 33 at%. The content of boron was 13 at%. 









44.0 33.1 9.9 13.0 
 
Furthermore, XPS analysis of the B-CDs showed five peaks in the C-1s spectrum at 284.8, 
286.0, 287.9, 288.8 and 282.8 eV which are attributed to the bonds of CC/CH, CO/CN, 
C=O, OC=C and CB, respectively. In the B-1s spectrum a peak at 192.1 eV, corresponding 
to BCO2/BO bonds, and peaks at 188.1 and 189.8 eV, corresponding to BC and BN bonds, 
respectively, could be detected (Figure 5) (9; 10; 11). These results confirmed the presence 
of boron in the B-CDs. 
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Pre-targeting strategies require the presence of a moiety capable to undergo bioorthogonal 
reactions on both components. In our case, because the antibody (Trastuzumab) was 
functionalized with a TCO moiety (see chapter 4), we tackled the incorporation of a tetrazine 
moiety on the newly developed B-CDs. With that aim, a NHS ester of tetrazine (tetrazine-
PEG5-NHS) was used, allowing a coupling reaction to free existing amine groups on the B-
CDs (Figure 6). The polyethylene glycol (PEG) linkage was chosen to increase the bio-
compatibility, and to increase the size of the particles aiming at prolonging the blood 
circulation time (2). 
 
Figure 6: Schematic representation of the functionalization of B-CDs with tetrazine, enabling the 
pre-targeting approach. 
To achieve functionalization, a solution of B-CDs in PBS (phosphate buffered saline, pH 
7.4) was prepared. The obtained pH was around 9 and Tz-PEG5-NHS was added without 
further adjustment of the pH. After incubation for a minimum of 1h, purification was 
performed by sephadex size exclusion column (NAP5® G-25 GE Healthcare) and the 
collected fractions lyophilized. However, the purification of the tetrazine functionalized B-
CDs was challenging. The purification by NAP5® column was limited to very few fractions 
as the majority of the dots co-eluted with the excess of unbound Tz-PEG5-NHS, as 
determined by high-performance liquid chromatography (HPLC, see below). A yield of only 
around 10 % pure B-CDs-Tz could be achieved. 
An alternative method commonly used in the synthesis of CDs is dialysis. However, by using 
Float-a-Lyzer®G2 (MWCO: 500-1000 Da) only incomplete purification after 3 days in MQ 
water could be achieved. In view of these results, we settled with the low yield but high purity 
obtained after NAP5® column.  
As mentioned above, to monitor the purification of tetrazine functionalized B-CDs (B-CDs-
Tz) after the tetrazine coupling, HPLC was performed. Therefore, a size exclusion column 
(TSKgel SuperOligo PW, 150x6 mm, 3 µm) was used as stationary phase and eluted with 0.1 
M ammonium formate (AMF, pH = 6) as the mobile phase (UV detection at 280 nm). 
Injection of naked B-CDs resulted in a broad signal including several peaks, with a main 
signal between 4.8 and 7 min (Figure 7 A). The little defined signal can be explained by the 
disparity of the B-CDs, containing different sized particles as shown by AFM. Moving to the 
functionalized B-CDs-Tz the main signal shifted towards 10 to 12 min. This result is quite 
surprising, as one may expect that attachment of the tetrazine moieties results in an increase 
in the particle size. This unexpected result could be explained because the attachment of the 
tetrazine moieties on the surface of the B-CDs not only induces a change in size (which is 
not expected to be very significant), but also a modification in the hydrophobicity of the 
particles. Hence, the longer retention of the functionalized B-CDs in the column could be 
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intuitive elution profile. Noteworthy, the presence of peaks with retention times in the range 
5-9 min suggest that a fraction of the B-CDs remain non-functionalized (Figure 7 B), or 
present a low degree of functionalization. 
 
Figure 7: HPLC chromatograms representing naked B-CDs (A) and B-CDs-Tz after 
functionalization and purification (B). 
The characterization of the fluorescent properties of the B-CDs was next tackled. The 
fluorescence spectra at various excitations were obtained for both B-CDs and B-CDs-Tz. 
The highest fluorescence intensity for the naked B-CDs was achieved with the excitation 
wavelength of 350 nm, while for B-CDs-Tz was achieved at 360 nm. Even though the shift 
for optimal excitation is small, an immense reduction of fluorescence to about 1/10th could 
be observed as a result of the functionalization (Figure 8). 
  
Figure 8: Emission spectra at different excitation wavelengths (310-410 nm) of B-CDs (left) and B-
CDs-Tz (right). 
To further analyze the impact of tetrazine functionalization on fluorescence properties, 
agarose gel electrophoresis was performed and analyzed using the Gel DocTM EZ Imager 
(BIO-RAD) in UV mode. The reduced fluorescence after tetrazine attachment could be 
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reaction to tetrazine, an increase in fluorescence proved the availability of tetrazine on the 
surface of B-CDs-Tz and its capacity to react with TCO moieties (Figure 9). The drawn-out 
distribution of the dots on the gel represents the variety of size which was already visible 
after AFM analysis (Figure 4). 
 
Figure 9: Agarose gel electrophoresis of B-CDs, B-CDs-Tz and B-CDs-Tz coupled to the 
fluorophore TCO-Cy3 and imaged using the Gel DocTM imager in UV mode. 
Finally, the bio-compatibility of the B-CDs-Tz was evaluated by cytotoxicity studies on BT-
474 breast cancer cells. The cells were incubated with B-CDs-Tz of up to 160 µg/mL and to 
72 h. Analysis by standard MTT assay showed, with cell survivals over 90 %, no induced cell 
death due to the particles in BT-474 cells, indicating negligible cytotoxicity (Figure 10). 
  
Figure 10: Cell viability in the presence of B-CDs-Tz for 48 h and 72 h on BT-474 breast cancer cell 
line; cells were incubated with increasing concentrations of the B-CDs-Tz and cell viability was 
determined by MTT assay (values are expressed as mean ± standard error mean, n = 3). 
To evaluate the behavior of B-CDs-Tz with BT-474 breast cancer cells in terms of 
internalization, fluorescence microscopy studies were carried out. As the dots are 
fluorescence by themselves, a first trial was carried out without additional labeling. However, 
due to the reduced fluorophore-intensity after tetrazine attachment, the fluorescence wasn’t 
sufficient for the studies. Hence, further trials were conducted by attaching Cy3-TCO via 
click reaction to tetrazine of the B-CDs-Tz. The cells themselves were stained for the nucleus 
and lysosomes with Hoechst33342 and Lysotracker-deep-red, respectively. Images were 
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ZEN-ZEISS software. After 2 h incubation at 37 °C, co-localization between the dots and 
the lysosomes was observed, confirming internalization of B-CDs-Tz (Figure 11). 
 
Figure 11: Representative images by live cell fluorescence microscopy of functionalized B-CDs-Tz 
after 2 h incubation. In green: B-CDs-Tz, fluorophore-labeled with TCO-Cy3; in red: Lysosomes, 
stained with Lysotracker-deep-red; in blue: nucleus, stained with Hoechst33342. Merged signals of 
B-CDs-Tz colocalizing with lysosomes appear in yellow. 
Cell uptake is a desired property for boron delivery agents, as the efficacy and selectivity of 
the treatment improves in case of proximity of boron to the nucleus. For the pre-targeting 
strategy, a co-internalization of the antibody-dots complex is favored. Yet, it can be expected 
that the click reaction between the mAb-TCO and the B-CDs-Tz is faster than the cell uptake 
of the particles alone, hence no restrictions were expected for pre-targeting due to the ability 
of the dots to internalize. Additionally, internalization of the dots without interacting with 
the antibody should also not result in decreased efficacy, and can be considered as a parallel 
uptake mechanism that contributes to accumulation of the boron atoms in the interior of the 
cells.   
To proof the occurrence of the click reaction between TCO-functionalized Trastuzumab 
and the B-CDs-Tz, HPLC analysis was performed. The same conditions as described above 
were used, with 0.1 M ammonium formate (pH = 6) as mobile phase on a size exclusion 
column (TSKgel SuperOligo PW, 150x6 mm, 3 µm). Chromatograms of mixtures in 
different ratios of the two pre-targeting components and respective controls were executed. 
As control, each component was injected alone (Figure 12, A-C: Trastuzumab without and 
with TCO and B-CDs-Tz). Furthermore a mix between non-functionalized Trastuzumab 
and B-CDs-Tz (Figure 12, D) was also injected as control; an almost separation could be 
achieved. When applying the mixture of Trastuzumab-TCO and B-CDs-Tz (Figure 12, E-
G) a shift of the signal corresponding to the dots towards the mAb could be observed, this 
signal increasing with higher mAb-TCO/B-CDs-Tz ratios. These results confirm that the 
click reaction takes place. The fact that the signal of the B-CDs-Tz between 5 - 9 min is still 
visible with the high ratio of 50:1 (Figure 12, G), whereas the signal at min 9 - 12 disappeared, 
correlates with the assumption made above, that the dots eluted in this area are non-
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Figure 12: HPLC chromatograms to demonstrate occurance of click reaction between Trastuzumab-
TCO and B-CDs-Tz including control chromatograms. (A) Trastuzumab, (B) Trastuzumab-TCO, 
(C) B-CDs-Tz, (D) control of non-functionalized Trastuzumab and B-CDs-Tz in a ratio of 2:1, (E-
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After the successful synthesis and functionalization of the B-CDs-Tz, including their 
characterization and confirmation of bio-compatibility and successful click reaction between 
the two pre-targeting components, we moved to the in vivo evaluation of pre-targeting. 
Hence, radiolabeling of the B-CDs-Tz with a positron emitting nuclide was necessary to be 
able to follow the dots after administration to mice by positron emission tomography (PET) 
imaging. 
5.3.2 Radiolabeling of B-CDs-Tz with [18F]FPyTFP 
 
Figure 13: Schematic representation of radiolabeling B-CD-Tz with [18F]FPyTFP. 
To radiolabel the dots, the radionuclide fluorine-18 (t1/2 = 109.77 min) was chosen, as 
relatively fast clearance was expected due to their small size. An easy and mild route to label 
biomolecules or nanoparticles with 18F is by using a prosthetic group, which is a small 
molecule that incorporates the radionuclide and has a functional group for fast and easy 
coupling to the (usually) bigger component. With free available amine groups on the surface 
of the B-CDs-Tz and with an automatized system for its production in hand, the prosthetic 
group [18F]FPyTFP (12) was chosen (see Error! Reference source not found. for synthesis 
of [18F]FPyTFP precursor and Radiosynthesis of [18F]FPyTFP). Therefore B-CDs-Tz were 
dissolved in PBS, the prosthetic group added and incubated for 10 min at 70 °C. The labeling 
was monitored by: (i) radio-TLC using silica gel coated aluminum sheets and 
methanol/dichloromethane 3:7 as the stationary and mobile phases, respectively (Figure 14); 
and (ii) by radio-HPLC using the size exclusion column (TSKgel SuperOligo PW, 150x6 mm, 
3 µm) as stationary phase, and 80 % 0.1 M ammonium formate (AMF, pH = 6) and 20 % 
acetonitrile, to enable elution of the prosthetic group, as the mobile phase (UV detection at 
365 nm) (Figure 15). Both methods confirmed quantitative labeling of the dots. 
 
Figure 14: Chromatograms of radio-TLCs monitoring of the radiolabeling reaction of B-CDs-Tz 
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Figure 15: Radio-HPLC chromatogram of [18F]B-CDs-Tz. Top: UV detection, bottom: radiometric 
detection. 
5.3.3 Pre-targeting B-CDs in vivo 
For the evaluation of pre-targeting B-CDs in vivo, BT-474 breast cancer xenograft bearing 
NOD/SCID mice were used (for details about tumor growth see Chapter 4). Two 
experimental groups were evaluated; the pre-targeting group (G1), in which TCO-
functionalized Trastuzumab was injected intravenously 24 h prior to the intravenous 
administration of [18F]B-CDs-Tz and a control group (G2) in which solely [18F]B-CDs-Tz 
were injected intravenously (Figure 16). Each group consisted of 3 animals. The amount of 
injected mAb per mouse was of 100 µg. For both groups 200-300 µCi (7.5 - 11.0 MBq) 
[18F]B-CDs-Tz were injected per mouse, corresponding to about 150-250 µg. Dynamic PET-
CT scans were performed immediately after injection of the B-CDs for 45 min using an 
eXploreVista-CT small animal PET-CT system (GE Healthcare). 
G1 pre-targeting G2 B-CDs-Tz 
 
 
Figure 16: Experimental set up with two experimental groups for in vivo evaluation of pre-targeting 
B-CDs. The pre-targeting group (G1) was injected with Trastuzumab-TCO followed by [18F]B-CDs-
Tz after 24 h; the second group (G2) received only [18F]B-CDs-Tz. 
To visualize the results after PET quantification with PMOD software the 45 min scans were 
averaged in 5 timeframes. First, we looked at the biodistribution profile and plotted the 
uptake in major organs. A fast clearance by elimination through kidneys and bladder could 
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Figure 17: Representative coronal PET images for each time frame (average of each timeframe) after 
intravenous administration of [18F]B-CDs-Tz. PET images have been co-registered with CT images 
(representative slice) for localization of the radioactive signal. 
 
Figure 18: Accumulation of [18F]B-CDs-Tz in different organs at 5 timeframes up to 45 min after 
intravenous administration, analyzed by PET imaging, obtained for the pre-targeting and control 
group (values are expressed as mean ± standard error mean, n = 3). 
However, a closer look to the tumor uptake revealed clear differences. In G2 the [18F]B-CDs-
Tz are washed out from the tumor, whereas the amount of dots in the pre-targeted tumors 
seems to be stable which lead to the conclusion that the desired retention of the dots was 
achieved. Further verification was given by the significant difference in the time frame 25–
45 min (P = 0.0005) (Figure 19). 
   
Figure 19: Left: Accumulation of [18F]B-CDs-Tz in the tumor, analyzed by PET imaging, at different 
timeframes after intravenous administration for the pre-targeting and control group (values are 
expressed as mean ± standard error mean, n = 3). Significant differences are found in the time frame 
25–45 min (P = 0.0005). Right: representative axial slices in the region of the tumor corresponding 
to PET-CT images obtained after administration of [18F]B-CDs-Tz in the time frame 25-45 min for 
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The results obtained confirm the effect of the pre-targeting strategy in terms of tumor 
retention. However, higher accumulation in the tumor would be desirable. This could be 
achieved by using a slower- or non-internalizing mAb which results in higher availability of 
the mAb at tumor site. Furthermore, it would allow a later administration of the B-CDs to 
achieve enhanced clearing of the mAb from non-targeted tissue. Finally, an increase of the 
circulation time of the CDs could enhance tumor accumulation. 
5.4 Summary and conclusion 
This chapter describes the successful approach of pre-targeting boron carbon dots (B-CDs) 
for the application in BCNT. The particles were successfully synthesized using a one-step 
microwave method, characterized among other by AFM, XPS and for their fluorescence, 
functionalized with tetrazine and radiolabeled with the prosthetic group [18F]FPyTFP which 
finally resulted in their evaluation in vivo in BT-474 breast cancer xenograft bearing 
NOD/SCID mice. Bio-compatibility was confirmed prior performing an MTT cytotoxicity 
test. 
The biodistribution of the B-CDs showed a rapid clearance over kidneys and bladder from 
blood, organs and tissue, including the tumor. However, in pre-targeted tumors a clear 
retention of the dots could be found, hence, the B-CDs-Tz clicked to the TCO-
functionalized mAb in tumor tissue, preventing the wash out as seen in the control group.  
Yet, low accumulation in tumor of, in average, only 2.8 ± 0.2 %ID/cm3 (which maintained 
almost the same over the 45 min PET scan) was observed. To obtain a higher tumor uptake 
and therefore higher boron concentrations in the tumor, necessary for a successful BNCT 
approach, a slow- or non-internalizing mAb should be used. It would allow a longer mAb 
clearing time before the injection of the B-CDs (e.g. from 24 h to 48 h) as well as an increase 
of available mAb on the cell membrane at tumor site. 
Nevertheless, the results of this chapter clearly show the desired retention of the boron 
delivery agent, the B-CDs, due to pre-targeting. Hence, B-CDs, combined with a pre-
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5.5 Experimental part 
5.5.1 Reagents 
All reagents were obtained from Sigma-Aldrich unless otherwise stated. Milli-Q water 
(resistivity 18.2 MΩ·cm at 25 °C) was used in all experiments. NHS-Cy3 was purchased from 
BroadPharm. The antibody Trastuzumab was purchased from Roche Farma, S.A. España. 
A stock of BT-474 cells was kindly donated by Instituto de Investigación Sanitaria 
Biodonostia (San Sebastián, Spain). Animals were purchased from Charles River 
Laboratories France.  
[18F] was generated in an IBA Cyclone 18/9 cyclotron by irradiation of [18O]H2O with high 
energy (18 MeV) protons via (p, n) reaction, and trapped on a QMA cartridge and the activity 
eluted with aqueous K2CO3. 
5.5.2 Instrumentation 
The synthesis of B-CDs was performed using a CEM Focused Microwave™ Synthesis 
System, Discover® SP. 
Atomic force microscopy (AFM) studies were performed using a Veeco Multimode AFM 
attached to a Nanoscope V controller. The sample was imaged in tapping mode in air, using 
TESPA-V2 doped silicon probe with k = 42 N/m. A drop of a diluted solution of the 
particles was placed on a glass substrate, the sample left to evaporate at room temperature 
and afterwards imaged. 
X-ray Photoelectron Spectroscopy (XPS) experiments were performed in a SPECS Sage HR 
100 spectrometer (Berlin, Germany) with a non-monochromatic X ray source (aluminum 
Kαline of 1486.6 eV energy and 252 W), placed perpendicular to the analyzer axis and 
calibrated using the 3d5/2 line of Ag with a full width at half maximum (FWHM) of 1.1 eV. 
The selected resolution for the spectra was 15 eV of Pass Energy and 0.15 eV/step. All 
measurements were made in an ultra-high vacuum (UHV) chamber at a pressure around 
6×10−8 mbar. An electron flood gun was used for charge neutralization. Gaussian Lorentzian 
functions were used for fittings (after a Shirley background correction) where the FWHM of 
all the peaks were constrained while the peak positions and areas were set free. Main C1s 
peak was used for charge reference and set at 284.8 eV. 
HPLC analysis was carried out using an Agilent 1200 series HPLC equipped with a 
quaternary pump, a multiple wavelength detector and a radiometric detector (Gabi, Raytest). 
A size exclusion column (TSKgel SuperOligo PW, 150x6 mm, 3 µm) was used as stationary 
phase with 100 % 0.1 M ammonium formate (AMF, pH = 6) or for radio-HPLC with 80 % 
0.1 M AMF and 20 % acetonitrile as mobile phase at a flow rate of 0.4 mL/min. UV detection 
at λ = 280 nm or, for radio-HPLC at 365 nm. Injection volume was 20 µL. 
Fluorescence spectra were measured at room temperature using a Perkin Elmer (LS 55) 
Fluorimeter. Excitation source: Pulsed Xenon lamp 8 W, Detector: PMT (200-650 nm), 
Polarizers anisotropy / polarisation measurements, Emission monochromator cut off filter 
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Cell observer microscopy experiments were carried out using a Zeiss Axio Observer 
Fluorescence microscope using Ibidi clear bottomed µ-slide 8-well microscopy plates and 
analyzed by ZEN2012-ZEISS. 
Successful preparation of synthetic products was confirmed by NMR spectroscopy. NMR 
spectra of CDCl3 or acetonitrile-d3 solutions were recorded on Bruker Avance III 500 MHz 
spectrometer at 302 K. The chemical shifts (δ) are reported in parts per million (ppm) and are 
referenced to the deuterated solvent used. The coupling constants (J) are reported in Hz, and 
the splitting patterns are indicated as s (singlet), d (doublet), dd (doublet of doublets), t 
(triplet), and tt (triplet of triplets). 
Radio-thin layer chromatography (radio-TLC) was performed using silica gel coated 
aluminum sheets and methanol/dichloromethane 3:7 as the stationary and mobile phases, 
respectively. TLC plates were analyzed using a TLC-reader (MiniGITA, Raytest). 
PET experiments were performed using an eXploreVista-CT small animal PET-CT system 
(GE Healthcare). Anesthesia was induced with 3-5 % isoflurane and maintained by 1.5-2 % 
of isoflurane in 100% O2. 
5.5.3 Tumor growth 
Cells 
BT-474 cells were cultured in DMEM medium (100X, 10378-016 Gibco; 10 % fetal bovine 
serum, 1 % penicillin-streptomycin) at 37 °C with 5% CO2 in a humid atmosphere. Cells 
were confirmed, using a Lonza Mycoplasma test, to be free of mycoplasma contamination. 
Animals 
All animal experiments were performed in accordance with the Spanish policy for animal 
protection (RD53/2013), which meets the requirements of the European Union directive 
2010/63/UE regarding the protection of animals used in experimental procedures. All 
experimental procedures were approved by the Ethical Committee of CIC biomaGUNE and 
authorized by the local authorities. All animals were housed in ventilated cages and fed on a 
standard diet ad libitum. The studies were performed on female NOD.CB17-Prkdcscid/J 
mice. 
Tumor growth 
To grow BT-474 cell line breast cancer xenografts on female NOD.CB17-Prkdcscid/J mice 
5-6 weeks old mice were operated to implant a 17β-estradiol pellet (belma technologies) 
subcutaneously at their neck. The next day 10*106 BT-474 tumor cells were inoculated per 
animal subcutaneously at the flank of the mouse. Prior to each inoculation cells were diluted 
in sterile PBS:Matrigel (1:1). The sizes of the tumors were measured every 2-3 days with a 
digital calliper and volumes calculated (𝑉 =
short diameter2∗ long diameter
2
). At the time the 
tumour reached 200-300 mm3 (around 2 weeks after inoculation) in vivo studies could be 
performed. The defined human endpoints were: (i) weight loss greater than 20 % in one 
week, (ii) one or more of the following clinical signs: abdominal distension, dyspnoea, 
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than 1.5 cm in average diameter and (v) ulcerated or necrotic tumors or wounds / aggressions 
severe infected.  
5.5.4 Chemistry and Radiochemistry 
Conjugation of TCO-NHS to Trastuzumab 
The antibody Trastuzumab was diluted in PBS (phosphate-buffered saline, pH 7.4) to a 
concentration of 3.0 mg/mL. The pH was adjusted to 8.6 – 9.1 with 0.1 M Na2CO3. 50-
55 moles eq. TCO-NHS (20 mM in DMSO) was added. After incubation (120 min, RT) non-
reacted TCO-NHS was removed by spin filtration (100 kDa, 12000 rpm) and the conjugated 
mAb washed three times with PBS. After recovering the mAb from the filter with PBS its 
concentration was determined by NanoDrop®. 
Synthesis of B-CDs and functionalization with tetrazine 
To a 10 mL microwave vessel were added citric acid monohydrate (1 eq., 18.0 mg), 
ethylendiamine (10 eq., 57.0 µL), sodium tetraborate (3 eq., 51.7 mg) and 300 µL MQ water. 
The vial was capped and introduced into the microwave. The reaction was performed in 5 
min with stirring at 220 °C, 200 W, 370 PSI and with 2 min ramp time. Purification was 
performed by sephadex size exclusion column (NAP5® GE Healthcare) and the collected 
fractions lyophilized. To attach tetrazine 6 mg B-CDs were dissolved in 500 µL PBS. The 
solution had a pH around 9 and Tz-PEG5-NHS (1.6 mg in 30 µL DMSO, 110 mM) was 
added without further adjustment of the pH. After incubation overnight purification was 
performed by sephadex size exclusion column (NAP5® GE Healthcare) and the collected 
fractions lyophilized. A yield of 12.4 % of pure B-CDs-Tz could be achieved. 
Agarose (1.5 %) gel electrophoresis  
A 1.5 % agarose gel was prepared following standard protocol. In brief 1.5 g agarose were 
suspended in 100 mL Tris-Borate-EDTA (TBE) buffer and heated until it almost reached its 
boiling point. The solution was poured in a gel chamber, the comb placed and let settle to 
polymerize. Samples were prepared in 20 µL aqueous batches, including 5 µL loading buffer. 
10 µL were loaded on the gel and run for approximately 1 h at 100 V. 
Proof of click reaction using SE-HPLC 
To proof the occurrence of the click reaction between TCO-functionalized Trastuzumab 
and the B-CDs-Tz, SE-HPLC analysis was performed. Therefore, a size exclusion column 
(TSKgel SuperOligo PW, 150x6 mm, 3 µm) was used as stationary phase with an isocratic 
mobile phase of 0.1 M ammonium formate (pH = 6). Chromatograms were first executed 
for controls of each component alone (non-functionalized Trastuzumab (2 mg/mL), TCO-
functionalized Trastuzumab (2 mg/mL) and B-CDs-Tz (1 mg/mL)) as well as a mix of non-
functionalized Trastuzumab (1 mg/mL) and B-CDs-Tz (1 mg/mL) in a ratio of 2:1. Finally, 
chromatograms of the two pre-targeting components combined in different ratios were 
executed (functionalized Trastuzumab (1 mg/mL) and B-CDs-Tz (1 mg/mL) in ratios of 
2:1, 20:1, 50:1). 
Synthesis of [18F]FPyTFP precursor 4 
The precursor for the preparation of [18F]FPyTFP was synthesized in a 3-step sequence as 
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2,3,5,6-tetrafluorophenol (750 mg, 4.5 mmol) and N,N’-dicyclohexylcarbodiimide (1.9 g, 
9 mmol) in dioxane (40 mL) was stirred at room temperature for 2 h. The mixture was 
filtered, the solvent evaporated, and the crude crystallized from hot hexane (25 mL), to give 
6-chloronicotinic acid 2,3,5,6-tetrafluorophenyl ester (945 mg, 3.1 mmol; 69 %) as a white 
solid. 
1H NMR (500 MHz, Chloroform-d) δ 9.21 (dd, J = 2.4, 0.8 Hz, 1H), 8.42 (dd, J = 8.4, 2.4 Hz, 
1H), 7.57 (dd, J = 8.4, 0.8 Hz, 1H), 7.11 (tt, J = 9.8, 7.0 Hz, 1H) (matches the literature data). 
Nicotinic ester (760 mg, 2.5 mmol) was dissolved in trimethylamine solution in 
tetrahydrofurane (1 M, 20 mL) and stirred at room temperature for 5 h. The white precipitate 
was collected by vacuum filtration and washed with diethyl ether (2 × 5 mL) to obtain 
N,N,N-trimethyl-5-((2,3,5,6-tetrafluorophenoxy)carbonyl)pyridin-2-aminium chloride 
(605 mg, 1.7 mmol; 68 %) as an off-white solid. This was suspended in trimethylsilyl triflate 
solution in dichloromethane (2 % w/w, 25 mL). The mixture was exposed to ultrasound for 
10 min, the solvent was evaporated and the crude washed with diethyl ether (2 × 10 mL) to 
give N,N,N-trimethyl-5-((2,3,5,6-tetrafluorophenoxy)carbonyl)pyridin-2-aminium trifluoro-
methanesulfonate (792 mg, 1.7 mmol; 100 %) as an off-white solid. 
1H NMR (500 MHz, Acetonitrile-d3) δ 9.28 (d, J = 2.3 Hz, 1H), 8.79 (dd, J = 8.7, 2.3 Hz, 
1H), 8.01 (d, J = 8.8 Hz, 1H), 7.37 (tt, J = 10.5, 7.3 Hz, 1H), 3.54 (s, 9H) (matches the 
literature data). 
Radiosynthesis of [18F]FPyTFP 
The synthesis of [18F]FPyTFP was performed using a TRACERlab FXFN synthesis module 
(GE Healthcare) by 18F-fluorination of the trifluoromethanesulfonate precursor, inspired by 
previously described procedure (12). The radiosynthesis was carried out in a fully automated 
manner and included HPLC purification and reformulation. 
Fluorine-18 (18F) was generated in an IBA Cyclone 18/9 cyclotron by irradiation (target 
current = 44 µA) of 18O-enriched water with high energy (18 MeV) protons via 18O(p, n)18F 
reaction. [18F]F– was trapped on a pre-conditioned Sep-Pak® Accell Plus QMA Light 
cartridge (Waters, Milford, MA, USA), and then eluted with a solution of Kryptofix 
K2.2.2/K2CO3 in a mixture of water and acetonitrile. After complete elimination of the 
solvent by azeotropic evaporation, a solution containing the precursor (10 mg) in a mixture 
of t-butanol and acetonitrile (4/1, v/v; 0.5 mL) was added and the mixture was kept at 40 °C 
for 15 min. The crude was diluted with acetonitrile/water (1/1, v/v; 2 mL) and purified by 
HPLC using RP Mediterranea Sea18 (10 × 250 mm, 5 µm particle size; Teknokroma, Spain) 
as a stationary phase and acetonitrile/0.1% TFA in milliQ water (80/20, v/v) as a mobile 
phase at a flow rate of 3 mL/min. The desired fraction (tR = 29–30 min) was collected, 
diluted with water (25 mL), and the radiotracer was retained on a C-18 cartridge (Sep-Pak® 
Light, Waters, Milford, MA, USA). The cartridge was washed with water (5 mL) and the 
radiotracer eluted with acetonitrile (1 mL). Chemical and radiochemical purity were 
determined by HPLC using a Mediterranean C18 column (4.6 x 150 mm, 5 µm) as stationary 
phase and 0.1% TFA/acetonitrile (0-1 min 25% acetonitrile; 9-12 min 90% acetonitrile; 13-
15 min 25% acetonitrile) as the mobile phase at a flow rate of 1.5 mL/min (retention time 
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HPLC analysis confirmed high radiochemical purity (> 99 %) of [18F]FPyTFP, obtained in 
14 % non-decay corrected yield. For the purpose of further use of the radiolabeled prosthetic 
group, [18F]FPyTFP was used dissolved in acetonitrile as obtained after elution from the 
cartridge. 
Radiolabeling of B-CDs-Tz with [18F]FPyTFP 
To radiolabel B-CDs-Tz 1.2 mg were dissolved in 100 µL PBS (phosphate buffered saline, 
pH 7.4) and 8 mCi (300 MBq) [18F]FPyTFP in acetonitrile added. After 10 min incubation at 
70 ºC the labeling was complete as monitored by radio-TLC (silica gel 60 F254 on aluminum 
sheets (Merck), methanol/dichloromethane 3:7) and radio-HPLC (TSKgel SuperOligo PW 
column, 150x6 mm, 3 µm, 0.1 M AFM/acetonitrile 80:20). 
5.5.5 in vitro studies 
Cytotoxicity studies 
To determine cell viability, BT-474 human breast cancer cells were incubated with 
functionalized B-CDs over 48 h and 72 h. Cells were seeded (3×104 cells/well, 100 µL/well, 
96-well plate), allowed to adhere overnight in complete media and maintained in a humid 
atmosphere at 37 °C and 5 % CO2. Then, media was removed and cells were left untreated 
(control) or incubated with the B-CDs-containing formulations, diluted accordingly in media. 
The experiments were performed in triplicates. After the desired time, cell supernatant was 
removed and 100 µL/well of MTT reagent (Roche), diluted in the corresponding media to 
the final concentration of 0.25 mg/mL, was added. After 1 h incubation at 37 °C and 5 % 
CO2, the excess reagent was removed and formazan crystals were solubilized by adding 
200 µL of DMSO per well. The optical density of each well was measured in a TECAN 
Genios Pro 96/384 microplate reader at 550 nm. Data was represented as the percentage of 
cell survival compared to control wells. 
In vitro internalizing studies of B-CDs-Tz-Cy3 
B-CDs-Tz were fluorophore-labelled with TCO-Cy3, using the click-coupling reaction and 
purified by sephadex size exclusion column (NAP5® GE Healthcare). BT-474 cells (ps. 17) 
were seeded in a poly-L-Lysine treated ‘Ibidi’ µ-slide 8-well-plate (30 000 cells/well in 0.3 
mL) and incubated overnight to adhere (37 °C, 5% CO2, humid atmosphere). The media was 
removed and 0.1 mL Hoechst 33342 (1 µg/mL medium) added to stain the nucleus. After 
10 min incubation (37 °C, 5% CO2, humid atmosphere) 0.1 mL LysoTracker deep red (1 
µg/mL in media) was added to stain the lysosomes. After 20 min incubation (37 °C, 5% CO2, 
humid atmosphere) media was removed and 0.3 mL of Cy3-labeled B-CDs (75 µg/mL 
medium) added. After 2 h incubation (37 °C, 5% CO2, humid atmosphere) the media was 
removed and replaced with fresh media. The images were taken with a Cell Axio Observer 
Fluorescence Microscope. Controls of single staining for each fluorophore were included. 
Images were analyzed by ZEN-ZEISS software. 
5.5.6 in vivo studies 
In vivo PET imaging studies 
Two groups of animals (n = 3) were selected out of female, BT-474 breast cancer xenograft 
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functionalized Trastuzumab (~2 TCO/mAb, determined by the direct method described in 
chapter 3) per mouse were injected intravenously via tail vein. 24 h post injection the [18F]B-
CDs-Tz (150-250 µg B-CDs-Tz in 100 µL PBS with 200-300 µCi (7.4-11.1 MBq) per mouse) 
were injected intravenously. The same amount of [18F]B-CDs-Tz was injected to the second 
group which did not receive Trastuzumab beforehand. Imaging studies were conducted using 
positron emission tomography (PET) in combination with computerized tomography (CT), 
using an eXploreVista-CT small animal PET-CT system (GE Healthcare). Dynamic whole-
body images (2 beds) were acquired immediately after injection for 45 min. PET images were 
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Chapter 6: General conclusion and future perspective 
6.1 General conclusion 
1. The analysis of antibodies for their number of moieties per mAb, conjugated with 
small ligands, can be carried out using different techniques, including direct titration, 
MALDI/TOF MS (Matrix-Assisted Laser Desorption-Ionization / Time Of Flight 
Mass Spectrometry) and UPLC/ESI-TOF MS (Ultra High Performance Liquid 
Chromatography / Electrospray ionization - Time Of Flight Mass Spectrometry). 
 
2. The different analytical techniques show overall similar trends and values, although 
UPLC/ESI-TOF MS offers reliable quantitative information about the different 
species present when functionalization with the desferrioxamine derivative p-NCS-
Bz-DFO is carried out.  
 
3. TCO conjugation of Trastuzumab did not compromise its binding ability to the 
target. However, the characteristic to internalize after binding to its receptor was a 
potential problem. Yet, in vivo internalization studies showed remaining mAb (about 
55 %) on the cell membrane 24 h postinjection. 
 
4. Small, spherical AuNPs (core size 3-5 nm) functionalised with polyethyleneglycol and 
cobalt-bis-dicarbollide (COSAN), show slow elimination and high uptake in organs 
of the mononuclear phagocytic system, such as the spleen and the liver. Hence, they 
didn’t follow the desired properties for pre-targeting. 
 
5. Nontheless, high boron loading was achieved and tumor uptake due to the EPR 
effect could be witnessed in a xenograft mouse model of breast cancer.  
 
6. Boron doped carbon dots show rapid elimination via kidneys and bladder, and 
therefore promising properties for pre-targeting. The use of a pretargeting strategy 
significantly increases retention of the boron-rich carbon dots in the tumour, as 
demonstrated using a xenograft mouse model of breast cancer. 
 
6.2 Future perspective 
Future studies should address the low tumor accumulation of the B-CDs in tumor tissue. 
Therefore several strategies can be followed. Using a non-internalizing mAb would lead to 
an increase of available mAb on the cell membrane at tumor site. Therefore, more dots could 
attach and be retained. Furthermore, a later administration of the B-CDs-Tz, that is, moving 
from 24 h to e.g. 48 h after the mAb injection, would enable enhanced clearing of the mAb 
from non-targeted tissue, hence, preventing the click reation with the dots to occur at other 
sites and increase their bioavailablity. Another way to enhance tumor accumulation could be 
to prolong the blood circulation time of the dots, which could, for example, be achieved by 
additional PEG liagnds, increasing size and biocompatibilty of the particles. It could increase 
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in non targeted tissues. Finally, the way of administration could be addressed. An alternative 
of giving a one time high dose could be a continus infusion which would allow more B-CDs 
to pass through the tumor and attach to the pre-injected antibodies, hence higher overall 
accumulation in tumor could be achieved. 
 
